Statistical Contributions to Medical Research in the South West Peninsula by Sanders, Hilary Patricia
statistical Contributions to Medical 
Research in the South West 
Peninsula 
A thesis submitted to the University of Plymouth in partial 
fulfilment for the degree of Doctor of Philosophy 
Hilary Patricia Sanders 
School of Mathematics and Statistics 
July 2007 
University of Plymouth 
Library 
Item No. 
Shelfmark 
Contents 
List of Research Papers 5 
Declaration 7 
Copyright Statement 9 
Abstract 11 
Acknowledgements 13 
Critical Appraisal 15 
A. Introduction 15 
B. A Multicentre Clinical Trial 17 
C. Follow-up CAMS Study 20 
D. CAMS Chemical Marker Paper 21 
E. Acute Health Care 22 
F. Research in Primary Care 24 
References for Critical Appraisal 26 
Statistical features of the main CAMS papers 27 
1. Design 27 
2. Methodology 43 
3. Discussion of Results 52 
References for Discussion of CAMS Statistical features 67 
Research Papers 104 
List of Research Papers 
1. Zajicek. J., Fox. P., Sanders, H., Wright, D., Vickery, J., Nunn, A. and 
Thompson, A. (2003). Cannabinoids for treatment of spasticity and other 
symptoms related to multiple sclerosis (CAMS study): multicentre 
randomised placebo-controlled trial. The Lancet, 362: 1517 - 1526. 
Zajtcek. J.P., Sanders, H.P., Wright, D.E., Vickery. P.J.. Ingram, W.M.. 
Reilly, S.M., Nunn. A.J.. Teare. L.J., Fox. P.J. and Thompson, A. J. 
(2005). Cannabinoids in Multiple Sclerosis (CAMS) Study: safety and 
efficacy for 12 months follow-up. J. Neurology, Neurosurgery and 
Psychiatry, 76: 1664 - 1669. 
Katona, S., Kaminski, E., Sanders, H. and Zajicek, J. (2005). 
Cannabinoid influence on cytokine profile in multiple sclerosis. Clinical 
and Experimental Immunology, 140: 580 - 585. 
4. Dimpel, H.L.. Sneyd, J.R., Sanders, H. and Dennis. I. (-1999). Oxygen 
administration and explicit memory: no improvement found in healthy 
volunteers. British Journal of Anaesthetics, 83: 801 - 804. 
5. Elford, J.. Wells, I., Cowie, J.. Hurlock. C. and Sanders, H. (2000). 
Computerised strain-gauge plethysmography - an alternative method for 
the detection of lower limb deep vein thrombosis. Clinical Radiology, 55: 
36-39 . 
6. Hilton. D.A., Penney, M., Pobereskin, L., Sanders, H. and Love. 8. 
(2004). Histological indicators of prognosis in glioblastomas: 
retinoblastoma protein expression and oligidendroglial differentiation 
indicate improved survival. Histopathology, 44(6): 555 - 560. 
7. Hilton, D.A., Penney, M., Evans. B. and Sanders, H. and Love, S. 
(2002). Evaluation of Molecular Markers in Low-Grade Diffuse 
Astrocytomas: Loss of p i 6 and Retinoblastoma protein is associated with 
short survival. American Journal of Surgical Pathology, 26(4); 472 - 478. 
8. Randall. C , Randall, H.. Dobbs, F.. Hutton, C. and Sanders, H. (2000). 
Randomised controlled trial of nettle sting for treatment of base-of-thumb 
pain. Journal of the Royal Society of Medicine, 93: 305 - 309. 
9. Baker. R. A.. Ferrer, 8., Perkins, V. J . and Sanders, H. (2006). 
Emergency Dental Clinic Patients in South Devon, their Anxiety Levels, 
expressed demand for treatment under sedation and suitability for 
management under sedation. Primary Dental Care, 13: 11 -18. 
10. Baker. R. A., Anthony, L. and Sanders, H. (2006). An audit of the quality 
of a referral document, designed in accordance vy/ith Scottish 
Intercollegiate Guidelines Network, for paediatric exodontias under 
general anaesthesia. International Journal of Paediatric Dentistry, 16: 
307 - 308. 
Declaration 
The research on which this thesis is based was completed by the candidate 
whilst employed by the University of Plymouth as a Senior Lecturer in Statistics 
over the period from September 1998 to January 2006. The papers are the 
result of original research work undertaken in collaboration with healthcare 
researchers in the South West Peninsula. This work reflects the 
multidisciplinary approach to modern healthcare research where the pivotal role 
of the Statistician, from concept through design and execution to the production 
of published papers, is crucial. Funding bodies, and in particular the Medical 
Research Council (MRC), expect a Statistician to be part of the project team 
and the statistical input and expertise included plays a key role in determining 
whether or not projects are funded and are subsequently successful. 
In particular, research described in Zajicek, J., Fox, P., Sanders, H. et al. (2003) 
and Zajicek, J.P., Sanders, H.P. et al. (2005) published in The Lancet and the 
Journal of Neurology, Neuroscience and Psychiatry respectively, forms the 
major part of the thesis. This work was undertaken as part of a £1.1million 
MRC funded project. "Cannabinoids in Multiple Sclerosis" (CAMS) for which, as 
the trial Statistician, I was one of the four investigators. This was the first large-
scale MRC trial funded in the South West Peninsula and as a result of its 
success the MRC has awarded a further £2.1 million for the Cannabinoid Use in 
Progressive Inflammatory brain Disease (CUPID) clinical trial which has 
recently started recruiting patients and on which I am currently working. These 
projects have provided the Peninsula with the experience from which a 
nationally accredited Clinical Trials Unit can be formed. An application for full 
registration of a Clinical Trials Unit is currently being considered by the UK 
Clinical Research Collaboration (registration expected September 2007). 
It will be noted that I am not named as first author on these papers. The end 
result of any four year multi-million pound project in healthcare is typically one 
or two papers with the statistician as second or third author with the lead clinical 
investigator(s) as first author(s). This should not detract from the pivotal role 
that statisticians have in healthcare research. 
In addition to the work on the CAMS trial, the thesis includes papers arising 
from other areas of healthcare research where I have designed and conducted 
significant statistical analyses. The papers included represent the breadth and 
complexity of the research in which I have been involved In recent years. They 
have also helped to build the experience and human infrastructure from which a 
flourishing healthcare research centre has now been established in the South 
West Peninsula. 
Signed Dated... 
Copyright Statement 
This copy of the thesis has been supplied on the condition that anyone who 
consults it recognises that its copyright rests v i^th the author and that no 
quotation from the thesis or information derived from it may be published 
without prior consent. 
Abstract 
The papers on which this thesis is based are the result of original research work 
undertaken in collaboration with healthcare researchers in the South West 
Peninsula. Modern healthcare research involves large scale multidisciplinary 
projects and the Statistician's role In these projects, from concept through 
design and execution to the production of published papers, is crucial. Funding 
bodies, and in particular the Medical Research Council (MRC), expect a 
Statistician to be part of the project team and the statistical input and expertise 
included plays a key role in determining whether or not projects are funded and 
are subsequently successful. 
The selection of papers concentrates on work in the specialty of Neurology, 
which forms the major part of the thesis, a trial of a complementary therapy in 
General Practice, work in Primary Dental Care and work in the Anaesthetics 
and Histopathology departments in Plymouth. Some of the papers are the 
outcomes resulting from NHS researchers approaching the candidate for 
statistical advice and assistance to support their clinical work In the South West 
Peninsula. Funding in 1997 enabled a small group of Statisticians In Plymouth 
to set up a Statistical Support Service for researchers in health care across the 
South West Peninsula. Clinical researchers have taken the opportunity to 
consult a statistician with regard to the design, execution, analysis and reporting 
of their research work over the past eight years and, whilst many consultations 
progress the researcher's work but are not major undertakings, a sizeable 
proportion have developed into significant contributions to the body of 
knowledge In the clinical specialty. 
The paper reporting the results of. Phase I of a trial on the use of Cannabinoids 
in Multiple Sclerosis (CAMS) has become a major reference work In Neurology 
and also specialties where pain relief is important, such as cancer. This was a 
high profile project partly as a result of the nature of the treatment and partly 
because of the type of patients involved. Anecdotal reporting often suggests 
alternative therapy to treating physicians but many of these remain untested 
and. in the evidence-based and cost conscious world, are increasingly coming 
under scrutiny using a scientific approach. The nature of this particular 
treatment necessitated extreme caution at every stage of the trial and the 
candidate was part of the Thai Management Group from inception to 
completion. This submission also includes a paper reporting the Phase II results 
and a further paper on chemical markers relating to the treatment. 
11 
With the emphasis on prevention in Health Care, more research is emanating 
from researchers in Primary Care and this is represented here by the results of 
a trial on the use of the common stinging nettle to treat arthritic pain in the 
thumb, and by work on anxiety in Dental Clinics. 
The remaining papers look at applications in radiology and histopathology, the 
laboratory based research on which clinical decisions so often depend but 
which frequently fails to grab the headline news. 
These papers represent just some of the output from my part in the developing 
role of the Medical Statistics group in the clinical research of the South West 
Peninsula. 
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Critical Appraisal 
A. Introduction 
It has long been accepted by scientists that their findings need to be evidenced 
by robust statistical analysis but the routine use of statistical methodology in 
medicine is a far more recent phenomenon. Despite the origins of many 
statistical methods being firmly rooted in clinical experimentation and practice, 
clinicians have frequently argued their preference for particular courses of 
treatment on the grounds of tradition and, all too often, anecdotal evidence. 
The prevailing emphasis on evidence-based medicine nationally and 
internationally is a strong driver for published research to be based on sound 
statistical principles in design, execution and analysis. However, healthcare 
professionals, even those involved in important research projects, are often 
lacking in understanding of these p r i n c i p l e s . W h i l s t the larger teaching 
hospitals have employed statisticians for well over a quarter of a century, the 
peripheral district general hospitals and the primary care sectors have been 
sadly lacking in resources on which to call in order to progress their, perhaps 
lower profile but nonetheless important, research. This problem is compounded 
by weaknesses in the reviewing process^ and the lack of statistical expertise 
and depth of scrutiny applied to journal submissions. 
Prior to 1996, statisticians at the University of Plymouth supported medical 
research on an ad-hoc basis. This was unsatisfactory in many ways; with no 
formal links, allocation of time to a project was usually given a low priority; with 
no direct link to the University, clinicians often attempted the statistical work 
themselves without the necessary expertise to design, collect and analyse 
appropriately and would bring along unsuitable designs or poor quality data or 
both; there was no clear structure and a lack of communication between 
statisticians sometimes resulted in repetition of parts of the work. Such a 
piecemeal approach often led to the results remaining unpublished as there was 
also not sufficient career incentive for those clinicians to write up their work. 
More recently, a move within the NHS to restructure career progression for 
clinicians has given more researchers the impetus to seek to publish their work. 
Faced with increasing demand for support, a group of Statisticians (Hilary 
Sanders. Steve Shaw and Dave Wright) from University of Plymouth set up a 
statistical service for local NHS researchers within the South and West of 
Devon, and Cornwall. With the aid of funding from the Cullyer Research 
allocation, we set up weekly statistical advice clinics. The success of this 
initiative is evidenced by published output in peer-reviewed medical journals 
and funding in excess of £3m from the Medical Research Council. Within 
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Plymouth we now have the experience and reputation from which a nationally 
recognised clinical trials unit can be formed. This submission is based on 
outputs arising from this support work. 
The selection of papers has been chosen to demonstrate the diversity of 
specialists with whom I have published work and the range of statistical 
methods used. Anyone involved in research will recognise that the published 
paper is the ultimate output from substantial work on design, execution, analysis 
and reporting. The statistical input given to these aspects is considerable and 
has been emphasised in the textual commentary given for each output. The 
papers are presented^in the order chosen to represent the significance of the 
work involved rather than In a chronology. 
The most substantial statistical contribution by the candidate in the papers 
presented here was made to the clinical trial of Cannabinoids in Multiple 
Sclerosis. CAMS, which was completed in 2003. CAMS was a multicentre 
studies, a facet which brings its own statistical problems - consistency across 
upwards of 30 acute hospitals in each case, with respect to selection, 
recruitment and assessment of the subjects, logistic challenges for the 
distribution of treatment and paperwork, and the coordination of the resulting 
data. The statistical features of this project are discussed in more detail 
following the critical appraisal section. 
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B. A Multicentre Clinical Trial 
1. Zajicek, J., Fox, P.. Sanders, H., Wright, D., Vickery, J., Nunn, A. and 
Thompson, A. (2003). Cannabinoids for treatment of spasticity and other 
symptoms related to multiple sclerosis (CAMS study): multicentre 
randomised placebo-controlled trial. The Lancet, 362: 1517- 1526. 
Contribution by candidate: 
The CAMS study was the outcome of an enquiry to the Statistics Clinic 
regarding the prospect of investigating the possible therapeutic benefits of 
cannabinoids to patients suffering from the debilitating disease. Multiple 
Sclerosis. Consultant Neurologist, John Zajicek, approached me with an idea 
for a clinical trial in this area. After careful consideration of the rationale of the 
design, an application was submitted to the Medical Research Council (MRC) 
for funding. I was a named applicant (one of four, the others being John 
Zajicek, Alan Thompson, a consultant neurologist at Queen Square, London 
and Andrew Nunn, MRC representative) and Dave Wright provided additional 
statistical support. A grant of £1.2m was awarded in January 2000 and a study 
team was set up. I was largely responsible for designing the clinical record 
forms (CRFs) for the study, collaborated in the production of the protocol and 
eventual running of the trial over the next three years. Including regular 
reporting to the Trial Steering Committee and production of various submissions 
to regulatory authorities. Also crucial to the completion of the trial was the 
collaboration with the pharmaceutical company, Solvay, who supplied the 
medication and the Institute for Clinical Research, IKF, Berlin, instrumental in 
the initial production of one of the treatment constituents. 
This was a high profile trial, by virtue of the cannabinoid element in the 
interventions, both from the novel use of an illegal substance and the timing of 
the decision by the Home Secretary to downgrade the classification of 
cannabis. There was also much interest in treatments which might be 
therapeutic in symptom relief, particularly at a time when NICE had 
recommended that Beta-interferon should not be made available to all Multiple 
Sclerosis patients. Three papers resulted from this work. The first was a key 
paper in a top journal which has already been cited by 119 other published 
articles, in 26 countries and 34 other clinical specialties although principally in 
the areas of MS and pain control for cancer patients. The second paper, 
reporting the results of following the trial participants for up to a year, is pf 
interest mainly because of the safety aspects, although there was encouraging 
evidence that the longer term benefits might be greater than initially supposed. 
There is much interest still in the part played by the placebo in trials of this kind 
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and It is expected that a paper on the placebo effect will also be published in the 
future. The third paper, using data from some of the participants in this trial, also 
relates to safety in the sense that chennical markers showed no change from the 
use of the treatments. The work published on the CAMS study has led to further 
MRC funding (CUPID trial £2m) to investigate possible delays in disease 
progression by the use of cannabinoids. 
I worked on all stages of the CAMS trial from the Initial grant application to the 
reporting of findings. Once the grant had been awarded, I then played a major 
role in getting the trial started including the appointment of staff. Being a high 
profile multicentre trial (33 centres in the UK) using treatments not previously 
trialled on a large scale, there were many logistical issues to be resolved before 
the trial could even commence, most having major statistical Implications In 
order to avoid potential sources of bias, ranging from the labelling and 
distribution of the treatment drugs and the randomisation of patients, to the 
training of the assessors across the country. 
Once a trial coordinator and data manger were appointed In June 2000, they 
were able to take on the day-to-day preparation for the trial to enrol the first 
patients In Plymouth In December 2000. Indications were that all the 
paperwork, CRFs and Query Notifications, and other procedures would be 
practicable and the trial started recruiting patients from other centres. 
Recruitment was highly successful thanks to a highly motivated team and, of 
course, the eagerness of this group of patients to participate in a clinical trial. 
Every six months during the conduct of the trial, the Trial Steering Committee, 
consisting of representatives from the MRC, the Multiple Sclerosis Society, and 
Independent Neurologists and Epidemiologists, reviewed all aspects of 
progress, and I oversaw the production of routine summaries e.g. number of 
patients from each centre, reports of missing data, adverse events etc. for 
presentation at those review meetings. The Committee was consistently 
pleased with the various statistical analyses and reports presented at these 
reviews. 
During the patient recruitment and data collection phases, the design and 
Implementation of robust systems for continuous monitoring enabled Impressive 
97% and 9 1 % records for completeness of data, on the primary and secondary 
outcome measures respectively, to be achieved, an Important Indication of a 
high quality trial. The final data was then subjected to a blind data review. 
I S 
Almost 2000 items of data were collected on each of the 660 patients in the 
trial, two-thirds of whom were, by design, taking a class of so-called 
'recreational' drugs only recently down-classified by the Home Secretary, 
making the final analysis a significant statistical challenge, and needing novel 
statistical approaches both in execution and interpretation. The results were 
presented to investigators prior to publication at a meeting in Torquay in 
September 2003. 
Statistical analysis was carried out using SAS Version 8e and S-Plus 2000 
Professional software. The results were published In the paper in November 
2003, but were presented ahead of publication to the investigators at a meeting 
in Torquay in September 2003. There was much discussion at that meeting as 
to the implications of the failure to find evidence of an effect on the primary 
outcome, spasticity as measured by the more objective Ashworth Scale, whilst 
at the same time the finding that patients in the trial on active treatments felt 
they had improved as determined by several subjective scales. It is my belief 
that the findings clearly demonstrate that patients involved in this trial, and 
probably any other clinical trial, benefitted markedly from the additional care and 
attention given to them by investigators and their supporting staff, and from the 
encouragement given by the Trial Coordinating Office staff through telephone 
and postal contact. 
The CAMS project was a clinical trial of a treatment hitherto untrialled on a 
substantial scale in a study population who are chronically disabled by the 
progressive nature of their disease Several charitable organisations (including 
the MS Society and the MS Trust) also had a particular interest in the results of 
the. trial as there is currently no cure for MS and the health burden in the UK 
falling on the NHS and carers is considerable. Researchers, both in the UK and 
abroad, specialising in other chronic and debilitating diseases such as cancer 
and Parkinson's have built upon the knowledge gleaned from the CAMS trial, 
particularly in the management of pain. 
Citations 119 
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C. Follow-up CAMS Study 
Zajicek. J.P., Sanders, H.P., Wright, D.E.. Vickery. P.J., Ingram, W.M., 
Reilly, S.M.. Nunn. A.J., Teare. L.J.. Fox, P.J. and Thompson, A. J. (2005). 
Cannabinoids in Multiple Sclerosis (CAMS) Study; safety and efficacy for 12 
months follow-up. J. Neurology, Neurosurgery and Psychiatry, 76 1664 -
1669. 
Contribution by candidate: All aspects of the design of the trial, development 
of the grant application, trial protocol, clinical record forms, data management 
systems, all statistical analysis and writing of journal papers as given for the 
paper above. This was a continuation of the above project to a total of 52 
weeks of treatment, principally to examine safety aspects of the use of 
cannabinoids in Multiple Sclerosis. 
The design of the trial was such that patients chose at the end of Phase I 
whether or not they wished to continue from the initial 13 weeks to a maximum 
of 52 weeks on their trial medication. As such the design no longer comprised a 
random allocation to three treatment groups. It was likely that those patients 
who reported an effect due to treatment were, in fact, on active treatment and 
would wish to continue. In fact, only a marginally smaller proportion of the 
placebo group opted to continue longer term. A full explanation of the results is 
given in the paper. 
Citations 17 
20 
D. CAMS Chemical Marker Paper 
3. Katona, S.-, Kaminski. E.. Sanders, H. and Zajicek, J. (2005). Cannabinoid 
influence on cytokine profile in multiple sclerosis. Clinical and Experimental 
Immunology, 140: 580 - 585. 
Contribution by candidate: All statistical analysis of the small subgroup 
(Plymouth patients only) from the CAMS study with particular reference to the 
chemical markers which might be depleted under treatment by cannabinoids. 
Applied statistical methodology was used here in a clinical area of increasing 
Importance, particularly where the burden of long-term disease presents the UK 
with a substantial economic problem. 
Citations 5 
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E. Acute Health Care 
The following 4 papers submitted are in acute health care and demonstrate 
basic applications of medical statistics to local problems. 
4. Dimpel, H.L.. Sneyd, J.R., Sanders, H. and Dennis, I. (1999). Oxygen 
administration and explicit memory: no improvement found in healthy 
volunteers. British Journal of Anaesthetics, 83: 801 - 804. 
Contribution by candidate: All statistical analysis, discussion and reporting of 
results. 
This study, by an anaesthetist, investigating the effect of receiving oxygen on 
memory, had a cross-over design. Such a design means that fewer subjects 
are required to achieve appropriate statistical power and it is particularly useful 
in situations where recruitment is difficult. In this study, healthy non-smoking 
volunteers were recruited, surprisingly hard to find in an acute hospital, and the 
primary outcome was remembered words from a given list. An analysis using a 
non-parametric test showed no evidence of improvement in memory with 
oxygen administration. The results section should have included the median 
(not mean) number of words which would have been consistent with the Mann-
Whitney test, but the journal preference was for means and ranges - just one of 
the idiosyncrasies of some medical journal editors! 
Elford, J., Wells, I.. Cowie. J., Hurlock, C. and Sanders. H. (2000). 
Computerised strain-gauge plethysmography - an alternative method for the 
detection of lower limb deep vein thrombosis. Clinical Radiology, 55: 36 - 39. 
Contribution by candidate: All statistical analysis, discussion and reporting of 
results. 
This work shows standard statistical methods applied to a study using a new 
piece of equipment to detect deep vein thrombosis (DVT) in the lower limb. 
Being a difficult condition to diagnose accurately using clinical examination 
alone, patients are usually exposed to additional invasive, or potentially 
hazardous, procedures for confirmation of DVT. Manufacturers of the Belfast 
DVT Screener claimed very high sensitivity for the device coupled with 
extremely low false negative rates - a highly desirable situation, which could 
reduce hospital stay and pressure on beds. However, this study, independent 
of any commercial interest, estimated that the false negative rate was between 
6.6% and 24.3% (95% Confidence Interval) - far higher than the current 
accepted gold standard of 4.4%. 
Citations 4 
6. Hilton, D.A., Penney, M., Pobereskin, L., Sanders, H. and Love, S. (2004). 
Histological indicators of prognosis in glioblastomas: retinoblastoma protein 
expression and oligidendroglial differentiation indicate improved survival. 
Histopathology, 44(6): 555 - 560. 
Contribution by candidate: All statistical analysis, discussion and reporting of 
results. 
Citations 3 
7. Hilton, D.A., Penney, M., Evans, B. and Sanders, H. and Love, 8. (2002). 
Evaluation of Molecular Markers in Low-Grade Diffuse Astrocytomas: Loss 
of p16 and Retinoblastoma protein is associated with short survival. 
American Journal of Surgical Pathology, 26(4): 472 - 478. 
Contribution by candidate: All statistical analysis, discussion and reporting of 
results. 
Citations 10 
These two papers (Nos. 6 and 7) by essentially the same group of researchers 
are examples of laboratory-based research. This work was of interest because 
of the growing need to find survival indicators for cancer patients. It is hoped 
that the ultimate goal of cures for such diseases may be a step nearer as a 
result of studies such as this. 
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F. Research in Primary Care 
The remaining three papers submitted are the results from projects in Primary 
Care in Plymouth and Torbay. There is increasing scope for research in the 
Primary Care sector as the Department of Health introduces more initiatives to 
encourage General Practitioners to treat patients within their practices rather 
than refer to Acute Hospital Care. 
8. Randall, H., Dobbs. F., Hutton, C. and Sanders, H. (2000). Randomised 
controlled trial of nettle sting for treatment of base-of-thumb pain. Journal of 
the Royal Society of Medicine, 93: 305 - 309. 
Contribution by candidate: All statistical analysis, discussion and reporting of 
results. 
This is an example of a contribution which did not begin until after the design 
and completion of the trial. Frequently a clinical researcher will not have had 
statistical input at the design stage, often giving results which are, at best, 
lacking in scientific rigour. Fortunately, this was not the case with this study 
which generated interest in an alternative therapy - first reported by the 
Romans, but with little recent scientific evidence of efficacy - for a common 
source of disability. Cross-over designs for trials make efficient use of a limited 
number of subjects where the aim of therapy is alleviation of symptoms for a 
chronic condition such as in this case. 
Citations 11 
9. Baker, R. A., Farrer, S., Perkins. V. J. and Sanders, H. (2006). Emergency 
Dental Clinic Patients in South Devon, their Anxiety Levels, expressed 
demand for treatment under sedation and suitability for management under 
sedation. Primary Dental Care, 13: 11 -18 . 
Contribution by candidate: All statistical analysis, discussion and reporting of 
results. 
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10. Baker, R. A., Anthony. L. and Sanders, H. (2006). An audit of the quality of 
a referral document, designed In accordance with Scottish Intercollegiate 
Guidelines Network, for paediatric exodontias under general anaesthesia. 
InternationalJournal of Paediatric Dentistry, 16: 307 - 308. 
Contribution by candidate: All statistical analysis, discussion and reporting of 
results. 
Papers 9 and 10 are examples of research in the Primary Dental Care service 
where a Dental Practitioner's research has been motivated partly by a huge 
increase in the number of patients due to recent initiatives by the Department of 
Health and a desire to treat them more effectively. 
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References for Critical Appraisal 
Altman, D.. Goodman, S. and Schroter, D. (2002). How Statistical 
Expertise is used in Medical Research. Journal of the American Medical 
Association: 287 (21). 2817-2820. 
Sterne, J. and Smith, G. (2001). Sifting the evidence - what's wrong with 
significance tests? British MedicalJournal: 322, 226-231. 
Bacchetti, P. (2002). Peer review of statistics in medical research: the 
other problem. British MedicalJournal: 324. 1271-1273. 
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statistical features of the main CAMS papers 
A number of statistical aspects of the CAMS papers are now discussed in more 
detail; the published statistical sections report mainly only sample size and 
results of analysis whereas this section describes the background work needed 
to obtain the various results around which the papers were written. 
1. Design 
1.1 Outcome measure 
The CAMS project was a Randomised Controlled Trial to assess the efficacy of 
cannabis-based treatment on a group of patients who had a wide range of 
symptoms with varying severity and debilitating effects as a result of Multiple 
Sclerosis. Some people suffer for periods of years with the effects of this 
disease and it is understandable that a proportion of these are driven to try 
alternative therapies when conventional medicines seem to be ineffectual. 
However, because of the wide range of symptoms, there was much debate at 
the design stage of the project as to what should constitute the primary outcome 
measure and, indeed, what was the most clinically important symptom affecting 
the lives of the patients. It is reflective of this feature that, at the time of the 
design, there were a large number of outcome measures, both patient-based 
and assessor-based, which had been used in the previous small trials in this 
area but that none predominated as the preferred outcome. The symptom 
which most affected patients, as reported to their clinicians, was spasticity, the 
'stiffness' of muscles, and a number of appropriate and validated scoring 
systems related to the effects of this and other symptoms were considered. For 
example, scales such as the Kurtzke Expanded Disability Status Scale (EDSS) 
and the Rivermead Mobility Index were discussed in addition to the Ashworth 
Score, as well as a straightforward time to walk a set distance plus a number of 
other measures which were patient-based, mainly self completion 
questionnaires [refs. 21, 25, 28,29 in Phase 1 paper]. 
The EDSS is a scale, progressing in steps of 0.5 from 0 to 9 where 0 indicates a 
normal neurological examination and 9 a helpless bed-bound patient through 
various descriptions, based on both ambulatory ability and functional disability. 
Whilst this had been used for several trials previously, it has the disadvantage 
of being restricted in practice for Multiple Sclerosis patients to a range of around 
3 to 7 and patients are unlikely to progress between points on the scale very 
quickly. In addition, a movement from classification of a patient from 3 to 4 
could not necessarily be regarded as equivalent to a change from 5 to 6, so this 
has all the disadvantages of an ordinal scale. 
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The Rivermead Mobility Index Is a roughly graded list of 15 dichotomous 
questions concerning mobility, ranging from whether a patient can turn over in 
bed without help to whether a fast walk for 10 metres is possible. This also is 
an aspect of patients' lives for which the change would be fairly long term. 
A limed walk was considered where patients would be timed over the middle 10 
metres of a 15 metre walk. The advantage of this measure is its objective and 
continuous nature which would lend itself to robust analysis using parametric 
techniques. However, it was expected that approximately half of all the group of 
patients likely to be recruited to this trial would be unable to walk at all thus 
increasing the total elapsed time for the trial considerably to achieve a 
reasonable sample size. In the event, the primary outcome could be examined 
for the two groups, ambulatory and non-ambulatory, giving more information on 
the groups and as a whole. The practicality of obtaining a 15 metre space for 
this assessment in all of the centres was also discussed in the light of hard-
pressed local facilities for clinics. 
Both the Rivermead and EDSS. as measures of disability, and a timed walk, 
were used as secondary outcomes. 
The outcome measure finally decided upon was the Ashworth [refs. 20, 30 In 
Phase 1 paper]. The Ashworth score is a summation over 20 muscle groups of 
an assessment by physician or physiotherapist of each muscle on a scale of 0 
to 4, where 0 represents no spasticity (stiffness) and an assessment of 4 
indicates a completely rigid muscle group. This scale therefore ranges 
theoretically from 0 to 80. There were both statistical and practical issues 
associated with using this as. the prirnary outcome but overall I think this was 
the appropriate choice. Each component of the Ashworth is a subjective 
assessment giving 20 ordinal variables which, when summed, were assumed in 
the literature to result in a variable that could be treated as Normally distributed. 
This assumption was comprehensively verified by considering a number of 
subsets of components in addition to the entire score. Muscle groups were 
from each side of the body so a left and right body score was constructed; also 
an upper and lower body score was of clinical interest for this group of patients 
in view of the mobility issues. 
This is the standard approach taken to produce Ashworth scores [ref. 20 in the 
Lancet paper]. Similar approaches are found in many applications, for example 
the SP36 Health Questionnaire (Jenkinson et al, 1996; McDowell and Newell, 
1996) used to assess quality of life (one of the secondary outcomes in CAMS), 
and the HADS (Hospital Anxiety and Depression Scale) used to assess general 
mood and well-being originally in a hospital outpatient setting (Zigmond and 
Snaith, 1983). A check for Normality was made before the recruitment of any 
patients to the study on a small pilot group of patients who were at a routine 
visit to the centre in Plymouth; a further check was made when almost 50% of 
the patients had been recruited and, naturally, at the end of the Phase 1 of the 
trial according to the Statistical Analysis Plan. Practical issues (later described 
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under Randomisation) dictated that there would be two visits by each patient 
before treatment was commenced. This gave an opportunity to check the 
consistency and distributional assumptions of the measure. 
The primary outcome was the change in total Ashworth from baseline (taken to 
be the mean of the two pre-treatment visits 1 and 2) to the end of Phase 1 (visit 
7) and assumptions were checked for this variable for the total score and the 
various subsets. A selection of graphical displays produced at the end of the 
recruitment period is presented in Figure 1 overleaf. These and the results of 
other analyses informed the final analysis plan. 
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Figure 1: Examples of Distributional checks on difference in Ashworth 
score from baseline to the end of Phase 1 of the trial 
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Figure 2: Examples of checks for consistency of the baseline visits after 
approximately 50% of patients had been recruited. 
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Following the publication of the CAIVIS paper, the use of a model-based 
approach was explored that recognises the ordinal nature of the item data. This 
is described section 3.4. 
A practical difficulty was that this scale is not routinely used as a clinical 
measure in all centres and a training programme was therefore necessary to 
ensure consistency across assessors. As the trial recruitment lasted for nearly 
two years, it was also vital that consistency was maintained for the whole 
period. 
To ensure that assessors at each centre were familiar with using the scale, the 
team's Specialist Registrar recorded a videotape alongside a written 'aide-
memoire' which was included in the training days given prior to recruitment in 
different regions of the country. Before entering patients to the study, all 
assessors from each centre were required to attend a regional training day. 
Each of these sessions included the use of the video, individual training by an 
experienced physiotherapist and hands-on practice for the trainee. Practice 
back at the centre was then expected before the centre entered patients on to 
the trial and if there were subsequent queries then the trainer was available by 
telephone to answer queries. Monitoring also took place by the Trial Co-
ordinator and her deputy during the trial period. 
Owing to the nature of the scale, it was clearly necessary to examine 
consistency in more detail and, following advice from the Trial Steering 
Committee, a small study was set up involving two centres in which the same 
patients were assessed by both recently trained assessors and the experienced 
physiotherapist from the Trial Co-ordinating Centre in Plymouth. The centres 
were chosen on a pragmatic basis, with respect to scheduling the visits. The 
TCC physiotherapist visited two clinic sessions at each of two centres, Lincoln 
and Newcastle, and assessed the same patients as the resident assessor, the 
patients being assessed at their Visit? and Visit8. Schematically, the design is 
illustrated in Figure 3 overleaf. 
To assess variation between centres, assessors within centres and patients the 
total Ashworth score was analysed using a mixed effects ANOVA model. A 
breakdown of the upper/lower body and left/right side muscle groups was also 
examined using the same approach. 
Figure 3: A designed experiment to verify consistency across assessors 
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Table 1 below summarises the results from the two centres. 
Table 1: Means & SD's of Ashworth scores by muscle group, centre and 
assessor. 
Muscle 
Groups 
Lincoln Newcastle 
T C C PhysiQ(P) Centre 
AssessortCA) 
DiHerence 
(P-CA) 
T C C Physio(P) Centre 
Assessor(CA) 
Difference 
(P-CA) 
Mean SO Mean SD Mean S D Mean S D Mean SD Mean SD 
Total 18.6 8.11 17.9 10.80 0.7 4.40 18.8 9.91 20.9 13.82 -2.1 7.72 
Right 8.4 4.28 9.4 6.28 -1.0 3.80 9.0 4.47 10.4 6.70 -1.4 4.14 
Left 10.2 4.73 8.5 4.80 1.7 2.26 9.8 5.90 10.5 7.73 -0.8 4.80 
Lower 13.8 7.10 13.8 7.96 0 1.94 12.1 7.62 16.1 10.70 -4.0 5.95 
Upper 4.8 2.49 4.1 4.20 0.7 3.59 6.6 4.03 4.75 4.46 1.9 4.20 
With reference to the table above, the variations in total Ashworth scores for all 
muscle groups were consistent with the published literature (UK Tizanidine. 
Group, 1994 and Smith et al, 1994), on which the sample size calculations were 
based, and, whilst there were some differences between assessors for 
individual muscle groups on individual patients, their total Ashworth scores 
tended to be consistent. 
The general aim of this type of study is to examine relative biases between 
operators and assess the extent of measurement errors. The latter can be 
achieved by estimating the error variance and comparing it with the so called 
true score variance within a classical measurement model (see. for example. 
Dunn, 2004). 
Clearly, with just three assessors and a total of 9 patients across the two 
centres, this study lacks precision and power serving to identify any gross 
relative biases between assessors and giving an estimate of inter-assessor 
reliability and measurement error variance; hopefully providing reassurance that 
the Ashworth measurements in this study are consistent with published 
evidence. 
The model used was Total Ashworth score as response, with Centre. Assessor 
and Visit as fixed effects, and Patient within Centre as random effects. 
Using a mixed effects ANOVA model for the total Ashworth score there was no 
evidence of any systematic differences in mean scores between centres 
(P=0.832), between local assessor and TCC physiotherapist (P=0.699) or 
between visits (P=0.932). 
There was also no evidence of interactions between any of the terms in the 
model (all other P values were >0.20) 
Appendix 1 shows the results for the Total Ashworth score, from which the 
following information is extracted. 
Variance Components, using Adjusted SS 
Source Estimated Value 
Patient{Centre) 100.970 
Ass_Trai*Patient(Centre) 8.217 
Visit'Patient(Centre) 9.325 
Error 11.278 
The estimated error variance from the study was 11.278 and the Inter-rater 
reliability coefficient, which represents the ratio of true score variance to error 
variance, was 0.83. These compare favourably with the published evidence on 
which the study was based [refs 20. 30 from the Lancet paper]. Nuyens et 
al.(1994) determined a value of 0.55 - 0.60, using Kendall's T . as the likely 
range of reliability of the Ashworth score. 
Applying the model to the right side, left side, lower and upper body muscle 
groups in turn also showed no systematic differences as for the mean total 
score. There were, however, statistically significant interactions in the lower 
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body score" between the patient and assessor, and between the patient and visit 
(P values <0.01). each of which accounted for less than 10% of the total 
variation of the random effects in the model for lower body scores. The above 
results generally supported our assumptions regarding the use of the Ashworth 
score for assessments. 
1.2 Patient-based measures 
At the time of the trial design, the Ashworth scale was considered by the trial 
team to be the most appropriate outcome measure, and some of the possible 
alternatives have already been discussed. However, these are ail assessor-
based variables and a strong argument could be made that a patient-based 
measure should have been used, particularly in the light of the previous few 
small studies having used a wide variety of scales. Several patient-based 
measures were included as secondary outcomes - the General Health 
Questionnaire (GHQ-30), the UK Neurology Disability Scale (UKNDS). the 
Barthel Index (a Disability scale), the King's Health Questionnaire and a series 
of Category Rating Scales (CRS) on symptoms such as pain, spasticity, tremor, 
etc. One of my reservations about these measures was the quantity of different 
questionnaires which the patients were expected to complete and I advised that 
these should be cut to a minimum. The large number of outcomes included 
was also problematic from data management and statistical perspectives. 
However, throughout the trial and especially in the design stage, the clinical 
members of the team were adamant that this group of patients would willingly 
complete any number of questionnaires and submit to batteries of clinical 
procedures due to the lack of effective therapies and that there would be no 
compromise in the quality of the data obtained. Some middle ground was 
realised in that patients were required to complete fewer repetitions of the 
instrument than originally proposed, but this number of instruments is far from 
ideal. The fact that none of these validated scales were designed specifically 
for MS was a major hurdle and. of course, a mix and match or custom designed 
instrument was not an option in the time scale involved. There was also an 
issue of the mood-enhancing properties of the active drugs which made an as 
objective as possible measure the preferred option. It is relevant to note here 
that more recently one of the Neurological international bodies has given some 
guidelines for use of new instruments in MS trials. 
As the result of a two-year process of discussion and data analysis, the task 
force recommended the Multiple Sclerosis Functional Composite (MSFC) as a 
new clinical outcome measure for future MS trials. MSFC consists of timed tests 
of walking, arm function, and cognitive function, expressed as a single score 
along a continuous scale. The task force recommended that MSFC be included 
in future MS trials, and recommended a series of validation studies. Subsequent 
studies have provided evidence that MSFC correlates moderately with 
Expanded Disability Status Scale (EDSS), and that correlation is driven by 
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strong correlations with the ambulatory function component; arm function and 
cognitive function correlate at lower levels with EDSS. The MSFC correlates 
better than EDSS with magnetic resonance imaging (MRI) variables, including 
brain atrophy, and shows significant correlation with patient-reported disease-
related quality of life (QOL). MSFC and short-term change in MSFC correlate 
with future clinical and MRI status, and the strength of the correlations 
compares favourably with well-known cardiovascular risk factors. The studies in 
aggregate indicate that MSFC and MSFC change are clinically meaningful, and 
that MSFC has substantial advantages over alternative clinical outcome 
measures for MS clinical trials (Rudick et al, 2002). 
With hindsight, the quality of the data collected and the commitment of staff and 
patients alike to give good quality complete responses may have mitigated in 
favour of a patient-based measure being the primary outcome but there was no 
scientific evidence and limited anecdotal information at the outset to make such 
a judgement and the prior call would have been poorer quality and incomplete 
data if a patient-based measure had been used. 
1.3 Intention to treat analysis 
The CAMS trial data was analysed on the intention-to-treat principle, the 
accepted standard for RCT's and recommended by the ICH guidelines. 
Analysis by this principle means the Inclusion of all randomised patients In the 
groups to which they were assigned regardless of the treatment they actually 
received or their non-compliance with the trial protocol for the entire period of 
the trial. The arguments in favour of this principle are that it guards against bias 
when drop-out is possibly related to outcome, that it obviates the need to 
consider how to analyse unusual observations and that the baseline 
comparability is preserved. However, whilst this may be the ideal, in practice it 
is rarely achievable and the aim is for as complete a data set as Is practicably 
possible. 
I believe in the case of the CAMS trial, which was double blinded, that the 
exclusion of a small number of patients who took no medication post-
randomisation was completely justifiable and did. in fact, mean that the data set 
analysed was the closest to the Intention to treat data set as was practically 
achievable. 
821 potential participants were screened and. of these. 154 were found to be 
not recruilable for a variety of reasons. The remaining 667 were asked to 
attend the first baseline visit at their respective local centres, at which informed 
consent was taken, eligibility in terms of history, etc, checked and the first 
Ashworth scores recorded. The appropriate forms were subsequently sent to 
the TCC, checked by the Trial Coordinating Team and 10 patients were then 
excluded for reasons of incorrectly judged eligibility. 
36 
The reason for two baseline visits was principally a practical one, to enable 
medication to be packaged in optimal quantities for individual participants based 
on their weight, and after the enrolment details and eligibility had been checked, 
the participant was randomised in readiness for their second baseline visit. Just 
prior to the second visit, the medication was dispatched to the participant's local 
centre ready for collection at visit 2 as long as eligibility criteria were still 
satisfied. Hence, at visit 2, the eligibility criteria were re-checked and the 
participants' Ashworlh score recorded. After this visit, the completed form was 
sent to the TCC. A number of participants became ineligible between visits 1 
and 2, mostly owing to changes in disease or usual medication or a change of 
willingness to take part, although the date of birth of one participant was found 
to have been incorrectly recorded at his local centre and two patients were 
found to have had their disease history incorrectly recorded at the first visit and 
did not subsequently receive their trial treatment. These patients would be part 
of an intention to treat analysis under the ideal definition but were also excluded 
from this intention to treat analysis. It is this group which could be regarded as 
the departure from the intention to treat analysis. There were similar numbers 
in the three arms (8, 10 and 9 in Cannabis extract, THC and placebo 
respectively) and at this point in the trial it was not possible for any treating 
physician or assessor (or patient) to have any notion of the treatment allocation 
to any individual. 
The reasons for exclusion were all related to eligibility (Ashworth score too low, 
patient too old, unstable disease, other serious illness) apart from a small 
number in each group (2 ,1 ,1) where the patient had changed their mind about 
taking part in the trial. There were also no outcome measurements other than 
the baseline measurements of the Ashworth, Rivermead and a timed walk. At 
the completion of the first phase of the trial there was a blind data review at 
which all the study participants were classified according to the definitions in 
Appendix 2 (extracted from the original CAMS Statistical Analysis Plan) of this 
chapter. 
So the interpretation of intention to treat in this trial was the result of a reflection 
of the actual conduct at the second baseline visit. From a philosophical 
viewpoint, a well-designed trial with no discernible bias should be our ultimate 
goal and I believe that as a considerable effort put into ensuring as little missing 
data as possible (only 3% of the primary outcome data was missing), the 
potential for bias was minimised. 
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1.4 Randomisation methods 
Prior lo commencement of the trial all Neurology centres in the UK were invited 
to participate in the. trial and to estimate how many subjects they were likely to 
be able to recruit. Some centres, usually in less densely populated locations, 
expected to recruit only a small number of subjects, usually owing to the 
number of patient visits required and stress to the subjects, whereas some 
centres, often in more urban areas, were likely to be constrained only by 
availability of assessors and treating physicians. If we were to obtain three 
arms which had balanced numbers according to the main prognostic factors 
then we needed a method of randomisation which would be flexible enough to 
achieve this but still maintain unpredictability in each centre. Two prognostic 
factors - ambulatory status and centre - were considered important in this trial 
and therefore stochastic minimisation was an appropriate method for use in this 
context. Minimisation is a method of treatment allocation through which an 
approximate balance across several possible prognostic factors can be 
achieved, whilst not allowing any physician to predict allocation for a particular 
individual (Pocock and Simon, 1975). In this trial there was likely to be a 
difference between ambulatory and non-ambulatory patients, and it was also 
desirable that a balance should be achieved across centres. Since some of the 
centres were unlikely to recruit large numbers, blocking could lead to allocations 
being readily predicted. The example overleaf shows how minimisation works. 
The first patient in the trial is allocated simply at random. For each subsequent 
arrival to the allocation scheme, a score is calculated for each treatment arm 
which reflects how 'balanced' the current allocation is in terms of the 
characteristics of this new subject. The simplest scoring system is a count of 
the current numbers in each prognostic grouping. The subject is then allocated 
to the treatment group with the lowest score with a probability > 0.5. thus 
introducing a random element (Altman. 1991). In this trial a probability of 0.7 
(this value minimising the predictability - Buyse and McEntegart, 2004) was 
used for allocation to the treatment arm with the lowest score, and 0.1 for each 
of the remaining three arms. There is thus a better chance of the final sample 
being balanced for the factors required. There has been a lot of debate on the 
merits of minimisation with and without a stochastic element (Weir and Lees, 
2003, Wade et al. 2006) but there is general acceptance that this is better 
practice in a multi-centre trial than stratification methods. 
So, for the CAMS trial, let us assume that the 'current' allocation of 178 
participants is as follows, and the next subject (179*^.) to be allocated is an 
ambulatory subject from centre 2. Then the current state would be as shown in 
Table 2 overleaf. 
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Table 2: Example of allocation 
Treatment 
Factor Level C M P 
Walking Ambulatory 30 28 29 
Non-
ambulatory 31 30 30 
Centre 1 30 31 31 
2 16 14 15 
2 15 13 13 
In arm C, the sum total (score) is 
30 (for ambulatory) + 16 (for centre 2) = 46. This considers a simple count of 
how many similar subjects have been allocated at each of the factors of 
interest. 
Similarly, for M, the score is 28 + 14 = 42, and for P, the score is 29 + 15 = 44 
Hence on a simple count alone, the 179'^. Subject would be allocated to the M 
arm. However, deterministic allocation on this basis is controversial and there 
has been some debate about whether this constitutes a randomization process. 
Treatment allocation would be predictable and so we adopted stochastic 
minimisation by allocation to the arm with the lowest score with probability p 
(=0.7). 
The ICH guidelines advise that randomisation is done centrally for a multicentre 
trial and this, coupled with the minimisation, also had some major logistic 
advantages, namely additional safeguards with regards to the treatment 
allocation and also the dispensing of the treatment medication which was being 
used under Home Office licence and thus under strict pharmacy regulation. If 
too many prognostic factors are used with this method of randomisation then 
the study sample will have the disadvantage of splitting the number of subjects 
into too many subgroups with only a few subjects in each. 
Some researchers would consider the use of minimisation to be overly complex 
but the team were fortunate in being able to customise some software written by 
Professor S. Evans (Queen Mary College. London) (Appendix 3) and in also 
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having a Pharmacist at Derriford Hospital (close to the Trial Coordinating 
Centre) who took responsibility for using this software for the allocation of 
treatment to patients. This ensured the degree of independence necessary, as 
well as the logistic link to the medication. The medication was then able to be 
uniquely packaged according to patient weight and sent to the patient's local 
centre pharmacy. The result of these features was certainly an economic 
saving on time and medication, often used an argument for not using 
minimisation. 
The following procedure was adopted for randomisation of a patient to the trial 
through to the receipt by the patient of the treatment drug for commencement 
on the trial treatment -
A centre who identified an eligible patient at the Screening Visit then telephoned 
the Trial Co-ordinating Centre (TCC) 
The Data Manager/Trial Co-ordinator then logged the patient's name, the 
physician's name and-the centre in the trial register 
The DM/TC then checked the eligibility of the patient by going through each 
item on the Trial Entry form and a Trial Number was then allocated (a 5 digit 
number consisting of 2 digits to identify the centre followed by 3 digits to identify 
the patient within the trial) 
For a patient confirmed as eligible, the physician was then informed that a 
Treatment Collection' visit appointment should be made for up to 4 weeks 
hence (this time period varied and this was the maximum time allowed), by 
which time the appropriate treatment pack would have been received at the 
centre's own pharmacy 
The following details were then entered by the TCC on a proforma -
Patient Name/ID 
Weight 
Trial Number 
Centre 
Ambulatory Status 
Date and Time 
The proforma was then faxed to the Physician and to the pharmacy at 
Derriford 
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At Derriford pharmacy, the details from the proforma were then 
entered into the randomisation programme which indicated by the 
method of minimisation the treatment to which this patient was 
allocated. 
The treatment was then packaged, according to the patient's weight, 
and labelled according to trial number (centre number and patient 
within the trial). This package was then stored by the centre until 
delivery took place within the following 3-4 week period to the 
appropriate centre's pharmacy. 
At the Treatment collection' visit the patient had their Ashworth score 
and 10 metre walk recorded on the appropriate form and then took 
the trial prescription to the centre's pharmacy in order to collect the 
treatment pack 
This procedure had several advantages 
Since the treatment was tailored to the individual patient there was 
neither the need to send out additional treatment packs for heavy 
patients nor the wastage associated with lighter than average 
patients. 
As the treatment was dispatched for patients who had already been 
confirmed as eligible and entered on the trial there would be no 
wastage associated with sending out 'blocks' of treatment packs 
which would then incur part used blocks if centre failed to recruit 
multiples of the block size. 
Similarly there was no cost of retrieving part used blocks of 
treatments at the end of the trial period. 
The responsibility for drug accountability was with the central 
pharmacy at Derriford, although centres clearly had to make suitable 
storage arrangements. 
It was easier to track all treatment drugs from the central pharmacy at 
Derriford since they had sole responsibility for allocation and labelling. 
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The randomisation was carried out by pharmacy staff who were 
independent of the trial management, data collection or clinical 
personnel, thus keeping all trial staff masked as to treatment of 
individuals. 
As there were two visits prior lo the patient commencing treatment, 
additional valuable information was obtained in assessing the 
variability and distributions of the Ashworlh score and walking times 
Although taken at the most pessimistic scenario each delivery was be 
for supplies for one patient only, this did not lend to occur since the 
centres came 'on stream' at staggered Intervals and centres were 
able to organise their treating and assessing resources such that 
several patients were recruited on the same day or in a short time 
interval. Hence the suggested time interval of up to 4 weeks between 
screening and treatment collection visits. 
The interval between screening and treatment collection visits also 
allowed for patients to ask the treating physician further questions 
which may only have become worrying after initial screening. 
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2. Methodoloqv 
2.1 Evidence to combine the placebo groups 
When the CAMS study was originally designed it was intended that there should 
be three arms - cannabis extract, THC and placebo. In the event, it was not 
possible to manufacture the active treatments to be identical capsules so it was 
necessary for each active arm to have its own matched placebo. Matching of 
the active and placebo capsules was undertaken by an independent specialist 
panel of the MRC (Appendix 4). Results indicated that there were no significant 
differences in any feature - shape, taste, appearance, colour or smell - for 
either active treatment and its placebo but for the cannabis extract and placebo 
it was important that the capsules were not chewed as the capsules were 
noticeably different in this case. Therefore a warning was added to the 
instructions issued on all the medication accordingly. 
The specialist MRC panel who compared the colour, appearance, etc of the 
capsules prior to the commencement of the trial regularly perform this service 
as independent assessors and gave their assessment of the similarity of the 
capsules. Ideally, this analysis would have been designed to check for 
equivalence and also to take account of several factors such as batch, subject 
and order effects. This does not appear to have been the case, and thus 
represents a lack of statistical rigour in the analysis as reported by the panel 
(Appendix 4). I failed to examine this report at the time and would now request 
that any future examination of such features would be designed in a more 
rigorous manner. An experiment to test for equivalence would require a 
considerably larger sample than was used by the MRC panel. Six panel 
members were each provided with a very limited sample (two capsules of each 
of the preparations) to be assessed for four different characteristics and 
therefore examined only 48 capsules in total, 12 of each active and placebo 
type. The distribution of comparisons which were different could be considered 
as hypergeometric as stated in one sentence, but there are inconsistencies 
even in the panel's inappropriate analysis such as different p-values being 
reported for identical results. At this stage, it is only possible to reconfigure the 
results of the experiment from the two tables provided, and this is shown in 
Tables 3 and 4 overleaf. 
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Table 3: Comparison of Marinol and 'Marinol Placebo' 
Feature Number of comparisons 
in which unmatched 
capsules were reported 
as different (A) - out of 
24 possible comparisons 
Number of comparisons 
in which the same 
capsules were reported 
as different (B) - out of 
12 possible comparisons 
Colour 2 2 
Shape & 
Appearance 
0 0 
Smell 0 0 
Taste 2 2 
Table 4 :Comparison of Cannador and "Cannador Placebo" 
Feature Number of comparisons 
in which unmatched 
capsules were reported 
as different (A) - out of 
24 possible comparisons 
Number of comparisons 
in which the same 
capsules were reported 
as different (B) - out of 
12 possible comparisons 
Colour 4 0 
Shape & 
Appearance 
8 4 
Smell 0 0 
Taste 4 1 
Inspection of the reconfigured tables indicates that Marinol and its placebo were 
viewed as indistinguishable, but that Cannador and its placebo were slightly 
less indistinguishable. It is perhaps worthwhile noting that there were no 
reports from participants that they could identify their treatment from the 
features of the capsules received - 'guessing' of allocation was from perceived 
benefit or side effects. 
44 
The fact that essentially the trial now had four arms - cannabis extract, 
cannabis extract placebo. THC and THC placebo - in the participant ratio 
2:1:2:1 presented some additional statistical issues to be dealt with before the 
analysis was undertaken. There was a small possibility that the contents of the 
placebo capsules might have been different but it was considered that if this 
unlikely situation arose, it would almost certainly be due to chance and if it did 
the action would be to compare the combined mean of the placebos with the 
two active treatment means as laid down in the protocol. In the event, a 
confidence interval for the primary outcome (95% interval for the Change in 
Total Ashworth score was -2.26. 1.35) confirmed that any difference which 
might exist was small) Similarly, examination of the pre-specified secondary 
outcomes (walk time, Rivermead mobility index and EDSS) in the two placebo 
arms gave no cause for concern, so the data from all placebo patients was from 
then on regarded as one arm. 
2.2 Treatment of missing values 
One of the perennial problems of analysing trial data is deciding what approach 
should be taken to deal with missing data. Whilst the goal of every trial team is 
100% completion, there will always be in practice the need for decisions 
regarding what is not recorded. Prompt data entry and hence timely follow-up 
when missing data was observed enabled a high record of completeness, and 
in CAMS 97% was achieved on the primary outcome with between 84% and 
9 1 % on the secondary outcomes. There are several possible methods, all of 
which aim to give a 'best guess" to each missing observation. The approach 
adopted for the CAMS trial was to carry forward the last observation actually 
made (LVCF - Last Value Carried Forward). This approach assumes that a 
participant would improve gradually as a trial progresses and that the last value 
observed would therefore be a conservative estimate of the state they might 
have achieved if still present at the scheduled end of the trial period. It was 
unlikely, owing to the natural history of MS, that patients would see any upward 
or downward trend In their condition, if not on treatment, in the relatively short 
period of this trial so carrying forward values optimised the observations 
available for analysis. The participants In this trial attended for 7 visits In phase 
1 with titration up, a plateau phase and a titration period down off treatment as 
shown In the diagram overleaf. 
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Figure 4: TRIAL SCHEDULE 
VISIT 1 2 3 4 5 6 7 8 9 10 11 
START OF W E E K -2 1 3 5 6 10 14 16 MONTHS 6 9 12 
•Treating Physician - ; - . 
Screening •/ 
Initial data + randomisation • 
Dose adjustment • • • 
Side effect monitoring • • • • • • • • 
Issue prescription • • • 
Assessor 
Ashworth • • • • • • • • 
RMI • • • • • •/ • • 
10 m walk • • • • • • 
E D S S • • 
Self completion questionnaires • 
GHQ-30 • 
C R S • • 
UKNDS 
Barthel Index • •/ 
Other 
Blood (London Queen Square and 
Plymouth) 
• • • • • • 
Urine (all centres) • • • • • •/ 
( ^ ) — Action dependent on whether patient continues on treatment for the long term phase or not 
-4 
to 
-2 
7 8 
Wee 
10 11 12 13 14 15 
On medication 
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In accordance with the protocol, if the Ashworth, for example, was missing at 
visit 7 then the visit 6 value was carried fonward, and if visit 6 value was missing 
also then the value for visit 5 was used. As a result, 39 scores were carried 
forward, 28 from visit 6 and 11 from visit 5 (12 cannabis extract, 17 THC and 10 
placebo) for the primary outcome. There was no evidence of a difference In 
these proportions in the three groups and being small proportions of the whole 
were unlikely to have had a large impact on the overall results. The reasons 
given by the 11 patients for withdrawing after visit 5 were as follows - 2 felt less 
well (both in Marinol arm). 2 wanted to drive again (1 Cannador and 1 Placebo), 
3 felt more tired (all in Marinol arm) 2 considered being on the trial to be too 
much of an intrusion (1 Cannador and 1 Marinol) and 2 felt no benefit (1 Marinol 
and 1 Placebo). 
Phase II of the trial was an extension of those Phase I participants who wished 
to continue for up to 52 weeks on their allocated medication. It was expected 
that only participants who perceived a benefit from their treatment would wish to 
continue and that this phase would then include only those who were allocated 
to Cannador or Marinol. In the event, the three arms were well balanced as 
shown in Table 5 below, with only slightly more choosing to discontinue 
medication in the placebo group. 
Table 5: Participants by Phase of Trial 
Treatment Cannador Marinol Placebo 
Number of Participants analysed in 
Phase 1 207 197 207 
Number of Participants who chose to 
continue on medication in Phase II . 138 . 125 120 
Number of Participants who chose to not 
to continue on medication In Phase II 69 72 87 
There were 55 participants who, owing to their date of recruitment In the overall 
trial timescale, were unable to complete 52 weeks on treatment and hence had 
no visit 11 measurements. These therefore had their visit 10 measures carried 
fonA/ard In the same manner as those missing in Phase I. However, these were 
fairly evenly distributed across the three treatment groups (19 Cannador, 14 
Marinol and 22 Placebo). For these participants their time on treatment was 
thus effectively nine months instead of 12 months. Because of the choice 
involved in staying on medication there seems to have been more of a 
commitment to the trial regardless of efficacy, although some who chose to 
discontinue did so because of the intolerable side-effects. In addition, because 
the numbers of participants who adhered to the protocol, was effectively 
reducing as the trial progressed the power of the study was effectively reduced 
and applying a sample size calculation to the final numbers analysed at the end 
of Phase II would give a power of 7 1 % to detect the background effect sizes 
looked for at the outset [From SPSS Sample Power 2). 
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Alternative Methods for dealing with missing values 
There is much discussion in the statistical literature of what method should be 
adopted in the case of missing data and there was considerable discussion of 
the CAMS trial team about the issue before the finalising of the statistical 
Analysis plan. In any particular trial, there will be a number of missing values 
for two principal reasons, those due to a participant withdrawing before the 
planned duration of the trial and those which occur for no systematic reason. 
Missing values were first classified by Rubin (1976) as 'missing completely at 
random' (MCAR) where the drop-out and measurement process are 
independent, "missing at random' (MAR) where the drop-out process depends 
on the observed measurements (i.e. if, conditional on the observed 
measurements, the missingness is independent of the unobserved 
measurements), and 'informative drop-out' (ID) where the drop-out process 
depends on the unobserved measurements (those which would have been 
observed had the participant not dropped out). These definitions have led to 
many alternative methods for analysing incomplete longitudinal data although 
many trials in clinical settings use the simple methods of LVCF or exclusion of 
complete cases (CC). However, as Molenburghs et al. (2004) observe 'it is 
unfortunate that such a strong emphasis is placed on methods like LOCF (last 
observation carried forward) and CC, since they are based on strong and 
unrealistic assumptions'. The authors argue that it is unlikely that the 
missingness is MCAR, and that likelihood-based methods which assume that 
missingness is MAR are far more flexible and useful. More recently. Diggle et 
al (2007) consider that the objectives of the study should carry more weight in 
decisions concerning methods for missing data. 
This notation needs to be put into the context of the CAMS trial before 
competing methods of dealing with the missing values can be considered. The 
participants dropping out of the CAMS trial could not be considered to do so 
completely at random and independently of the measurement process -
examination of the reasons for those who withdrew show a range of reasons in 
each treatment arm, from worsening of symptoms to inconvenience of not being 
allowed to drive i.e possibly dependent on the observations to date. It was 
more likely that the missingness is MAR since withdrawal is dependent on the 
previously observed values. There did not appear to be a systematic 
withdrawal from one or more arms or of a subgroup of participants but it is 
difficult to exclude MNAR(Missing Not at Random), although a per-protocol 
analysis subsequently gave no concern that such an element was present. 
There are a number of ways in which the missing values can be treated. As 
referred to above, a complete case (CC) analysis could be carried out where all 
cases to be included are complete in all measurements. A simple concept and 
straightforward to execute, but in general this will give biased estimates of the 
AS. 
treatment effect and may exclude important features of the study population as 
a whole, as complete cases may differ from incomplete cases. The altemative 
is some form of imputation of the missing values and there are a number of 
possibilities, all of which will create bias. 
Carrying forward the latest observation made before the participant drops out of 
the study (LOCF or LVCF) Is a common strategy. This, as described, was the 
method used in CAMS. However, this method treats all observed and imputed 
values with equal weighting and naturally introduces an unknown bias and 
inflated precision. This bias can be in either direction and, even though this 
bias could be consistent across all treatment arms, may be sufficient to lead to 
the conclusion, quite spuriously, that a treatment effect exists. Examination of 
the attrition rates in each of the groups would be informative but not conclusive. 
A second imputation method (Little and Rubin. 1987) uses the unconditional 
mean of the variable across all non-missing values of the other participants to 
impute all missing values of that variable. This has the drawback of using an 
imputed value for a participant which is out of context with his other 
measurements measurement, again introducing . unknown bias and 
overestimating precision. In a more complex extension of this (Little and Rubin, 
1987), the mean from the regression of the missing observations on the 
observed measurements is used for each of the missing values, thus including 
past history of the individual as well as the overall pattern for all participants. 
However, this will still produce overestimated precision. 
The choice of method for dealing with missing values has necessarily to be laid 
down in the Statistical Analysis Plan at the outset, and much care has to be 
taken in judging the nature of the likely missing values, and the impact that the 
choice could make on the final results of the study. A sensitivity analysis, where 
a variety of scenarios are simulated and the resulting alternatives assessed, will 
confirm the validity of any assumptions made to impute missing values in the 
data set. 
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2.3 Change in Ashworth as opposed to analysis of covariance 
The primary outcome of this trial was the change in the Ashworth score of 
spasticity. In simplistic clinical terms the neurologists were trying to find out 
whether either of the two treatments could provide an effective treatment to 
alleviate a troublesome symptom of this debilitating and progressive disease. 
In statistical terms there were several possibilities for analysis of the primary 
outcome - using the endpoint score alone, a change In score from baseline to 
endpoint and modelling the endpoint with baseline measurement as a covariate. 
There has been much debate about the merits of always using ANCOVA as the 
analysis of choice (Senn (2006). VIckers and Altman (2001)) on the grounds 
that an analysis of covariance adjusts each patlent*s follow up score for his or 
her baseline score, but has the advantage of being unaffected by baseline 
differences. Senn and others argue that analysis of covariance wilLgive the 
same result whether or not there is baseline imbalance. If there are baseline 
differences such that baseline scores are worse in the treatment group, the 
treatment effect will be underestimated by an analysis of the follow-up scores 
and overestimated by looking at change scores (because of regression to the 
mean). Analysis of covariance, however, will adjust for the individual's baseline 
score whilst being invariant to any baseline differences, thus making it the 
preferred method. 
However, a balance will usually need to be struck between the philosophical 
arguments and the practical issue of interpretation of the results of the analysis, 
particularly as the choice of method must be chosen before the collection of the 
data. In this trial, the Interpretation of any results would always have to be 
easily understood by a wide range of interested parties, and there was also no 
reason to assume that there would be any systematic differences at baseline 
since every precaution was taken to achieve a balance in baseline 
characteristics, so the change score was used. After the primary analyses had 
been completed, ANCOVA was used lo check the validity of these assumptions 
and the results, using baseline Ashworth score as covariate led to the same 
conclusions as the change score analysis. 
An alternative analysis could have been a repeated measures ANOVA using 
Ashworth scores at visits 1 and 2 (baseline not on treatment), 5, 6 and 7 (on 
treatment) and the argument could be made that not doing this was wasteful of 
information. However, It was feasible that there may have been an effect in the 
very early stage of titration that disappeared In the subsequent plateau phase of 
the dose. A very short term effect such as this would have been difficult to 
interpret. Again, simplicity and the desire for knowledge about the longer term 
helped to dictate that this approach should be secondary to the change score 
analysis. The graphs in Figure 4 of the main CAMS paper clearly show the 
Ashworth scores by visit as 'matching' well (in all arms) with the phases of 
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befpre, on and after treatment with relatively small changes in mean scores for 
any of the three treatments. 
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3. Discussion of Results 
3.1 Reasons for a significant centre effect 
The analysis of the prinnary outcome showed evidence of a highly significant 
centre effect and the variation between centres (estimated variance, 4.045) 
is large compared with the variation explained by treatments. However, the 
main analyses show that the total variation in Ashworth change scores 
explained by centres is small, reflecting the smallness of treatment effect. The 
breakdown is given in the Analysis of Variance below. With a large number of 
centres the Mean Square value of 117.91 gives a p-value < 0.0001 
Figure 5: Linear Model for Change in Total Ashworth 
Source DF Sum of Squares 
Mean 
Square F Value Pr> F 
Model 35 4343.24820 124.09281 2.76 <.0001 
Error 575 25826.31607 44.91533 
Corrected 
Total 610 30169.56428 
Source DF Type III SS Mean Square F Value Pr> F 
GroupTreat 2 112.650308 56.325154 1.25 0.2861 
Centre 32 3773.189021 117.912157 2.63 <.0001 
Walk 1 375.974740 375.974740 8.37 0.0040 
Generated by the SAS System (Local.WIN_NT) on 16JUL2003 at 6.24PM 
3.2 Number of patients and change in total Ashworth by centre 
A breakdown of the number of randomised patients recruited by centre shows 
the wide variation, from 4 in centre 25 up to 91 in centre 1. To gauge interest in 
the trial, centres were initially asked how many patients they were likely to 
recruit with an expected minimum of 18-20. 
Half of the centres failed to enrol the initial minimum for a variety of reasons 
(staff availability, optimism about patients in rural areas being willing to give up 
driving, etc.) resulting in imbalances across centres. 
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Table 6: Recruitment by Centre 
Centre No. of Centre No. of Centre No. Of Centre No. of 
Patients Patients Patients Patients 
recruited recruited recruited recruited 
1 91 12 20 23 13 35 7 
2 45 13 18 24 23 36 18 
3 21 14 13 25 4 37 18 
4 18 15 14 26 19 38 5 
6 19 16 15 28 16 39 14 
7 26 17 20 29 21 40 6 
9 8 20 16 31 13 
10 24 21 20 32 16 
11 30 22 6 34 13 
The box plots in Figure 6 overleaf demonstrate how evidence of a difference is 
likely to be found. Centres 10 and 26 are different in location from the others, 
and these are also centres where the variation is larger than other centres. We 
could expect that there would be centres where, due to varying sample sizes, 
the features of the centre's patient population and their responses might be 
different, such as different symptom presentation, stage of disease and 
probably local support mechanisms. The variation between assessors is also a 
contributory factor, some assessors seeing few patients and getting less 
practice at performing the technique. 
Figure 6: Box Plots of Change in Ashworth score by Centre 
t 2 3 4 6 7 g 10 11 12 13 14 15 to 17 20 21 22 23 W 25 ZB 29 29 31 32 35 3G 37 3a 39 40 
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3.3 A hierarchical approach to modelling the change in Ashworth score 
The analysis was carried out according to the Statistical Analysis Plan but 
additional exploratory analyses were conducted after completion of the planned 
analyses. The results confirmed the robustness of the planned analysis and 
conclusions based on this. The analysis of centre effects and interactions 
between treatment and centre using hierarchical models was included in this 
exploratory analysis. Appendix 5 shows the relevant output from this analysis. 
The change in Ashworth score was explored by fitting a null model (ie with none 
of centre, ambulatory status or treatment being considered) and then adding 
sequentially these three factors. This was done for the total Ashworth (models 
in A), followed by changes in the upper body score (models in B) and the lower 
body score (models in C). The models were fitted using R software - the null 
model used the gim framework followed by the /mer framework when the effects 
were added. Thus a total of five models are shown in each of A, B and C. In A, 
mO is the null model and m1 is the model with centre added. When compared, 
using the difference in 2*LogLikelihood, this showed a evidence of centre effect, 
confirming the planned analysis. The ANOVA table at the end of A summarises 
the results of comparing the log likelihood of each model as a measure of the 
additional deviance explained by the additional terms in each case. The 
change in deviance is compared with the Chi-squared distribution and the final 
column shows that, of the additional terms, ambulatory status was a significant 
effect but that once the variation between this and the centres was accounted 
for, there was not sufficient evidence to conclude that there was a difference 
between treatments. This was consistent with all other planned analyses 
performed on the CAMS data. Exploration of upper and lower body muscles 
separately (B and C) also gave results consistent with the planned analyses. 
3.4 Implications of placebo effect on designs for the future 
This study showed no evidence of a beneficial effect due to either Marinol or 
Cannador on the primary outcome in the first phase up to 15 weeks. However, 
there was evidence, based on the category rating scales, that pain, assessed 
by self-report questionnaires, was reduced more in the Marinol and Cannador 
arms of the trial than in the placebo arms. This feature gave rise to much 
discussion surrounding the opinion that this was inevitable with treatments 
which were likely to have mood-altering properties being used in a relentless 
and debilitating disease. It is notable that the principal Investigator had several 
patients, who apparently benefited greatly from treatment, agreeing to 
participate in a televised release coinciding with the main trial publication. 
These patients all turned out to be on the placebo arm of the trial! This clearly 
underlines the importance of the 'placebo effect'. I would suggest that this is 
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not merely an effect due to psychological factors but one that affected all the 
trial participants, that of simply taking part in a clinical trial. Prior to the start of 
the trial, each participant would have seen a clinician perhaps as frequently as 
once every six months but more likely as a stable patient it would have been 
less frequently often only once per year. With a condition which can make 
employment, social enjoyment, participation in normal everyday events or just 
day-to-day living range from difficult to impossible, it is likely that the attention 
given by the highly committed trial teams across all the centres and in particular 
the trial coordinating centre team, would have had a significant bearing on the 
well-being of these patients even without the possible mood-enhancing effects 
of the active treatments. Even a telephone conversation with a member of the 
trial team about something as seemingly minor as when a next appointment 
might be arranged or one of the questions on a mobility instrument could have 
given much needed support producing a positive effect on the patient's 
perception of their health. 
This 'trial effect' is, of course, well-known (Braunhollz, 2000) and well reported 
but nevertheless raises an important question when considering designs for 
future trials. The major effect is that linked to the objectivity of the primary 
outcome. In this trial the Ashworth score was considered at the time to be the 
most objective means of assessing the most troublesome symptom of MS but 
future trials must take into account new work in the development of patient-
based measures and the use of alternative more objective measures. Magnetic 
Resonance Imaging is one development which could provide more objective 
assessment of change in MS, but current costs would be prohibitive for a 
sufficiently sized project. A current trial (CUPID) is using MSIS (Hobart et al., 
2004) and relapse history amongst the outcomes to be measured. MSIS-29 is 
a patient-based physical impact scale and the overall mean change from 
baseline is to be considered as the primary outcome jointly with the physician-
based EDSS with deterioration confirmed at two consecutive six monthly visits. 
3.5 Implications of unmasking effect 
Two of the three treatments were expected to have significant reporting of side 
effects relating to possible mood-enhancing states and at all stages of the trial 
there was much speculation amongst all groups of clinicians, patients and 
particularly the media thai any evidence of therapeutic value from cannabinoids 
would be entirely predictable due to unmasking. The unmasking is now 
examined, both in terms of reported adverse events and accurate prediction. 
The table overleaf shows the adverse events by treatment arm. 
Most of the categories are fairly evenly spread across the three treatment 
groups, but symptoms that could be associated with the mood-enhancing 
properties of cannabinoids are clearly more frequent in the Cannador and 
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Marinol groups - for example, dizziness, attention disturbance, feeling 
abnormal, and euphoric mood. The numbers of patients experiencing these are 
generally small and multiple reports were common. 
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Table 7: Adverse events by treatment arm 
System Organ Class^'^ 
Low Level Term^'^ 
Cannabis extract 
N = 211 
A^-THC 
N = 206 
Placebo 
N = 213 
N /o N % N /o 
Nervous system disorder 146 69.2% 153 74.3% 98 46.0% 
Dizziness 62 29.4% 73 35.4% 23 10.8% 
Somnolence 35 16.6% 31 15.0% 22 10.3% 
Headache 23 10.9% 16 7.8% 25 11.7% 
Disturbance in attention 14 6.6% 15 7.3% 3 1.4% 
General disorders and 
administration site 
conditions 
121 57.3% 115 55.8% 117 54.9% 
Fatigue 49 23.2% 37 18.0% 42 19.7% 
Asthenia 47 22.3% 47 22.8%. 54 25.4% 
Feeling abnomnal 11 5.2% 15 7.3% 2 0.9% 
Musculoskeletal and 
connective t issue disorders 
105 49.8% 96 46.6% 110 51.6% 
Muscle spasms 45 21.3% 46 22.3% 46 21.6% 
Musculoskeletal stiffness 44 20.9% 43 20.9% 50 23.5% 
Pain in limb 29 13.7% 15 7.3% 18 8.5% 
Gastrointestinal disorders 104 49.3% 103 50.0% 64 30.07o 
Dry mouth 44 20.9% 57 27.7% 14 6.6% 
Constipation 26 12.3% 10 4.9%, 7 3.3% 
Diarrhoea nos 24 11.4% 25 12.1% 14 6.6% 
Nausea 23 10.9% 18 8.7% 18 8.5% 
Psychiatric disorders 68 32.2% 66 32.0% 43 20.2% 
Euphoric mood 16 7.6% 12 5.8% 3 1.4% 
Infections and infestations 52 24.6% 51 24.8% 58 27.2% 
Urinary tract infection nos 32 15.2% 30 14.6% 40 18.8% 
Renal and urinary disorders 36 17.1% 33 16.0% 28 13.1% 
Urinary frequency 14 6.6%. 3 1.5% 7 3.3% 
Respiratory, thoracic and 
mediastinal disorders 
27 12.8% 17 8.3% 24 11.3% 
Eye disorders 26 12.3% 23 11.2% 10 4.7% 
Skin and subcutaneous tissue 
disorders 
21 10.0% 11 5.3% 30 14.1% 
Metabolism and nutrition 
disorders 
16 7.6%. 11 5.3% 4 1.9% 
Ear and labyrinth disorders 14 6.6% 9 4.4% 8 3.8% 
Injury, poisoning and 
procedural complications 10 
4.7% 11 , 5.3% 11 5.2% 
Any A E 200 94.8% 193 93.7% 177 83.1% 
N = number of patients 
' according to MedDRA 5.1 
^ System Organ Class: AEs in at least 5% of patients in any treatment group 
^ Low Level Term: AEs in at least 10% of patients In any treatment group or difference of al least 5 % between 
treatment groups 
Note; a patient could have findings in multiple categories 
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Table 8 below shows the percentage of treating physicians, assessors and 
patients in each arm who correctly predicted to which arm they or their patients 
had been assigned when asked at the end of visit 8. 
Table 8: Number and percentage of Treating Physicians, Assessors and 
Patients who correctly surmised at Visit 8 which treatment had been taken. 
Cannabis Extract A^-THC Placebo 
Number % Number % Number % 
Treating 
Physician 140 71 119 66 85 43 
Assessor 90 44 73 ' 39 86 42 
Patient 151 77 139 77 98 50 
By considering the results in the table above, it can be seen that overall 60% of 
treating physicians, 42% of assessors and 67% of patients were able to 
correctly surmise their arm of treatment. The adverse events were reported via 
the treating physician and further analysis of the primary data shows that for 
84% of all the subjects the response to the patients question on visit 8 asking 
'do you think you received the active treatment or the placebo?' is in complete 
agreement with the treating physicians' response to the same question. For 
example, Table 9 below shows the cross-tabulation for Cannador where 86% of 
physicians and patients are in agreement. 
Table 9: Perception of allocation of Cannador treatment 
Responses for Cannador Treating Physician thought 
patient was on...? Total 
Active Drug Placebo 
Patient's 
opinion of 
their 
treatment? 
Active Drug 132 19 151 
Placebo 
8 36 44 
Total 140 55 195 
Similar tables for Marlnol and Placebo show that 82% of physicians and 
patients in each group are in agreement, although not necessarily correct! This 
suggests that a degree of discussion would understandably have taken place in 
the course of reporting of symptoms and monitoring of side effects which is in 
contrast with the proportion of assessors correctly surmising which treatment 
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arm the patients had been assigned. The assessors were given instructions not 
to refer back to the observations of previous visits when assessing the 
Ashworth and other measures but this had to be left to the integrity of the 
assessor and would have been difficult to monitor in practice. It is likely that 
patients made every effort. If they felt their quality of life was improved in areas 
such as pain, to show an improvement in other measures and this would give a 
positive bias to the results thus over estimating any benefit. Having found no 
evidence of a therapeutic effect on the Ashworth scale of spasticity and other 
mobility measures in a fairly large and well-powered trial such as this would 
suggest therefore that any improvements judged to accrue by the patients* are 
very subjective and based largely on the mood-enhancing properties of both the 
active treatment and the human support received as part of the trial. 
The following two tables give added weight to the argument that the properties 
of the treatment and being in a clinical trial was felt to be helpful by the patients. 
Patients were asked at the end of phase 1 of the trial how helpful they found the 
treatment to be. There is no evidence that any of the treatments was thought to 
be more helpful than the others. 
Table 10: Did the patient find the treatment helpful? 
Cannador Marinol Placebo Total 
Yes 82(66%) 77(60% 79(62%) 238(62%) 
No 43(34%) 52(40%) 49(38%) 144(38% 
Total 125(100%) 120(100%) 128(100%) 382(100%) 
These data provide no evidence of any association between treatment and 
patient assessment of treatment (P value =0.615). 
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Table 11: If the patient reported treatment helpful, how helpful did they feel it 
was? 
Cannador Marino! Placebo Total 
A lot 41(50%) 39(51% 35(44%) 115(48%) 
Moderately 30(37%) 25(32%) 27(34%) 82(35% 
A little 11(13%) 13(17%) 17(22%) 41(17%) 
Total 82(100%) 77(100%) 79(100%) 238(100%) 
Again there is no evidence of any association between treatment and patient 
assessment of treatment (P value =0.710). 
f>0 
Table 12: Frequency of minor adverse events. 
Data are number of episodes (number of patients) 
A^'-THC Cannabis extract Placebo 
Chose to continue trial 
medication ? Yes(n = 125) 
No 
(n = 91) 
Yes 
(n = 138) 
No 
(n = = 81) 
Yes 
(n = 120) 
No 
(n = 102) 
Adverse event 
Bladder 26(16) 9(6) 37 (24) 3(3) 42 (22) 12(11) 
Depression or anxiety 11 (9) 3(3) 11 (11) 3(3) 10(10) 2(2) 
Dizzy or lightheadedness 19(17) 1 (1) 27 (20) 1(1) 5(4) 1(1) 
Dry mouth 3(3) 1 (1) 2(2) 0(0) 1(1) 1(1) 
Falls 10(7) 1 (1) 10(10) 5(5) 4(3) 4(4) 
Fatigue or sleep 
disturbance 
15(14) 3(3) 15(15) 3(3) 14(13) 10(8) 
Gastrointestinal tract 22(17) 3(3) 30(24) 2(2) 14(11) 5(5) 
Infection 17(14) 7(5) 26(19) 7(5) 20(17) 10(7) 
Memory or concentration 5(5) 0(0) 5(4) 0(0) 1 (1) 1 (1) 
Miscellaneous 17(13) 3(3) 15(11) 9(5) 13(11) 6(5) 
MS relapse or 
exacerbation 11(9) 2(2) 13(10) 4(4) 9(9) 5(5) 
Numbness or 
paraesthesia 
9(8) 2(2) 5(4) 5(5) 5(5) 3(3) 
Other skin problem 3(3) 0(0) 7(7) 5(4) 10(8) 6(5) 
Pain 24(18) 5(3) 36(26) 15(11) 20(14) 9(9) 
Pressure sores 1 (1) 0(0) 2(2) 1(1) 5(5) 1 (1) 
spasms or stiffness 30 (26) 6(5) 35(23) 10(9) 36 (23) 7(7) 
Tremor or lack of 
coordination 
9(9) 1(1) 4(4) 1(1) 2(2) 3(3) 
Vision symptoms 4(4) 1(1) 1(1) 4(4) 1 (1) 0(0) 
Weakness or reduced 
mobility 16(15) 
9(7) 20(19) 11(7) 24 (22) 15(13) 
Total 
252 (87) 57 (22) 301 (95) 89 (30) 236 (85) 100 (42) 
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3.6 Further exploration of the CAMS primary outcome 
All the analyses reported in the Lancet paper were performed as planned at the 
start of the trial, and documented, according to ICH guidelines, in the Statistical 
Analysis Plan. However, with a large and complex data set such as this, there 
was, and probably still is, plenty of scope for further exploration of the data. For 
example, we fitted an Item Response Theory (IRT) latent trait model to the item 
level data on the individual Ashworth scores using the WinBUGS software. The 
fitted item characteristic curves are shown in Appendix 6. The conclusions 
obtained from the latent trait scores from the IRT model mirror those of the main 
analysis. What the results from this analysis do reveal is that the lower body 
muscles are more discriminating than the upper body muscles. 
The summation of ordinal item scores to provide a total Ashworth score is 
questionable form a methodological perspective. The use of dynamic latent trail 
models (Dunson, 2003) provides a natural way of modelling these data taking 
explicit account of the ordinal responses. These models assume that at any 
given time the spasticity of an individual is represented by a latent trait or factor. 
The ordered categorical responses for each item are determined from the latent 
trait using an ordinal logistic regression which differs for each Item. To lake 
account of the longililudinal nature of the data, the latent traits are assumed to 
develop according to a random walk. The effect of treatment and other factors 
can be modelled as fixed effects as illustrated in Figure 7 overleaf. The latent 
trail at baseline is assumed to follow a standard normal dislribulion. Figure 8 
shows the posterior distributions of treatment effects. These are presented for 
the effect of each active treatment versus placebo, and the blue vertical line 
represents no Irealmenl effect. Thus for Marinol, a large proportion of the 
distribution is to the right of this, reflecting that the evidence points towards 
treatment benefit. However, a substantial area to the left shows that this 
evidence is insufficient to justify the conclusion of treatment benefit. The plot for 
Cannador shows a smaller proportion on the beneficial side of the distribution. 
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Figure 7 
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Figure 8: Posterior distributions of treatment effects 
Marlnol 
THC Effect 
Cannador 
0.0 0.1 0.2 
Cannabis Extract Effect 
0.3 0.4 
The final conclusions from this Bayesian analysis are very similar to those from 
the original planned analysis which showed no firm evidence of any treatment 
effect. 
However, if we consider Figure 9 and 10 (extracted from Appendix 6). we see 
that in Figure 9 the curves for item scores 1 - 4 are consistent with each other 
and only the curve for score 0 (participants who have no problem with this 
muscle group) is different from the others. This is a consistent result across the 
muscle groups from the upper body, whereas in Figure 10 for a muscle group in 
the lower body, the pattern is one of different distribution curves at each level of 
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the score. Thus, although the posterior distribution curves above indicate 
consistency with the conclusions from the planned analysis, this latent trait 
approach suggests additionally that more Information is obtained from the lower 
body muscles than from the upper body ones. 
Figure 9: Elbow Extensors 
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3.7 Sub-Studies - Cytokines 
The cytokine study focussed on the possible alteration in cytokines that might 
be produced by the taking of cannabinoids. 
This was one of several opportunistic sub-studies conducted by members of the 
clinical team. Where the participants are selected in a pragmatic non-random 
fashion it is always conceivable that evidence of real effects may not be 
revealed. In this sub-study, only samples from a small number of participants 
were used, this being a function of how much blood was available for chemical 
analysis. With such a limitation very small numbers of observations for 
statistical analysis were inevitable. Data for some or all of the outcomes from 
both before and after treatment were only available for 100 patients (33, 32 and 
35 in the Cannador, Marinol and Placebo arms respectively). For each of the 
outcomes there were outliers which could not be justifiably excluded on an 
immunological basis. Appendix 7, however, shows examples of how the data 
was affected when these outliers were removed. Although there is obviously a 
reduction in the sample size, the variation is considered for the remaining 
observation and it can be seen that there was very little evidence of an effect 
due to the active treatments and it is possible that evidence of a difference in 
these outcomes would have been found had the sample size been considerably 
larger. 
A retrospective power calculation suggests that with the differences in means 
found in these small samples for IFN-y (6.11 in Cannador, 0.70 in Marinol and 
0.28 in Placebo) and an estimated pooled standard deviation of 23.79, for 90% 
power, a sample of 960 (320 in each arm) would be required, substantially more 
than the 22 in each arm available for analysis for this cytokine.. 
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APPENDIX 1 
General Linear Model: Total versus Centre, Ass_Train, Visit, Patient 
F a c t o r Type L e v e l s Values 
Centre f i x e d 2 1 2 
Pa t i e n t ( C e n t r e ) random 9 1 2 3 4 
A s s _ T r a i f i x e d 2 1 2 
V i s i t f i x e d 2 1 2 
5 1 2 3 1 
A n a l y s i s of Variance for T o t a l , using Adjusted SS for T e s t s 
Source DF Seq SS Adj SS Adj MS F p 
Centre 1 21 70 21 70 21 70 0 05 0 832 
Pa t i e n t ( C e n t r e ) 
X 
Ass T r a i 
7 3151 69 3151 69 450 24 9 71 0 002 
1 2 78 4 51 4 51 0 16 0 699 
Centre*Ass_Trai 1 17 73 17 73 17 73 0 64 0 4 50 
A s s _ T r a i * Pat i e n t ( C e n t r e ) 7 193 99 193 99 27 71 2 46 0 105 
V i s i t 1 0 00 0 23 0 23 0 01 0 932 
C e n t r e ^ V i s i t 1 19 01 19 01 19 01 0 64 0 452 
V i s i t * P a t i e n t ( C e n t r e ) 7 209 49 209 49 29 93 2 65 0 087 
E r r o r 9 101 50 101 50 11 28 
T o t a l 35 3717 89 
X Not an exact F - t e s t . 
Unusual Observations for T o t a l 
Obs T o t a l F i t SE F i t Res i d u a l St Resid 
27 29.0000 33 0000 2.9083 -4.0000 -2.38R 
28 46.0000 42 0000 2.9083 4.0000 2.38R 
35 35.0000 31 0000 2.9083 4.0000 2.38R 
36 36.0000 40 0000 2.9083 -4.0000 -2.38R 
R denotes an observation with a l a r g e standardized r e s i d u a l 
Expected Mean Squares, using Adjusted SS 
Source Expected Mean Square for Each Term 
1 Centre (9) + 2 0000(8) + 2.0000(5) + 4.0000(2) + 
4, 7] 
2 Pa t i e n t ( C e n t r e ) (9) + 2 0000(8) + 2.0000(5) + 4.0000(2) 
3 A s s ^ T r a i (9) + 2 0000(5) + Q(3, 41 
4 Centre*Ass_Trai (9) + 2 0000(5) + 0(4) 
5 Ass__Trai*Patient (Centre) (9) + 2 0000(5) 
6 V i s i t (9) + 2 0000(8) + Q[6, 7) 
7 C e n t r e ' V i s i t (9) + 2 0000(8) + Q[7] 
8 V i s i t * P a t i e n t ( C e n t r e ) (9) + 2 0000(8) 
9 E r r o r (9) 
E r r o r Terms for T e s t s , using Adjusted SS 
Source E r r o r DF E r r o r MS Synthesis of E r r o r MS 
1 Centre 7 00 4 50. 24 (2) 
2 P a t i e n t ( C e n t r e ) 8 54 46. 36 (5) + (8) - (9) 3 A s s _ T r a i 7 00 27. 71 (5) 
4 Centre*Ass_Trai 7 00 27. 71 (5) 
5 Ass T r a i * P a t i e n t ( C e n t r e ) 9 00 11 . 28 (9) 
6 V i s i t 7 00 29. 93 (8) 
7 C e n t r e * V i s i t 7 00 29. 93 (8) 
8 V i s i t * P a t i e n t ( C e n t r e ) 9 00 11 . 28 (9) 
+ Q t l , 
Variance Components, using Adjusted SS 
Source 
Pa t i e n t ( C e n t r e ) 
A s s _ T r a i * P a t i e n t ( C e n t r e ) 
V i s i t * P a t i e n t ( C e n t r e ) 
E r r o r 
Estimated Value 
100.970 
8.217 
9.325 
11 .278 
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APPENDIX 2 
Definition of patient samples 
There will be five patients samples of interest - the all patients seen sample, the 
all patients randomised sample, the intention to treat sample (comprising all 
patients provided with study medication), the per-protocol patients sample and 
the safety sample. The intention to treat sample will be primary for the purpose 
of assessment of efficacy. A supporting analysis of the per-protocol patients 
sample will be undertaken. The all-patients seen sample and the all patients 
randomised sample will be used to present premature termination data, cases 
where patients were randomised but did not take study medication, etc. 
1. The all-patients seen sample will consist of all patients who: 
were screened for inclusion and attended visit 1. 
2. The all patients randomised sample will consist of all patients who: 
attended visit 1 and were randomised. These patients were 
scheduled to attend visit 2 when their eligibility was checked and, 
if judged eligible, they were provided with a prescription for study 
medication. 
3. The intention to treat sample will consist of all patients who: 
were randomised at visit 1, were deemed eligible at visit 2 and 
were provided with a prescription for study medication. 
Note that ttie second visit was included for logistical purposes in order to 
provide study medication appropriate for the particular weight group of 
the patient. 
4. The per-protocol patients sample will consist of all patients who: 
were provided with study medication, 
completed the 15 week treatment period, 
look the study medication as prescribed, 
provided valid data for the study period, 
when on placebo, did not have a urine sample which tested 
positive for cannabis, 
presented no other major violation from the protocol as defined by 
the Blind Data Review Report. 
5. The safety sample will consist of all patients in the intention to treat sample 
who: 
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have been prescribed any study medication and have been 
assumed to have taken at least one dose and for whom there is 
some data on treatment. 
The complete list of subjects excluded from any of the samples defined above 
as well as the reason for exclusion can be found in the report of the blind data 
review, which will be finalised before the study data base is unblinded. 
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APPENDIX 3 
INSTRUCTIONS FOR RUNNING MINIM TO ALLOCATE PATIENTS TO 
TREATMENTS ON CAMS TRIAL 
MINIM is a program for randomising patients to treatment groups in clinical 
trials by the method of minimisation 
It has been written by Stephen Evans. Simon Day and Patrick Royston. 
It was obtained from 
Stephen J W Evans 
Department of Epidemiology & Medical Statistics 
LHMC, Queen Mary & Westfield Campus 
Mile End Road 
London E l 4NS 
Telephone +44 (0)171 982 6397 
NOTE - An example file has been set up so that familiarity with the 
program can be gained before using the CAMS file 
When using the program, MINIM offers you two options: 
1 You can assign new patients to treatment groups by the method of 
minimisation; 
2 You can tell the program that some patients have been assigned to 
treatment groups by some other method. This is crucial if, for example, 
your computer is occasionally unavailable and a few patients have to be 
entered into the trial by simple randomisation. 
To start the program, type minim, foltowed by carriage return (you will always 
need to press return after each instruction). 
Note: In these notes, all instructions or answers to questions that you need to 
type are shown as lower case, underlined. 
When typing, it does not matter if you use upper or lower case characters. 
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Example File 
The example file should be used for practice before the 'real' CAMS file is 
used, but is set up with the same factors as the actual file. These factors are 
walking status and centre.[The actual CAMS file is called CAMS.dat] 
Once in MINIM, in answer to the question 
'What is the name of your data file? ' 
type example.dat. followed by carriage return. 
Firstly, you are shown the current stale of the data file 
Next, you have three options: 
'A' Use this most often to run the program properly (ie. to use 
the 
minimisation procedure). 
'U' Use this if for some reason patients have been entered into the 
trial without using the program. This may be because the computer was 
broken or not available etc. You should not be using this routinely, but if 
necessary, patients can be forced into the data file in this way. 
'S' ,to stop the program. 
Firstly, try typing a. You are asked.'Do you have details of a patient? ' 
Answer y. 
Press RETURN to continue 
You can enter the description of the patient as follows: 
Walking Status 'Ambulatory' option ^, 'non-ambulatory' option 2 
Centre 'Plymouth' option 1, 'Queen Square' option 2, etc 
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Instead of typing the option numbers, you can type the text, eg.ambulatory or 
an abbreviation of it. 
These options are then re-printed and you can confirm that they are correct. If 
they are wrong, you can edit all, or some, of them. If you confirm the details to 
be correct, then there will be a message saying either: 
'Patient allocated to Treatment Cannador' or 'Patient allocated to Cannador 
Placebo' or 'Patient allocated to Treatment 'Marinol' or 'Patient allocated to 
'Marinol Placebo" 
The patient has been allocated mostly on the basis of the method of 
minimisation but partly by pure randomisation. You can enter as many 
patients as you like in this way. When you say you have no more patients, 
you will be shown the updated state of the trial and asked If you want to stop 
the program. Answer n and you will go back to the three options (given 
above) of allocating, updating or stopping. Now answer y (ie. you do want to 
stop) and you will have the option of either saving the new state of the data, or 
discarding the changes. 
Press RETURN to continue 
Usually you will want to save the data, but if you are showing someone how to 
use the program or perhaps you have made some errors in entering patients 
you may wish to discard the changes and leave the data as it was before 
starting this session. Type y to update the data. The program now finishes. 
You should now try starting It again (type minim) to check that the new 
patient(s) have been included in the example data set. 
If instead of asking for option a to allocate patients, you asked for option u to 
update the data, exactly the same sequence is followed, except that in place 
of the statement like: 
'Patient allocated to Treatment A' 
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you will be asked to say which treatment the patient received and they will 
then be forced into the data set under that treatment heading. Any further 
patients entered by minimisation will then take account of such patients that 
may have been entered by simple randomisation. 
Keeping Records 
A log of what you have entered is recorded on a separate file and every time 
that new patients are added then this will be updated. To ensure a complete 
record please make sure that at the end of every session you make a copy of 
this log file and name it uniquely using the current date. 
It is also important that a complete paper record is made so that it is known at 
any stage by the Derriford pharmacy which treatment has been allocated to a 
particular patient. This record can be accessed by the Trial Statistician 
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APPENDIX 4 
Comparison of Cannador Capsules with placebo 
Samples o f Cannador capsules and matched placebo were tested for goodness o f match, by a panel o f si; 
testers. 
Method 
Each tester was given four coded samples, t w o specimens o f each o f the active and placebo preparations 
numbered 1 to 4 in a random order. Each sample was compared w i t h each o f the other t luee g iv ing a to' 
o f six comparisons, o f wh ich two were o f the same preparation and four were o f dif ferent preparations. 
For each set o f tablets four features were examined: colour, shape and appearance, smell and taste. 
The six comparisons were carried out for each feature. Jf a difTerence was detected between a pair o f 
samples the tester entered a 1 in the appropriate box on the fo rm, otherwise a 0 was entered. 
Calculation of results 
1. D i f fe rent ia l 
A n estimate o f the closeness o f the match was obtained by subtracting f r om the percentage o f 
comparisons in wh ich di f ferent preparations were reported to be d i f ferent , the percentage o f comparison 
in wh ich the same preparations were reported to be di f ferent. This di f ference is the "d i f fe ren t ia l " 
between the two preparations, a h igh value indicat ing a bad match and a l ow value a good match. A n 
overal l value for the di f ferent ia l is given as we l l as values for ind iv idual features. 
2. Calculat ion o f p-valucs 
In order to calculate p-values for the chance o f finding the observed dif ferences i f no differences exist, j 
empir ical distr ibut ion is generated. 
Under the nul l hypothesis o f no difference between the active and placebo tablets, the number o f Is 
appearing in the f irst two responses (comparisons o f the same preparat ion), g iven the total number o f Is 
for that tester, fo l lows a h>'pergeomeiric d istr ibut ion. 
Peauire % o f comparisons in wh ich 
unmatched tablets were 
reported di f ferent ( A ) 
% o f comparisons in 
wh ich the same tablets 
were reported di f ferent f B ) 
Di f ferent ia l 
( A ) - C B ) 
p-value 
Colour 16.7 0 16.7 0.131 
Shape and 
Appearance 
33.4 16.7 16.7 0.425 
Smel l 0 0 0 _ 
Taste 16.7 0 16.7 0.140 
Overal l 16.7 4.2 12.5 1 
Conclusions 
N o signi f icant difference in any feature; taste, shape and appearance, colour and smel l , was reported 
between act ive and placebo capsules. Comb in ing al l features there was also no s igni f icant overal l 
di f ference (p -1 .0 ) . 
N B . It is important that indiv iduals don' t chew the tablets since the active capsules are noticeably 
di f ferent in this case; having both strong smel l and taste. 
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APPENDIX 4 (continued) 
Comparison of Marino! Capsules with placebo 
Samples o f Mar ino l capsules and matched placebo were tested fo r goodness o f match , by a panel o f si> 
tesiers. 
Method 
Kach tester was given four coded samples, two specimens o f each o f the active and placebo preparai ioi 
numbered 1 to 4 in a random order. Each sample was compared w i t h each o f the other three g i v i ng a t* 
o f six comparisons, o f wh ich two were o f the same preparation and four were o f d i f ferent preparations. 
For each set o f tablets four features were examined: colour , shape and appearance, smell and taste. 
'ITie six comparisons were carried out for each feature. I f a di f ference was detected between a pair o f 
samples the tester entered a I in the appropriate box on the f o rm , otherwise a 0 was entered. 
Calculation of results 
1. DifTerential 
A n estimate o f the closeness o f the match was obtained by subu^ct ing f rom the percentage o f 
comparisons in wh ich di f ferent preparations were reported to be di f ferent , the percentage o f compariso 
in wh ich the same preparations were reported to be di f ferent. 'ITiis di f ference is the "d i f ferent ia l ' * 
between the two preparations, a h igh value indicat ing a bad match and a low value a good match. A n 
overal l value for the di f ferent ia l is g iven as wel l as values for ind iv idual features. 
2. Calculat ion o f p-valucs 
In order to calculate p-values for the chance o f l l nd ing the observed differences i f no di f lcrenccs exist, 
empir ical d ist r ibut ion is generated. 
Under the nul l hypothesis o f no di f ference between the active and placebo tablets, the number o f Is 
appearing in the first two responses (comparisons o f the same preparation), given the total number o f I 
for that tester, fo l lows a hypcrgcomctr ic distr ibut ion. 
Feature % o f comparisons in wh ich 
unmatched tablets were 
reported di f ferent ( A ) 
% o f comparisons in 
wh ich the same tablets 
were reported di f ferent ( B ) 
Di f ferent ia l 
( A ) - ( B ) 
p-value 
Colour 8.3 8.3 0 1 
Shape and 
Appearance 
0 0 0 -
Smell 0 0 0 -
' Taste 8.3 8.3 0 I 
1 Overal l 4.2 4.2 0 0.617 
Conclusions 
N o signif icant dif ference in any feature; taste, shape and appearance, colour and smel l , was reponed 
between active and placebo capsules. Combin ing alt features there was also no s igni f icant overal l 
dif ference (p=0.617). 
77 
APPENDIX 5 
Notation -
ObjectA/ariable Name Explanation 
mO [ml ] Null model [next level model with additional term,...] 
difftotal Change in Ashworth for all.muscle groups 
upperdiff Change In Ashworth for muscle groups in the upper 
body 
lowerdlff Change in Ashworth for muscle groups in the lower 
body 
Walk Ambulatory status where 1=able to walk, 0=unable to 
walk. 
Comparisons made with the unable to walk level 
Treati Treatment where 0=Placebo, 1=Cannador, 2=MarinoL 
Comparisons made with Placebo level 
A. Change in Total Ashworth Score 
Null Model fitted us ing Genera l L inear Model 
> sunimary(mO) 
Call;glm(formula = d i f f t o t a l - 1, data = hs) 
Deviance Residuals: 
Min IQ Median 30 Max 
-27.3254 -3.8254 -0.3254 3.674 6 27.174 6 
C o e f f i c i e n t s : 
Estimate Std. Error t value Pr(>|t|) 
( I n t e r c e p t ) 1.3254 0.2851 4.648 4.1e-06 ^ 
S i g n i f . codes: 0 ' * - ' 0.001 0.01 0.05 '.' 0.1 ' ' 1 
(Dispersion parameter for gaussian family taken to be 49.66854) 
Null deviance: 30298 on 610 degrees of freedom 
Residual deviance: 30298 on 610 degrees of freedom 
AIC: 4123.1 
Number of Fi s h e r Scoring i t e r a t i o n s : 2 
7S 
Models adding Centre (Random Effect) . Walk & Treatment (Fixed Ef fects)sequent ia l lv 
> m l < - l m e r ( d i f f C o t a l - l + ( 1 I C e n t r e ) , data=hs, method="ML"} 
> summary(ml) 
Linear mixed-effects model f i t by maximum l i k e l i h o o d 
Formula: d i f f t o t a l ~ 1 + (1 | Centre) Data: hs 
AIC BIC lo g L i k MLdeviance REMLdeviance 
4101.593 4110.423 -2048.797 4097.593 4097.232 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 4.4400 2.1071 
Residual 45.4733 6.7434 
number of obs: 611, groups: Centre, 33 
Fixed e f f e c t s : 
Estimate Std. E r r o r t value 
(Intercept) 1.36800 0.47779 2.8632 
> m2<-lmer(difftotal-Walk+(1ICentre), data=hs,method="ML") 
> summary(m2) 
Linear mixed-effects model f i t by maximum l i k e l i h o o d 
Formula: d i f f t o t a l - Walk + (1 | Centre) Data: hs 
AIC BIC lo g L i k MLdeviance REMLdeviance 
4094.081 4107.326 -2044.040 4088.081 4087.082 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 4.0595 2.0148 
Residual 44.8783 6.6991 
number of obs: 611, groups: Centre, 33 
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Fixed e f f e c t s : 
Estimate Std. E r r o r t value 
( I n t e r c e p t ) 0.49452 0.54214 0.91218 
Walk 1.75143 0.56462 3.10194 
C o r r e l a t i o n of Fixed E f f e c t s : 
( I n t r ) 
Walk -0.518 
> m 3 < - l m e r ( d i f f t o t a l - T r e a t l + Walk+(1|Centre) , data=hs,method="ML") 
> summary(m3) 
L i n e a r mixed-effects model f i t by maximum l i k e l i h o o d 
Formula: d i f f t o t a l - T r e a t i + Walk + (1 | Centre) 
Data: hs 
AIC BIC logLik MLdeviance REMLdeviance 
4096.005 4118.08 -2043.002 4086.005 4083.235 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 4.0905 2.0225 
Res i d u a l 44.7103 6.6866 
number of obs: 611, groups: Centre, 33 
Fixed e f f e c t s : 
Estimate Std. E r r o r t value 
( I n t e r c e p t ) 0.054819 0.661516 0.08287 
Cannador 0.392366 0.660892 0.59369 
Marinol 0.960821 0.669145 1.43589 
Walkl 1.748923 0.563680 3.10269 
SO 
C o r r e l a t i o n of Fixed E f f e c t s : 
( I n t r ) Cannador Marinol 
Cannador -0.498 
Marinol -0.492 0.496 
Walkl -0.424 0.003 -0.002 
> m 4 < - l m e r ( d i f f t o t a l - T r e a t l * Walk+(1|Centre) , data=h5,method="ML") 
> summary(m4) 
Linear mixed-effects model f i t by maximum l i k e l i h o o d 
Formula: d i f f t o t a l - T r e a t l * Walk + (1 I Centre) 
Data; hs 
AIC BIC logLik MLdeviance REMLdeviance 
4096.233 4127.139 -2041.116 4082.233 4074.93 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 4.0593 2.0148 
Residual 44.4373 6.6661 
number of obs: 611, groups: Centre, 33 
Fixed e f f e c t s : 
Estimate Std. E r r o r t value 
( I n t e r c e p t ) 0.4 37866 0.7 65011 0.57237 
Cannador 0.37054 3 0.93524 2 0.39620 
Marinol -0.193339 0.951239 -0.20325 
Walkl 1.016827 0.943736 1.07745 
CannadorrWalkl 0.017598 1.323998 0.01329 
Marinol:Walkl 2.274 834 1.338016 1.70015 
SI 
C o r r e l a t i o n of Fixed E f f e c t s : 
( I n t r ) Cannador Marinol Walkl T11:W1 
Cannador -0.616 
Marinol -0.609 0.198 
H a l k l -0.625 0.501 0.489 
Cannador:Wlkl 0.439 -0.710 -0.349 -0.700 
MarinolrWlkl 0.437 -0.355 -0.713 -0.687 0.492 
C o m p a r i s o n of mO and m1 
> a s.numeric(2*(logLik(ml)-logLik(mO))) 
(1) 21.53116 
> pchisq(21.53,1,lower=F) 
(11 3.483365e-06 
Alternative Compar ison (confirming that there is s t rong ev idence of a centre effect) 
A n a l y s i s of Variance Table 
Response: d i f f t o t a l 
Df Sum Sq Mean Sq F value Pr(>F) 
Centre 32 3920.0 122.5 2.6842 2.758e-06 
R e s i d u a l s 578 26377.8 _ 45.6 
S i g n i f . codes: 0 0.001 '*'' 0.01 0.05 '.' 0.1 ' ' 1 
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C o m p a r i s o n of m l and m2.m3.m4 
> anova(ml,m2,m3,m4) 
Data: hs 
Models: 
ml: d i f f t o t a l - 1 + (1 | Centre) 
m2: d i f f t o t a l - Walk + (1 I Centre) 
m3: d i f f t o t a l - T r e a t i + Walk + (1 | Centre) 
m4: d i f f t o t a l - T r e a t i * Walk + (1 | Centre) 
Df AIC BIC logLik Chisq Chi Of Pr(>Chisq) 
ml 2 4101.6 4110.4 -2048.8 
m2 3 4094.1 4107.3 -2044.0 9.5121 1 0.002041 * 
m3 5 4096.0 4118.1 -2043.0 2.0763 2 0.354101 
m4 7 4096.2 4127.1 -2041.1 3.7716 2 0.151709 
S i g n i f . codes: 0 0.001 0.01 **' 0.05 0.1 
> deviance(ml,m2,m3, m4 , ) 
11] 4097.593 
> deviance(m2) 
[I] 4088.081 
> deviance(m3) 
[1] 4086.005 
> deviance(m4) 
I D 4082.233 
> 
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B. Change in Upper Body Ashworth Score 
Null Model fitted using General Linear Model 
> mOu<-glm(upperdiff-1,data=hs) 
> sununary (mOu) 
C a l l : g l m ( f o r m u l a = u p p e r d i f f - 1, data = hs) 
Deviance Residuals: 
Min IQ Median 3Q Max 
-20.08607 -1.58607 -0.08607 1.91393 15.91393 
C o e f f i c i e n t s : 
Estimate Std. E r r o r t v a l u e Pr(>|c|) 
( I n t e r c e p t ) 0.08 607 0.17356- 0.^96 0.62 
{ D i s p e r s i o n parameter f o r g a u s s i a n f a m i l y taken t o be 18.37559) 
N u l l deviance: 11191 on 609 degrees o f freedom 
R e s i d u a l deviance: 11191 on 609 degrees o f freedom 
AIC: 3509.8 
Number o f F i s h e r S c o r i n g i t e r a t i o n s ; 2 
Models adding Centre (Random Effect). Walk & Treatment (Fixed Effects)sequentiallv 
m l u < - l m e r ( u p p e r d i f f ~ H ( 1 ( C e n t r e ) , daCa=hs,method="ML") 
> summary(mlu) 
L i n e a r m i x e d - e f f e c t s model f i t by maximum l i k e l i h o o d 
Formula: u p p e r d i f f - 1 + (1 | Centre) Data: hs 
AIC BIC l o g L i k MLdeviance REMLdeviance 
3491.905 3500.732 -1743.952 3487.905 3488.649 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 1.3517 1.1626 
R e s i d u a l 17.0294 4.1267 
number o f obs: 610, groups: C e n t r e , 33 
S4 
Fixed e f f e c t s : 
E s t i m a t e Std. E r r o r t v a l u e 
( I n t e r c e p t ) 0.030429 0.274886 0.11070 
> in2u<-lmer ( u p p e r d i f f~Walk+(1 ICentre) , data=hs,method="ML") 
> summary(m2u) 
L i n e a r m i x e d - e f f e c t s model f i t by maximum l i k e l i h o o d 
Formula: u p p e r d i f f - Walk + (1 I Centre) Data: hs 
AIC BIC l o g L i k MLdeviance REMLdeviance 
3488.596 3501.837 -1741.298 3482.596 3483.622 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 1.3627 1.1674 
Resi d u a l 16.8732 4.1077 
number o f obs; 610, groups: Centre, 33 
Fixed e f f e c t s : 
E stimate Std. E r r o r t v a l u e 
( I n t e r c e p t ) -0.36857 0.32476 -1.1349 
Walkl 0.79910 0.34602 2.3094 
C o r r e l a t i o n o f Fixed E f f e c t s : 
( I n c r ) 
Walkl -0.532 
> m 3 u < - i m e r ( u p p e r d i f f - T r e a t l + W a l k + ( 1 I C e n t r e ) , data=hs;raethod="ML") 
> summary(m3u) 
L i n e a r m i x e d - e f f e c t s model f i t by maximum l i k e l i h o o d 
Formula: u p p e r d i f f - T r e a t l + Walk + (1 I Centre) Data: hs 
AIC BIC l o g L i k MLdeviance REMLdeviance 
3490.121 3512.189 -1740.061 3480.121 3481.331 
S5 
Random e f f e c t s : 
Groups Name Varianc e Std.Dev 
Centre ( I n t e r c e p t ) 1.3800 1.17'17 
R e s i d u a l 16.7964 1.0983 
number o f obs: 610, groups: C e n t r e , 33 
Fi x e d e f f e c t s : 
Estimate S t d . 'Error t va l u e 
( I n t e r c e p t ) -0.60731 0.40018 -1.51757 
Cannador 0.12272 0.4 0539 0.30272 
M a r i n o l 0.61222 0.41038 1.49182 
Wa l k l 0.79872 0.34534 2.31284 
C o r r e l a t i o n of Fixed E f f e c t s : 
( I n t r ) Cannador M a r i n o l 
Cannador -0.508 
M a r i n o l -0.501 0.497 
Wal k l -0.433 0.005 0.001 
> m4u<-lmer ( u p p e r d i f f - T r e a t l ^ Walkf-(1 ICentre) , data=hs,method="ML"') 
> summary(m4u) 
L i n e a r m i x e d - e f f e c t s model f i t by maximum l i k e l i h o o d 
Formula: u p p e r d i f f T r e a t l * Walk + (1 | Centre) Data: hs 
AIC BIC l o g L i k MLdeviance REMLdeviance 
3489.702 3520.596 -1737.851 3475.702 3474.35-
Random e f f e c t s : 
Groups Name Va r i a n c e Std.Dev. 
Centre ( I n t e r c e p t ) 1.3423 1.1586 
R e s i d u a l 16.6855 4.0848 
number o f obs: 610, groups: C e n t r e , 33 
S6 
Fixed e f f e c t s : 
E s t i m a t e S t d . E r r o r t v a l u e 
( I n t e r c e p t ) -0.445285 0.464222 -0.95921 
Cannador 0.282512 0.574095 0.49210 
M a r i n o l -0.051986 0.583901 -0.08903 
Walkl 0.4 95188 0.579353 0.85473 
Cannador rVJalkl -0.337355 0.811706 -0.41561 
M a r i n o l : W a l k l 1.306204 0.820506 1.59195 
C o r r e l a t i o n o f Fixed E f f e c t s : 
( I n t r ) Cannador M a r i n o l Walkl T11:H1 
Cannador -0.626 
M a r i n o l -0.619 0.500 
Walkl -0.636 0.504 0.492 
CannadoriWlkl 0.446 -0.710 -0.351 -0.701 
M a r i n o l : W l k l 0.445 -0.357 -0.714 -0.689 0.493 
Comparison of m1u and mOu 
> a s . n u m e r i c ( 2 * ( l o g L i k { m l u ) - l o g L i k ( m O u ) ) ) 
[1] 17:92343 
> pchisq{17.92,1.lower=F) 
m 2.303873e-05 
S7 
Comparison of m1u with m2u. m3u. m4u 
> anova(ralu,m2u,m3u,m4u), Data: hs 
Models: 
mlu: u p p e r d i f f - 1 + (1 I Centre) 
m2u: u p p e r d i f f - Walk + (1 | Centre) 
m3u: u p p e r d i f f - T r e a t l + Walk + (1 | Centre) 
m4u: u p p e r d i f f - T r e a t l * Walk + (1 | Centre) 
Df AIC BIC l o g L i k C h isq Chi Df Pr{>Chisq) 
mlu ''2 3491.9 3500.7 -1744.0 
m2u 3 3488.6 3501.8 -1741.3 5.3085 1 0.02122 * 
m3u 5 3490.1 3512.2 -1740.1 2.4750 2 0.29011 
m4u 7 3489.7 3520.6 -1737.9 4.4195 2 0.10973 
S i g n i f . codes: 0 0.001 0.01 0.05 '.' 0.1 
> dev i a n c e ( m l u ) 
[1 ] 3487.905 
> deviance(m2u) 
[1 ] 3482.596 
> deviance(m3u) 
[1 ] 3480.121 
> deviance(m4u) 
[1 ] 3475.702 
SS 
C Change in Upper Body Ashworth Score 
Null Model fitted using General Linear Model 
> m 0 1 < - g l m ( l o w e r d i f f - l , d a t a = h s ) 
> summary(mOl) 
C a l l : g l m ( f o r m u l a = l o w e r d i f f - 1, da t a = hs) 
Deviance R e s i d u a l s : 
Min IQ Median 3Q Max 
-17.7117 -2.7117 -0.2117 2.7883 19.2883 
C o e f f i c i e n t s : 
E s t i m a t e S t d . E r r o r t v a l u e P r ( > | t | ) 
( I n t e r c e p t ) 1.2117 0.1852 6.544 1.27e-10 
S i g n i f . codes: 0 0.001 0.01 0.05 . ' 0.1 1 
( D i s p e r s i o n parameter f o r gaussian f a m i l y taken t o be 20.94825) 
N u l l deviance: 12778 on 610 degrees o f freedom 
Res i d u a l deviance: 12778 on 610 degrees o f freedom 
AIC: 3595.6 
Number o f F i s h e r S c o r i n g i t e r a t i o n s : 2 
Models adding Centre fRandom Effect). Walk & Treatment (Fixed Effects)sequentiallv 
> m l l < - l m e r ( l o w e r d i f f - l + ( 1 { C e n t r e ) , data=hs,method="ML"} 
> summary(mll) 
L i n e a r m i x e d - e f f e c t s model f i t by maximum l i k e l i h o o d 
Formula: l o w e r d i f f - 1 + (1 I Centre) Data: hs 
AIC BIC l o g L i k MLdeviance REMLdeviance 
3583.17 3592 -1789.585 3579.17 3579.797 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 1.4941 1.2223 
Residual 19.6125 4.4286 
number o f obs: 611, groups: Centre, 33 
SO 
F i x e d e f f e c t s : 
E stimate S t d . E r r o r t v a l u e 
( I n t e r c e p t ) 1.29803 0.29144 4.4539 
> m 2 1 < - l m e r ( l o w e r d i f f - W a l k + ( 1 I C e n t r e ) , data=hs,method="ML") 
> summary(m21) 
L i n e a r m i x e d - e f f e c t s model f i t by maximum l i k e l i h o o d 
Formula: l o w e r d i f f - Walk + (1 I Centre) Data: hs 
AIC BIC l o g L i k MLdeviance REMLdeviance 
3578.293 3591.538 -1786.146 3572.293 3573.166 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 1.2594 1.1222 
Re s i d u a l 19.4816 4.4138 
number o f obs: 611, groups: Centre, 33 
F i x e d e f f e c t s : 
E s t i m a t e Std. E r r o r t v a l u e 
( I n t e r c e p t ) 0.80406 0.33342 2.4115 
Walkl 0.98062 ( j , 36989 2.6511 
C o r r e l a t i o n " of Fi x e d E f f e c t s : 
( I n t r ) -0.554 
> m 3 1 < - l m e r ( l o w e r d i f f - T r e a t l + Walk+(1|Centre) , data=hs,method="ML") 
> summary(m31) 
L i n e a r m i x e d - e f f e c t s model f i t by maximum l i k e l i h o o d 
Formula: l o w e r d i f f - T r e a t l + Walk + (1 | Centre) Data: hs 
AIC BIC l o g L i k MLdeviance REMLdeviance 
3581.315 3603-391 -1785.658 3571.315 3572.087 
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Random e f f e c t s : 
Groups Name Variance Std.Dev 
Centre ( I n t e r c e p t ) 1.260 1.1225 
Resi d u a l 19.449 4.4101 
number o f obs: 611, groups: Centre, 33 
Fixed e f f e c t s : 
E stimate S t d . E r r o r t v a l u e 
( I n t e r c e p t ) 0.58047 0.41657 1.39345 
Cannador 0.24948 0.43552 0.57282 
M a r i n o l 0.43404 0.44095 0.98432 
Walkl 0.98015 0.36960 2.65192 
C o r r e l a t i o n o f Fixed E f f e c t s : 
( I n t r ) Cannador M a r i n o l 
Cannador -0.522 
M a r i n o l -0.515 0.496 
Walkl -0.444 0.004 -0.001 
> ra41<-lmer(lowerdiff-Treatl* Walk+(1ICentre) , data=hs,method="ML") 
> summary(m41) 
L i n e a r m i x e d - e f f e c t s model f i t by maximum l i k e l i h o o d 
Formula: l o w e r d i f f - T r e a t l * Walk + (1 I Centre) Data: hs 
AIC BIC l o g L i k MLdeviance REMLdeviance 
3584.49 3615.396 -1785.245 3570.49 3568.364 
Random e f f e c t s : 
Groups Name Variance Std.Dev. 
Centre ( I n t e r c e p t ) 1.2741 1.1287 
Residual 19.4164 4.4064 
number o f obs: 611, groups: Centre, 33 
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F i x e d e f f e c t s : 
E s t i m a t e Std. E r r o r t v a l u e 
( I n t e r c e p t ) 0.747388 0.489153 1.52792. 
Cannador 0.139763 0.617624 0.22629 
M a r i n o l 0.038854 0.628238 0.06185 
Wa l k l 0.657904 0.622197 1.05739 
Cannador:Walkl 0.211666 0.873885 0.24221 
M a r i n o l : W a l k l 0.779210 0.883423 0.88203 
C o r r e l a t i o n of Fixed E f f e c t s : 
( I n t r ) Cannador M a r i n o l W a l k l T11:W1 
Cannador -0.636 
M a r i n o l -0.629 0.497 
Wal k l -0.645 0.502 0.490 
Cannador:Wlkl 0.453 -0.710 -0.350 -0.701 
M a r i n o l : W l k l 0.451 -0.355 -0.713 -0.689 0.492 
Comparison of mil and mOI 
> a s . n u m e r i c ( 2 * ( l o g L i k ( m i l ) - l o g L i k ( m O l ) ) ) 
[ 1 ] 12.46807 
> p c h i s q ( 1 2 . 4 7 , l , l o w e r = F ) 
[ 1 ] 0.0004135401 
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Comparison of m1l with m2l. m3l. m4l 
> anova(ml1,m21,m31,m41)Data: hs 
Models: 
m i l : l o w e r d i f f - 1 + (1 I " C e ntre) 
m21: l o w e r d i f f - Walk + (1 I Centre) 
m31: l o w e r d i f f - T r e a t l + Walk + (1 I Centre) 
m41; l o w e r d i f f - T r e a t l * Walk + (1 | Centre) 
Df AIC BIC l o g L i k 'Chisq Chi Df Pr(>Chisq) 
m i l 2 3583.2 3592.0 -1789.6 
m21 3 3578.3 3591.5 -1786.1 6.8768 1 0.008732 
m31 5 3581.3 3603.4 -1785.7 0.9776 2 0.613365 
m41 7 3584.5 3615.4 -1785.2 0.8253 2 0.661881 
S i g n i f . codes: 0 0.001 0.01 0.05 *.' 0.1 
> d e v i a n c e ( m i l ) 
[11 3579.17 
> deviance(m21) 
[1 ] 3572.293 
> deviance(m31) 
[1] 3571.315 
> deviance(m41) 
(1] 3570.49 
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APPENDIX 6 
Item Characteristic Functions for Ashworth Scores for Different 
Muscle Groups 
Legends for the following graphs -
0,1,2,3,4 - Level of Ashworth Score for the particular muscle group 
Theta-Latent trait-N(0.1) 
Dotted line - Left hand side of body 
Solid line - Right hand side of body 
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APPENDIX 7 
(i) Change in IFN-y (pg/ml) 
Treatment 
Box Plot above is plotted without observation of -180.0 in the Cannador (C) 
group 
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(ii) Change in IL-10 (pq/ml) 
£ 0.0 
Treatment 
Box Plot above is plotted without observation of -52.1 in the Cannador (C) 
group 
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(iii) Change in IL-12 (pg/ml) 
T r e a t m e n t 
Box Plot above is plotted without observations of 82.5 in the Cannador (C) 
group and -41.5 in the Placebo (P) group 
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(iv) Change in CRP (mg/ml) 
T r e a t m e n t 
Box Plot above is plotted without observations of 82.5 in the Cannador (C) 
group and -41.5 in the Placebo (P) group 
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A r t i c l e s 
QCannabinoids for treatment of spasticity and other symptoms 
related to multiple sclerosis (CAMS study): multicentre 
randomised placebo-controlled trial 
John Zajicek. Patrick Fox, Hilary SandefS, David Wright. Jane Vickery, Andrew Nunn, Man Thompson, on behalf of the UK 
MS Research Croup* 
Summary 
Background Multiple sclerosis is associated with muscle 
stiffness, spasms, pain, and tremor. Much anecdotal 
evidence suggests that cannabinoids could help these 
symptoms. Our aim was to test the notion that cannabinoids 
have a beneficial effect on spasticity and other symptoms 
related to multiple sclerosis. 
Methods We did a randomised, placebo-controlled trial, to 
which we enrolled 667 patients with stable multiple sclerosis 
and muscle spasticity. 630 participants were treated 
at 33 UK centres with oral cannabis extract (n=211), 
:i^-tetrahydrocannabinol (:i*-THC; n=206). or placebo 
(0=213). Trial duration was 15 weeks. Our primary outcome 
measure was change in overall spasticity scores, using the 
Ashworth scale. Analysis was by intention to treat. 
Findings 611 of 630 patients were followed up for the 
primary endpoint. We noted no treatment effect of 
cannabinoids on the primary outcome (p=0-40). The 
estimated difference in mean reduction in total Ashworth 
score for participants taking cannabis extract compared with 
placebo was 0-32 {95% CI - 1 0 4 to 1-67). and for those 
taking A'-THC versus placebo it was 0-94 (-0-44 to 2-31). 
There was evidence of a treatment effect on patient-reported 
spasticity and pain (p=0 003). with improvement in spasticity 
reported in 61% (n=121. 95% CI 54-6-68-2). 60% (n=108. 
52-5-66-8}. and 46% (n=91. 39-0-52-9) of participants on 
cannabis extract, A"-THC. and placebo, respectively. 
Interpretation Treatment with cannabinoids did not have a 
beneficial effect on spasticity when assessed with the 
Ashworth scale. However, though there was a degree of 
unmasking among the patients in the active treatment 
groups, objective improvement in mobility and patients' 
opinion of an improvement in pain suggest cannabinoids 
might be clinically useful. 
Lancet 2003: 3 6 2 : 1517-26 
See Commeniary page 1513 
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Introduction 
Of the many symptoms encountered in mukiple sclerosis, 
muscle spasticity' (muscle stillness as a result of increased 
pyramidal tone) and spasms occur in up to 90% of 
patients at some point. ITiis sy-mptom often leads to 
considerable distress from pain, reduced mobility, and 
interference with activities of daily living. Other disabling 
features of the disease include ataxia and tremor in up to 
80% of patients, and sensor>' symptoms, including pain, 
in up to 50%.' I^wer urinary tract dysfunction is present 
in more than 90% of people with long-standing multiple 
sclerosis,* with the most frequent symptoms being urinar>' 
frequency and urgency.' Although many symptoms 
resolve in the remitting phase of multiple sclerosiSj 
spasticity, weakness, ataxia, and bladder symptoms arc 
often characteristic of progressive disease and tend to 
worsen over time. 
Symptomatic therapy often provides inadequate relief 
and can be limited by ioxicit>'. As a consequence, people 
with multiple sclerosis have experimented with many 
alternative therapies, including cannabis, to ease their 
physical problems.'-* l l i e r e is much anecdotal suggestion 
that cannabis and its major components, the 
cannabinoids, have beneficial efTccis on disease-related 
pain, bladder symptoms, tremor, and particularly 
spasticity,^ but little scientific evidence exists for their 
efTicacy. There is widespread unlicensed and often illegal 
use of cannabinoids in muUipie sclerosis, involving 
various formulations and routes of administration, and 
esrimates suggest' that between 1% and ' 1 % of patients in 
the U K use cannabis for symptom relief. 
The plant Cannabis saliva is complex and has more than 
60 oxygen-containing aromatic hydrocarbon compounds, 
known as cannabinoids. Most of their effects seem to be 
mediated through carmabinoid receptors, two types of 
which have been isolated and cloned: CB, ' and CB..* CB, 
receptors arc distributed widely in the ner\'Ous system, and 
seem to have a general role in the inhibition of neuro-
transmitter release, whereas CB, i-cccptors arc mainly found 
on cells of the immune system. The identification of a range 
of endogenous cannabinoids, the most imponant of which 
are thought lo be 2-arachidonoylglycerol and arach-
idonoyleihanolamide (anandamide),'" has also provoked 
considerable interest, and there is some evidence" '- that 
cannabinoids have a neuroprotective oction. 
I'our small, randomised, double-blind, placebo-
controlled studies'^"* have been undertaken to assess the 
elTect of cannabinoids on spasticity related to multiple 
sclerosis, the largest of which'" was a crossover study of 
16 patients. The results suggest that cannabinoids 
produce subjective symptomatic improvement, but 
provide no objective evidence for efficacy. Our aim was 
to ascertain whether either A"-ietrahydrocannabinol 
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(A'*-THC) or an ethanol extract of whole cannabis is 
cfTecrive for the treatment of spasticity and a range of other 
disease-related s\*mptoins in patients with multiple sclerosis. 
Methods 
Pat ients 
Between December, 2000, and October, 2002, we 
enrolled patients aged 18-64 yeare with clinically definite 
or laboratory-supported multiple sclerosis who, in the 
opinion of the treating doctor, had had stable disease for 
the previous 6 months, with problematic spasticit>' 
(Ashworth score of 5^ 2 in two or more lower limb muscle 
groups). Since cannabinoids can potentially afTect cardiac 
function (reducing heart rate and blood pressure), the 
exclusion criterion of ischaemic heart disease and the 
upper age limit were imposed. Furthermore, we made 
ever>' attempt to stabilise factors that affect spasticity, so 
any physiotherapy regimen or medication likely to alTeci 
spasticity' was optimised before the study and not altered 
in the 30 days before start of treatment. Patients with 
active sources of infection, or taking medication such as 
beta interferon, which could afTeci spasticity, were 
excluded, and we asked individuals not to have any 
immunisations associated with foreign travel over the 
15 weeks of the study. Patients were also asked not to 
drive while they were receiving medication and, i f unable 
to comply, were excluded. Other exclusion criteria 
included fixed-tendon contractures, severe cognitive 
impairment, past history of psychotic illness, major illness 
in another body area, pregnancy, use of ^ - -THC at any 
time, and use of cannabis in the 30 days before the start of 
the study. 
We recruited participants from 33 neurology and 
rehabilitation centres in the U K . We undertook the'siudy 
on an oui-paticnt basis, with each patient attending eight 
clinic visits over 15 weeks, including two pre-treatmeni 
visits (visits 1 and 2; see webiable I at htip://image. 
ihelancet.com/extras/03art9446webtablel .pdf for visit 
schedule). Potentially suitable patients were identified by 
the local investigator, referred by other clinicians, or 
self-referred as a result of pubiicit>' about the study. 
Prospective patients were invited to attend for screening 
2-*! weeks before stan of therapy. We reassessed 
individuals with respect to inclusion and exclusion criteria 
before trial treatment began. Patients who did not fulfi l 
the criteria at either of the pre-ireatment visits were 
excluded from the trial. 
The study was approved by the South West multicentre 
research ethics committee and was undertaken under 
licence from the U K Home OfTice. A l l participants 
provided written infonned consent. 
Procedures 
We randomly assigned patients to receive one of two 
active treatments or placebo at visit 2, using M I N I M 
(version 1.5)." Participants were allocated in a two-to-
on e-io-two-to-one ratio at trial cniry to cannabis 
extract, cannabis extract placebo. A ' - T H C , or ^ - -THC 
placebo. Patients were randomly assigned by adaptive 
randomisation to minimise imbalance between centres and 
ambulatory status (defined as able to walk at least 
15 m).'"-'' Once written informed consent had been 
obtained from an eligible patient, the investigator 
contacted the coordinating centre by telephone. The 
coordinating centre allocated the patient a trial number 
and then forwarded relevant details to the central trial 
phannacy, where randomisation took place, using a 
dedicated stand-alone computer. The appropriate 
medication was dispatched directly to the centre. 
Throughout the study, the list of treatment allocation 
codes was kept at the central trial pharmacy, located 
separately f rom the coordinating office. 
We were unable to make the active treatments look 
identical, so each had its own matched placebo. Matching 
o f active and placebo capsules was assessed by an 
independent panel before the start of the study to ensure 
there was no obvious difference between them. Active 
treatment consisted of either synthetic : i ' ' -THC (Marinol, 
Solvay Pharmaceuticals, Atlanta, USA) or a cannabis 
extract, containing A^-THC and cannabidiol as the main 
cannabinoids (Cannador, Institute for Clinical Research, 
I K r , Beriin, Germany). Capsules were manufactured to 
contain 2 5 mg of A"-THC equivalent, 1-25 mg of 
cannabidiol, and less than 5% other cannabinoids per 
capsule. Independent capsule analysis was undenaken to 
assess concentrations of : \"-THC and cannabidiot at 
various time points over the course of the study. Results 
showed A ' - T H C concentrations varied within 2% of 
2-5 mg per capsule over 9 months, with similar low 
degrees of variation in mean cannabidiol concentrations. 
Placebo capsules contained the respective vegetable oil 
vehicle. Dose of study medication was based on 
hod>aveight, with a maximum possible dose of 25 mg daily 
(table 1). Medication was taken twice daily, after food. Al l 
other medication was taken as usual, except other oil-
based capsules—eg, evening primrose oil—which we 
asked patients to take separately from trial medication to 
•void possible interference with absorption. 
The study stancd with a 5-wcek dose titration phase 
(visits 3 and 4) because of the well recognised 
considerable interindividual variation in the tolerated dose 
with oral administration of cannabinoids. During this 
period, we asked patients to increase their dose by one 
capsule (2 5 mg A ' - T H C equivalent) twice daily at weekly 
intervals. I f side-effects developed, patients were advised 
not to increase the dose, and if side-effects were 
considered intolerable, the dose was reduced. Weeks 6-13 
constituted a plateau phase, during which participants 
remained on a stable dose of medication (visits 5, 6, and 
7). During week 14, patients reduced their medication by 
one capsule twice daily each day until they were of f study 
medication. Patients remained off trial medication during 
week 15, and a final assessment was undertaken at the end 
of this week (visit 8). 
Patients were scheduled to attend clinic visits at the 
same time of day wherever possible to reduce the effect of 
any diurnal variation in spasticity. I f rescheduling of visits 
was needed for any reason, arrangements were made for 
patients to attend within 1 day of the scheduled visit date 
i f possible. T o detect any illicit cannabis use, urine 
Bodywcight 
30-49 kg 50-69 hg 7 0 ^ 9 kg >89kg 
Daily target dose (number of capsules) 
Cannabis extract 
.I'-THC 
Placebo 
4 
16(2-34 11 44|) 
13 (3-22 11-121) 
14 (3-57 11-24]) 
6 
S7 (4-7811-7811 
80(4-5811-801) 
94 (5-21 11-461) 
S 
78 (5-79 12-331) 
84 (6-30(2-101) 
75(7.11(1-891) 
10 
30(7-99 (2-861) 
28(6-56(3-271) 
31 (B-47 12-23)) 
Oala arc numoci o^ patients (mcon |SD] dose received) unless omcrvntsc indicated. 
Table 1: Dose of study medicat ion 
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samples were collected at visits 2, 5, 6, and 8 and assayed 
for cannabinoids at a central laboratorj' by ELISA. Blood 
samples for cannabinoid assay, using gas chromatography 
and mass spectrometry, were collected at baseline and all 
subsequent visits from about 150 patients at the two 
largest centres, for convenience (unpublished data). To 
maintain blinding at the coordinating centre in Plymouth, 
all blood and urine results were held at an independent 
siic (MRC Clinical Trials Unit, London) until statistical 
analysis began. 
Our primary outcome measure was the change in 
spasticity related lo multiple sclerosis, using the Ashworth 
score of spasticity .'" Assessment of the Ashworth score 
was made at six visits: two pre-treaiment (visits I and 2), 
three whilst on treatment (visits 5, 6, and 7), and one after 
discontinuation of treatment (visit 8). ' I l i e Ashwonh 
score is an assessment of biological impairment, rather 
than disability or handicap, and is dependent on the 
estimation of the doctor or physiotherapist. The score 
consists of a 5-point scale (O=normal, l=slight catch when 
the limb is moved, 2=an>ihing more than a catch but not 
restricting movement, 3=considerablc increase in tone 
limiting passive flexion, 4=limb rigidity- in flexion or 
extension). We assessed ten muscle groups on each side of 
the body (elbow flexors, extensors, pronators and 
supinators; wrist and finger flexors; hip adductors, knee 
flexors and extensors, and fool plantar flexors). 'ITie 
reliability- of the Ashwonh score depends on assessor 
experience, thus we made every effon to ensure that the 
same assessor monitored spasticity in individual patients 
at all visits. Assessors attended one of six regional training 
sessions or received individual instruction to ensure 
uniformity in application of the Ashworth score. Wc 
provided all centres with a training video demonstrating 
the Ashworth assessment. Each patient was assessed 
supine on a couch, or as close to this position as was 
loleraiedj after resting for 15 min. 'Vhe limb was moved 
rapidly in the direction required by assessment. As 
spasticity can change with passive limb movement, the 
number of movements of each joint was kept to a 
minimum. After a muscle spasm, the Ashworth score can 
increase greatly for some minutes, we therefore asked 
assessors to wait for 5 min after a spasm before reassessing 
that limb. The presence of more than seven beats of 
clonus on examining a Joini was taken as implying at least 
grade 2 spasticity. 
Secondary- outcome measures included the Rivermead 
mobility index," a timed 10 m walk, and four self-
completion questionnaires—the United Kingdom 
neurological disability score ( U K N D S ) , " the Barthel 
index,'* the general health questionnaire (GHQ-30)," and 
a series of nine caiegory-raung scales. The Rivermead 
mobility index and timed walk were assessed at the same 
six time points as the Ashworth score. The U K N D S , 
Barthel index, and GHQ-30 were administered once pre-
ireatment (before visit 2) and once at the end of the 
treatment phase (before vi.sii 7). The category rating 
scales were administered at the end of the treatment phase 
only. For this assessment, we asked patients to assess how 
their symptoms had been over the previous week 
compared with how they were just before the study 
started. Categories included irritability, depression, 
tiredness, muscle stifTness, tremor, pain, sleep, muscle 
spasmSj and amount of energy. At the end of the 15 weeks 
(visit S), the treating doctor also asked participants four 
specific questions about the overall effect of medication 
on changes in spasticity, tremor, pain, and bladder 
function. We calculated the Kunzke expanded disability 
status score (EDSS)-* before and after treatment to 
provide a widely accepted measure of overall degree of 
disability in the trial population. 
The study coordinating team, all investigators, the data 
monitoring committee, and patients were unaware of the 
treatment allocation for the duration of the study. Because 
of the potential for loss of patient blinding with active 
medication, a treating doctor and an assessor had to 
be present at each centre, plus deputies to cover for 
absence. The treating doctor monitored dose, side-effects, 
and patients* well-being, and the assessor (usually a 
physiotherapist) ascertained the Ashworth score, timed 
the 10 m walk, and administered the Rivermead mobility 
index. Assessors remained unaware of any discussion of 
dose or side-effects and, when assessing patients* 
spasticity, were asked not to have access to their 
assessment scores from previous visits. We assessed 
degree of blinding at the end of the study (visit 8) by 
asking patients and study personnel which treatment they 
thought patients had received. Because it was not possible 
to match all capsules in the study, some patients might 
have guessed that they were on either the A ' -THC 
placebo or the cannabis-extract placebo, which is why the 
exclusion criterion of previous exposure to : i ' ' -THC was 
included. We felt the degree of unmasking and bias from 
this cause was likely to be small compared with any 
unmasking as a result of side-effects. 
Our study was undertaken under a Doctors and 
Dentists Exemption Certificate from the U K Medicines 
Control Agency. A pilot study was done in Plymouth on a 
cohort of 24 patients to test the procedures and to 
monitor closely any adverse events. During the dose 
ntration phase of the pilot study, patients were contacted 
by the Plymouth coordinating centre by telephone every 
3 days, and an extensive checklist o f questions with 
respect to adverse events was administered. In all other 
centres, standard adverse-event monitoring took place at 
each visit with classification according to International 
Conference on Harmonisation good clinical practice 
definitions. The coordinating centre in Plymouth was 
notified of any serious adverse events immediately; data 
were then forwarded to the data monitoring and ethics 
committee. Tor the purposes of this study, any hospital 
admission was regarded as a serious adverse event, even if 
it was related to multiple sclerosis and not necessarily 
unexpected. 
Stat ist ical analysis 
T o identify an appropriate sample size, we based our 
power calculations on the assumption thai the standard 
approach of using total Ashworth score as the primary 
cndpoint to measure spasticity would be adopted. 
A double-blind, placebo-controlled U K trial of the 
antispasiicity agent tizanidinc* reported a baseline 
Ashworth score with a mean of about 17. The placebo 
group showed a decrease in Ashworth score of 1-2 
whereas the treatment group showed a decrease of 4-4. 
The power calculations for our study assumed that the 
combined placebo group, the cannabis extract group, 
and the i " - T H C group would have mean decreases 
of 1-2, 4-4, and 2-8, respectively (corresponding to 
placebo, tizanidine, and the mean o f placebo and 
tizanidine). A rate of 37Q of illegal use of cannabis was 
assumed in the placebo and A ' - T H C groups with a loss 
to follow-up rate of 20%, distributed evenly across the 
three groups. 
With these assumptions, recruitment o f 220 patients in 
each group provided 90% power to detect a significant 
difference at the 5% level in the one-way ANOVA, 
assuming an SD of S for the change in Ashwonh score.-' 
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S2l patients screened 
154 ineligible 
667 enrolled 
657 randomised 
10 excluded 
2 Ashwonh score too low 
2 disease not stable 
2 history of heart disease 
1 antispasticiiy drug altered 
1 immunosuppressants taken 
1 open pressure sores 
1 patient choice 
219 allocated cannabis extract 
8 not treated 
3 Ashworth score too low 
2 patient choice 
1 Ashworth score 
incomplete 
1 disease not stable 
1 norvattendance 
216 allocated A -^THC 
10 not treated 
5 Ashworth score too low 
1 too old/young 
1 antispasticity drug 
altered 
1 other serious illness 
1 patient choice 
1 patient died 
211 (5*) included in intention-to-
treat analysis 
4 tost to follow-up 
2 intolerable side-effects 
1 death of husband 
1 lack of efficacy 
222 allocated placebo 
108 cannabis extract placebo 
114 :^ 9-THC placebo 
9 not treated 
6 Ashwonh score too low 
1 history of heart disease 
1 open pressure sores 
1 unwilling to give up 
driving 
206 (4*) included in intention-to-
treat analysis 
9 lost to follow-up 
7 intolerable side-effects 
1 non-attendance 
1 unwilling to continue 
207 (5") analysed 
213 (5") included in intentron-lo-
treat analysis 
6 lost to follow^p 
3 lack of efficacy 
2 travel difficulties 
1 increase in weakness 
197 (4*) analysed 207 {5*) analysed 
Figure 1: Trial profile 
•Patienis >ivith low Ashwonh score already sianed on ueatment. 
This calculation assumed there was no difference 
heiween placebo groups and that it was valid to combine 
them. 'ITiis assumption was validaied before the placebo 
groups were combined. No interim analysis was planned 
or done. 
T o minimise daia-emo' errors, we used a double 
data-entry system. A l l decisions with respect to primary 
outcome data were finalised and agreed by a blind 
data review panel before unblinding. We used S-Plus 
2000 Professional and SAS version Se software for 
analysis. Data analysis was by intention to treat and 
was undertaken in accordance with an analysis plan 
drawn up and agreed by the trial steering committee 
before unblinding. We judged a p value of 0 0 5 
significant. 
As planned, we compared the cannabis extract placebo 
and i i ' - T H C placebo groups in terms of changes in 
Ashwonh scores, Kivermcad mobility index, and walk 
limes. Since no evidence of any ditTerences was noted 
between placebo groups, they were combined into a single 
placebo group for all further analyses. The primary-
outcome, mean change from baseline in Ashwonh score, 
was then compared, using analysis of variance, with 
treatments as fixed effects. We also added centres and 
ambulatory status to the model. 
The analysis of limes taken to complete a 10 m walk 
for mobile patients is complicated by the absence of 
data f rom patienis who were physically unable to walk 
at one or other assessment. Initial analysis of these 
data suggested the effects were relative rather than 
additive and that a log-transformed ratio of walk time 
(baseline/follow-up) was appropriate. I'or patients who 
were ambulatory at baseline but unable to walk at 
follow-up, we assumed a suitably small value for the log 
ratio representing longer walk rime at follow-up, so that 
patients who were unable to walk ai follow-up had the 
lowest rank. We analysed data with the Kruskal-Wallis 
test and used non-parametric methods to produce 
9 5 % C I s for the median. 
The Rivermead mobility index, U K N D S j Banhel index, 
and GHQ-30 were each analysed with non-parametric 
analysis of variance to compare the groups. We analysed 
patients' perception questions and category rating scales 
w'nh contingency lable analysis. No adjustments were 
made for multiple comparisons. 
Two subsiudies were incorporated into the main CAMS 
programme. These focused specifically on lower urinary 
iraci symptoms (CAMS-LUTS) and psychological effectii 
of cannabinoids (CAMS-PKC). The results from both 
studies will be published sepamiely. 
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Treatment group 
Cannabis extract (n =211) ;i'-THC (n=206) Placobo (n=213) 
Number of patients Mean (SD)/% Number ol patients Mean (SD}/% Number of patients Mean (SD)/% 
of group of group of group 
Sox 
Male {n=217) 7G -• 63 78 
Female (n=413) 135 143 135 
Ago (years) (n=630) 211 50-5 (7-6) 206 50-2 (8-2) 213 50-9 (7-6) 
Height (cm) (n=624) 209 167-5 (9-3) 205 167-9 (9-8) 210 168 0 {10-4) 
Weight (kg) (n=630) 211 7 1 7 (15-9) 206 71-2 (16-5) 213 71-6 (15-9) 
Body-mass index (kg/m') (n=624) 209 25-6 (5-6) 205 Z5-2 (5-2) 210 25-4 (5-1) 
Mean tusclino Ashworth 
Upper-body muscles (n=629) 211 5 0 (4-8) 206 5-9 (5-6) 212 5-4 (4-9) 
Lower-body muscles (n=630) 211 ie-8 (G O) 206 16-7 (6-6) 213 16-1 (5-8) 
All muscle groups (n=630) 211 21-8 (8-7) 206 22-6(10-1) 213 21-4 (8-5) 
Form ol multiple sclerosis 
RelaDSing/rcmiuine (n=33) 6 3% 14 7% 13 6% 
Primary progressive (n=145) 53 25% 43 21% 49 23% 
Secondary progressive (n3452) 152 72% 149 72% 151 71% 
Ambulatory status 
Able to walk with or without aid (n=303) 103 49% 95 46% 105 49% 
Unable to walk (rt=327) lOS 51% 111 54% 108 51% 
EDSS 
0-3-5 (n=3» 0 0% 1 0-5% 2 1% 
d-5-5 (r\=23) 6 3% 9 4% 8 4% 
(r>=299) 104 49% 94 46% 101 47% 
7-9 (n=299) 99 47% 99 48% 101 47% 
Missing (rv=6) 2 1% 3 1-5% 1% 1% 
Table 2: Baseline charactcrisics 
Role of the funding source 
The sponsors of the study had 
data collection, data analysis, 
wriring of the report. 
no role in study design, 
data interpretation, or 
R e s u l t s 
I-igure 1 shows the trial profile. Of the 630 parients 
included in the inteniion-to-treat analysis, follow-up data 
on the primar>' outcome was obtained for 611 (97%). 
Completion and return of data for the secondary outcome 
measures was also generally high, with data available for 
analysis from 84-91% of patients, including for the four 
questions posed at the end of study. 
Table 2 shows the baseline characteristics of the 
participants. Patients' demographics in the intention-io-
treat sample were matched across the different treatment 
groups except that proportionately fewer patients with 
relapsing/remitting multiple sclerosis were allocated to 
cannabis extract than to the other treatment groups. 
Since relapsing/remitting multiple sclerosis represents 
only 5% of the total sample, however, this imbalance is 
unlikely to have greatly affected our results. 
With respect to analysis of Ashworth scores, 
8 1 % (n=5I3) of patients had the same assessor 
throughout or had a different assessor at just one visit 
(cannabis extract 82% In=173], d'-THC 82% (n=168], 
placebo 8 1 % (n=172J). The primary outcome was 
defined as the change from baseline (mean of two 
baseline pre-treatmeni visits) to the end of the 13-\veek 
treatment period (visit 7). In accordance with the 
protocol, missing Ashworxh scores at visit 7 were replaced 
by carrying fonvard the most recent Ashworth score 
available during the treatment phase. 39 scores were 
carried forward; 28 from visit 6 and 11 from visit 5, 
distributed across treatments (12 cannabis extract, 17 A"-
T H C , ten placebo). Primary outcome data were not 
available for '16 patienis originally randomised 
(12 cannabis extract, 19:\ ' ' -THC, 15 placebo). There was 
no evidence of an eflect of treatment on change in loial 
Ashworth score from baseline to 13 weeks' follow-up 
(p=0-29 with adjustment for ambulatory status and 
centre, p=0 '10 without adjustment). Mean (SD) changes 
in total Ashworth scores (baseline minus follow-up) were 
1-24 (6-60),. 1-86 (7-95), and 0-92 (6-56) for cannabis 
extract, i i ' - T H C , and placebo, respectively. Corresponding 
figures for upper-body muscle groups were -0-05 (411) , 
0-48 (4-70), and - 0 1 1 (4 04), and for lower-body muscle 
groups were 1-29 (4-37), 1-39 (5-21), and 104 (4-20). 
I'igure 2 shows estimates (95% CI) for the treatment effect 
adjusted for centre and for ambulator>^ status; with both 
active treatments there is a small (less than 3 points) 
though insignificant improvement over placebo. 
There was no evidence of a treatment effect on changes 
in lower-body (adjusted for centre and ambulatoo' status 
p=0-7l , unadjusted p=0-74) or upper-body (p=0-20 and 
p=0-31) components of the Ashworth score, and no 
evidence of any interaction effect beiween centre and 
treatment, between ambulator)* status and treatment, or 
between baseline Ashworih score and treaimeni. 
3-| Cannabis extract A^-THC versus Mean active 
versus placebo placebo versus placebo 
0) 
2-
1 -
0 
- 1 -
-2-
-3-' 
Favours 
treatment 
Favours 
control 
so-* 5?^ 
ngure 2: C h a n g e s in Ashworth s c o r e s from base l ine to 
1 3 weeks* follow-up, adjusted for ambulatory s ta tus and 
centre e f fects 
Estimates (95% CI) shown for lower-botJy. upper-body. arxJ total scores 
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- Cannabis extract 
- A9-THC 
Norvambulatory 
Ambulatory 
Lower Upper Total Lo»'er Upper Total 
Ftgure 3: Effect of ambulation on Ashworth scores by 
treatment group 
Mean (95% CI) for reduction in lower-body, upper-body, orxl total scores. 
Both centre (p<0'0001) and ambulatory- status 
(p=0-002) had a significant cfTect on change in Ashwonh 
score (figure 3). The estimated mean reduction in total 
Ashwonh score for ambulatory patients relative to non-
ambulatory patients was 1-78 adjusted for treatment and 
centre (95% C I 0'6-2-9). There was an improvement in 
the mean scores with treatment, occurring in all 
treatment groups, including placebo (figure 4). 
Wi th respect to secondary outcome measures, 
322 patients provided at least one baseline walk time. Of 
these, seven (one cannabis extract, three i i " - T H C , three 
placebo) dropped out of the trial. Walk times were 
obtained from 278 patients at visit 7. 20 patients were 
unable to walk (eight cannabis extract, five A ' - T H C , 
seven placebo) and verj ' large walk times were 
substituted for these individuals. I f patients forgot their 
walking aids at visit 7, walk times were carried forward 
f rom visit 6 (four patients) or visit 5 (one patient). 
Follow-up walk data for visits 5, 6, and 7 were missing 
for 12 patients. ' I l iere was • significant treatment effect 
on walk time f rom baseline to visit 7 (p=0 015). 
The median time taken to walk 10 m was reduced 
f rom baseline to follow-up by 12% with A ' - T H C 
(95% CI 6-21) compared with a reduction with cannabis 
extract of ' 1 % (0-10) and placebo of 4% (-2 to 7). 
Figure 5 shows the median walk time by visit and 
treatment group for patients who provided walk-time 
information at all six assessor visits. 
Placebo (n=134) 
Cannabis extract (n=184) 
- - - A9-THC(n=l62) 
23 
Before On medication 
medication medication 
22 
^ 20 
18-
Visit 
Figure 4: Changes in Ashworth scores by visit and treatment 
group 
Mean iQS% CI) (01 reduction in lower-body, upper body, and total scores. 
Only cases in which observations on all muscles were nvailable at all 
visits arc included. 
We used category rating scales to assess whether 
patients felt their symptoms had improved while on 
treatment relative to before start of treatment, with the 
rating scale only being completed i f patients were affected 
by that panicular symptom. Patients fell that symptoms of 
pain, sleep quality, spasms, and spasticity had improved 
while on active treatment, though no efleci was noted 
with respect to irritabilit>', depression, tiredness, tremor, 
or energy (table 3). 
There was no evidence of a treatment efTect in any of 
the other secondary outcome measures (Rivcrmcad 
mobilit>' index, Banhel index, GHQ-30, and U K N D S ; 
see webtoble 2 at httpV/image.thelancct.com/extras/ 
03art9446webtable2.pdf for raw data). For all measures 
except the Rivermead mobility index (where the baseline 
represented the mean of visits 1 and 2), the comparison 
between treatments was for the change from visit 2 
(before treatment) to visit 7 (end of 13 week period on 
treatment). 
At visit 8 (post-treatment) the treating doctor asked the 
patient specific questions about whether treatment had 
improved pain, tremor, spasticity, or bladder symptoms. 
Table 4 shows the patients' responses to these questions. 
More patients perceived an improvement in spasticity' and 
pain when taking the active treatments than when taking 
placebo. Difference in perception of improvement in 
tremor was not significant and no treatment effect on 
bladder symptoms was identified. Although there was no 
stratification for these specific symptoms between groups, 
the groups were broadly balanced for these symptoms 
apart from bladder symptoms, where there were fewer 
patients with urinary- symptoms in the group taking 
: \ ' - T H C . 
There was a significant association between the actual 
treatment and the treating doctors* assessment of whether 
the patient was on active treatment (p<0 0 0 l ) . According 
to the treating doctors' assessment, 7 1 % (n= l40) of the 
cannabis extract group, 66% ( n = n 9 ) of the i i ' - T H C 
group, and 43% (n=85) of the placebo group were on 
active ireatmeni. Similarly there was an association 
between the actual treatment and the patients* .view of 
what they had taken (p<0 001). According to patients' 
reports, 77% (n=15I) , 77% (n= l39) , and 50% (n=98) of 
the cannabis extract, A ' - T H C , and placebo groups, 
respectively, thought that they, had been on active 
treatment. 
— Ptecebo |n=87) 
Cannabis exiraci (n=83) 
• - - iS.THC |n=73) 
Before On medication 
medication medication 
Visit 
Figure 5: Median 10 m walk times by visit and treatment group 
Only cases in v;hich patients weie ambulatory at baseline and walk 
information w3S available at all six visits included. In cases where patient 
v.-as physically unable to walk a suitably large value v.-as substituted. 
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Response P* 
Improvement Same Dotcrioration 
Cannabis Placebo Cannabis A'-THC Placebo Cannabis ^•-THC Placebo 
extract enlraci extract 
Irritabilily (n=346) 46 (39K) 37 (33%) 31 (26%) 42 (36%) 42 (38%) 63 (54%) 30 (25%) 32 (29%) 23 (20%) 0-619 
Depression (ns3S2) 43 (36%) 36 (29%) 3S (28%) 44 (37%) 47 (38%) 64 (47%) 33 (28%) 42 (34%) 3 5 (26%) 0-298 
Tiredness (n=4901 46 (28%) 35 (22%) 37 (22%) 51 (31%) 46 (29%) 79 (47%) 58 (41%) 76 (48%) 52 (31%) 0-068 
Spasticity (n=543) 95 (52%) S9(51%) 67 (37%) 43 (23%) 40 (23%) 52 (28%) 46 (25%) 47 (27%) 64 (35%) O O l O 
Shake/tremor [n=3gi) 49 (38%) 52 (41%) 45 (33%) 48 (38%) 44 (34%) 53 (39%) 31 (24%) 32 (25%) 37 (27%) 0-398 
Pain (n=419| 68 (46%) 64 (50%) 42 (30%) 48 (32%) 43 (33%) 58(41%) 32 (22%) 22(17%) 42 (30%) 0-002 
Sleep (n=479) S2 (50%) 71 (47%) 59 (36%) 52 (38%) 57 (38%) 79(48%) 20 (12%) 24(16%) 25 (15%) 0-025 
Spasms (i»=520) 96(53%) 81 (49%) 67 (39%) 50 (28%) 49 (29%) 68 (39%) 34 (19%) 37 (22%) 38 (22%) 0-038 
Energy (n=540) 61 (33%) 61 (35%) 45 (24%) 73 (40%) 63 (36%) 78 (42%) 49 (27%) 49 (28%) 61 (33%) 0-140 
Data are number (% of trealnieni group). 'Obtoined by comparing three treatment Broups on ofig'rniil ll-point rating scale. 
Table 3: Responses to category rating scales 
There . was no associadon between the assessors* 
opinion of treatment and the actual treatment (p=0-72). 
The proportions viewed by the assessor as being on active 
medication in the three groups were 44% (n=90) cannabis 
extract, 39% (n=73) A - - T H Q and 42% (n=86) placebo. 
Compliance with study protocol was generally good. 
592 patients provided pre-treatment urine samples, of 
which ten (2%) tested positive for cannabis. A small 
proportion of patients (cannabis extract 2% [n=41, 
A--THC 2% [n=4], placebo 1% (n=2)) therefore 
probably took cannabis in the month preceding the trial, 
in contravention of the protocol. In the placebo group, 
three (2%) patients had positive urine tests at visit 5, 
and four (2%) were positive at visit 6. Concomitant 
medication was monitored during the course of the study. 
At the Stan of the study, 376 patients were taking 
medication for their spasticity', with no difference between 
the groups (128 cannabis extract, 120 A ' -THC, and 
128 placebo). During the 15 weeks of the study, a further 
34 patients commenced medication for their spasticity 
(12 cannabis extract, 11 i i " -THC, and 11 placebo). 
Table 5 shows a summary of the serious adverse events 
reponed, which on no occasion resulted in unmasking of 
treatment. Numbers of events arc similar across the 
treatments, with slightly more events in the placebo group. 
Most of the events were expected in our study population. 
There was one death from pneumonia, occurring at week 
13 in the ^- -THC group. There were a large number of 
minor adverse events (table 6). As expected from the degree 
of uiimasking among patients and the known side-effects of 
cannabinoids, there were more episodes of dizziness or 
light-headedness, and of dry mouth among the active 
groups. There were some dilVerences between groups for 
gastrointestinal side-effects. Constipation seemed more 
Treatment group P 
Canrvibis CAtract 
(n=l97) 
.i*-THC 
(n=181| 
Placebo 
(n=l98) 
Symptom improvement 
Bladder 0-149 
Yes 68 {4i)%) 67 (40%) 51 (33%) 
No 87 (55%) 97 (59%) 102 (57%) 
Pain 0 0 0 3 
Yes 83(57%) 64 (50%) 51 (37%) 
No 63 (43%) 64 (50%) 86 (63%) 
Tremor 0-052 
Yes 53 (48%) 44 (40%) 43 (33%) 
No 64(52%) 67 (60%) 89 (67%) 
Spasticity 0 0 0 3 
Yes 121(61%) 108 (60%) 91 (46%) 
No 76 (39%) 73 (40%) . 107 (54%) 
frequent in the cannabis extract group, though there was 
no concomitant increase in hospital admissions for 
constiparion (26 events, compared with nine in the A--THC 
group and five in the placebo group). Diarrhoea was more 
common in both active groups (38 events in cannabis 
extract group and 36 in A ' -THC) compared with placebo 
(15 events). Increased appetite was also an expected side-
effect in treatment groups, although at low levels (four 
cannabis extract, six A"-THC, one placebo). 
Discussion 
Treatment with cannabinoids did not improve spasticity-
associated wiih multiple sclerosis as measured with the 
Ashworth scale, but did result in some benefit in secondary-
outcome measures, assessing mobility and patients* 
perceptions of the effect of spasticity. These findings are 
consistent with those of smaller smdics,""'" which showed 
some subjective, but no observ'er-verified, improvement in 
disease-related spasticity with use of cannabinoids. Our 
results should be considered in the context of a degree of 
patient unmasking in the active treatment groups. 
Our aim was to assess spasticity with the Ashworth 
scale, and the power calculations were based on data from 
a previous study of tizanidine in multiple sclerosis.* 'ITie 
limitations of the Ashworih scale in measuring the highly 
complex symptom of spasticity are well known,^ and 
there is a need to develop new patient-oriented scales to 
enable measurement of what matters to them." One 
possible explanation for our results is that the Ashwonh 
scale is too insensitive to identify small but clinically 
Treatment group 
Cannabis A»-THC Placebo Total 
extract (n=ia) (0=20) {n=50) 
(n=12) 
Advciso ovcnt 
Multiple sclerosis relapse or 1 1 7* g 
possible letapse 
Urinary tract inlection 1 3 4 s 
Pneumonia 1 2 (1 death) 1 A 
Blocked/insertion of 1 1 2 4 
suprapubic catheter 
Constipation 1 3 4 
Grand mal seizures 1 1 2 
Other 6t 11* 2§ 19 
Total 13 I S 20 50 
Data are numtier (% ol particuUir symptom within group). Not oil patients 
responded to ciiiesiHins. panirularty it thni s>-mpiom v.-as not a mojoi probtem 
(or [tiem. 
Table 4: Assessment of treatment benefit at visit 8 
•One paiieru had two relapses. One event eoch ol: funftary tract 
inleciion/relapse, collapse/bradycaidia. tall at home, diuiness (inappropriate 
SAE icport). oooominal pain ol unh/wwrn cause, aaivc duodenal ulcc» and 
HcficoboHcr pyioti: ^collapse of unknown cause, possible transient ischaemic 
Qllack/syncope, viral gastroenteritis, chronic pleural effusion, pneumonia and 
renal stones', chest intcction/uiinary tract infection, cellulitis of leg/diarrhoea 
ond vomiting, emergency hip replacement, disease progression (not relapse), 
urinary tract infection/diarmoea and vomiting, back pain; and § d e e p ^ i n 
ttirornbosis. minor CCrcbiO»,'OSCul3f Cvcnt. 
Table 5: Frequency ol serious adverse events 
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Adverse ovcnt 
Bladder 
Gasiroiniestinal iraci 
Pain 
Depression or anxiety 
Vision 
Infection 
Dizzy Of lightheadedness 
Dry mouth 
Weakness or reduced mobility 
Sleep 
Spasms or stiffness 
Tremor or iDCk of coordination 
Numbness or paraesthesia 
Miscellaneous 
Improvement in symptoms 
Total 
Treatment group 
Connabis extract il'-THC Placebo 
Number of patients Number of Number of patients Number of Number of patients N*umber of 
reporting syrrpiom events reported reporting svTnptom events reported reporting symptom events 
{% of total ITT patients) (% of total ITT patients) (% of total ITT patients) reponed 
55 (26%) 80 49 (24%) 67 49 (23%) 73 
79 (3796) 132 62 (30%) 96 42 (20%) 65 
51 12A%) 89 53 (26%) 76 69 (32%) 93 
20 (9%) 29 20(10%) 22 18(8%) 20 
16 [&%) 18 12 (6%) 13 5 {2%) 8 
34 (10%) 40 30 (15%) 37 3G (17%) 40 
105 (50%) 183 121(59%) 209 38(18%) 53 
42 (20%) 47 54 (26%) 60 14 (7%) 15 
48 (23%) 66 52 (25%) 67 43 (20%) 53 
85 (40%) 121 73 (35%) 101 70 (33%) 93 
69(33%) 98 70(34%) 102 70(33%) 105 
21 (10%) 24 25 (12%) 30 17 (8%) 22 
14 (7%) 19 19(9%) 23 14 (7%) 15 
64 (30%) 95 53 (28%) 84 47 (22%) 73 
3(1%) 3 2(1%) 3 1 (0-5%) 1 
706 1044 700 990 533 729 
in=intenUon to treat. 558 patients reported adverse events: 196 cannabis e«troct. 193 S*-1HC. 169 placebo. 
Table 6: F r e q u e ncy of minor adverse events 
significant effects on spasticit>'. Nevertheless, wc'are 
confident that we have excluded any major observer-
assessed efTect on spasticit>', and the Ashwonh score is the 
most reliable and well-validated measure of spasticity, 
which has been used in previous studies.*"*" Another 
explanation for our results is that we might not have 
achieved high enough systemic medication concen-
trations. Higher doses of drug might have achieved a 
greater effect on the Ashworth score, but most patients 
within the active treatment groups did not reach their 
target dose because of side-effects, suggesting that higher 
doses would not be tolerated. \Vc arc analysing scrum 
concentrations of cannabinoids in a large subgroup of 
patients to examine the relation between serum 
concentrations and clinical effect. 
Spasticity is a complex symptom, which might be 
assessed differently by patients (who note the degree of 
stiffness) and doctors (who use the Ashworth score). 
Cannabinoids might affect patients' perceptions of 
spasticiti', thereby improving their symptoms. This notion 
is supponed by the finding of a significant difference 
between active and placebo groups with respect to patients' 
opinion that the medication had helped their spasticity-, on 
both the overall elVect question at the end of the study and 
the category-rating scales of muscle stiffness and .spasms. 
Our results are also consistent with a report from a 
crossover study," the findings of which indicated trends in 
reduction of spasms and improved mobility in 50 patients 
who received cannabis extract. The absence of subjective 
effect on tremor suggests that any treatment effect is 
unlikely to be mediated through a general masking of all 
negative symptoms, and there seems to be a differential 
effect in specific areas. Overall, the significant subjective 
effects on pain and muscle spasms, together with the 
patients' belief that these drugs helped spasticity, suggests 
there might be a reduction in the manifestations of 
spasticity, rather than an effect on muscle stiffness per se. 
Our finding of a small improvement in 10 m walking 
time in ambulant patients is noteworthy, particularly since 
other measures, such as the Rivermead mobility index, 
indicated no effect of treatment. Assuming that no major 
effect on spasticity underlies this improvement, a 
reduction of discomfort during walking could explain 
these results. Further work is necessary lo assess the 
mechanism of action by which cannabinnids seem to 
improve mobility in patients with multiple sclerosis. 
To obtain the patients' perspective, pain was assessed 
with • category rating scale and an overall assessment at 
the end of the study. In both measures, there was a 
significant beneficial effect from treatment. This finding is 
consistent with previous data,'' suggesting that 
cannabinoids are effective, i f modest, analgesics. 
However, since many patients have indicated simple 
analgesia ineffective in pain control, we speculate that 
cannabinoids might have a more specific role in the 
management of chronic neuropathic pain. Rcsuhs of 
studies done in animals" suggest that cannabinoids have 
analgesic action, which is independent of the opiate 
system. Furthermore, a report" has provided evidence for 
improvement in pain control and pain-related sleep 
disturbance in patients with multiple sclerosis who use a 
cannabis-based medicinal extract. 
The main measures used by us to detect any overall 
effect on disability were the U K N D S and the Barthel 
index, which showed no significant effects between 
treatment groups. We chose the GHQ-30 as a measure of 
general psychological wcllbcing or distress. I f this class of 
drugs simply made people feel better, then we would 
expect to find differences on the GHQ-30, which we did 
not. Although we might have derived more information if 
we had used a range of other quality-of-life measures, 
both disease-specific and generic, we were conscious of 
demands on both patients and investigators, and therefore 
tried to keep assessments to a minimum to maximise 
recruitment and retention. Once again, the measures used 
might not have been sensitive enough to assess fully the 
effect of symptoms on degree of disability. It is 
noteworthy that our results do not agree with those of a 
previous smaller study,"" which used the same 
cannabinoids as our study. In the earlier study, no 
evidence of any therapeutic effect was obtained using 
"subjects* global impression" and other measures. This 
finding could have been the result of inadequate dosing, 
since participants were only titrated up to a 5 mg twice-
daily maximum dose. 
The placebo response seen in our study was high, with 
almost half of patients feeling that their medication had 
improved spasticity after treatment for 13 weeks with 
placebo capsules. About 35% of patients in the placebo 
group fell their pain had improved, similar to figures 
obtained from, for example, treatments for acute 
migraine. *!lie extent and duration of placebo response in 
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trials of multiple sclerosis should affect the design of 
future studies and the interpretation of previous studies in 
this unpredictable chronic disease. There was an expected 
unmasking of both treating doctors and patients, but 
blinding was maintained in the assessing individuals, 
suggesting that bias is unlikely to have occurred in the 
assessors' data. 
We used oral capsules as the mode of medication 
delivery. There are inherent difllcuUies in predicting 
individual dose-response with cannabinoids, which is why 
a titration phase was incorporated into the study. 
Smoking cannabis results in more rapid and reproducible 
blood concentrations of cannabinoids than oral 
administration; this group of drugs are lipid soluble and 
lung inhalation also avoids liver metabolism and hence 
improves consistency of administration. We chose oral 
administration because it was considered unethical to 
expose individuals to the risks associated with smoking 
cannabis, and oral medication was readily available when 
ihc study was designed. Alternative routes of 
administration are being tested that might allow for more 
predictable dose-response relations. 
There was no evidence for any distincuon in terms of 
efficac>- bcuveen ^ - -THC and whole cannabis extract, and 
any differences observed in the data presented might 
.simply indicate chance, since the study was not powered 
to detect such differences. Although these drugs were 
generally well tolerated, there were some slight differences 
in degrees of adverse events beiween groups, particulariy 
in the number of gastrointestinal side-effects. 
'l"he finding of reduced hospital admissions for relapses 
in the two active treatment groups compared with placebo 
was unexpected. Our study was designed to assess the 
effects of camiabinoids on symptoms related to multiple 
sclerosis in individuals with fairly stable disease, so most 
patients had slowly progressive disease. Nonetheless, 
cannabinoid receptors are present on cells of the immune 
system, and the finding of a reduced relapse raie in what is 
commonly regarded as an autoimmune condition, is 
worthy of further investigaiion. 'ITiis finding is consistent 
with some findings of studies of animal models of 
dcmyelinating conditions," in which synthetic 
cannabinoids used in established disease significantly 
improved both neurological deficits as well as histological 
evidence of immune activation. 
W^en assessing our results, it should be acknowledged 
(hat the degree of evidence for many of the commonly 
used drugs to combat symptoms is weak. A Cochrane 
review"* of antispasiiciiy agents for multiple sclerosis 
concluded that the paucity of evidence meant no 
recommendations could be made to guide prescribing, 
and that better outcome measures need to be developed. 
We used the findings of two studies,*" '^  using tizanidinc to 
treat spasticity in patients with multiple sclerosis-related 
.spasticity^ in our power calculations. One study noted a 
difference in Ashworth scores comparing active treatment 
with placebo," whereas the other showed no effect." 
Neither of these studies detailed any difference in walking 
times, and even when a significant effect was obtained 
in the Ashwonh score, there was no difference in 
pain measures or sleep quality' on active medication.** 
Although there is slightly more evidence for the use 
of aniicon\'ulsanis in chronic pain s>-ndromes," few 
controlled trials have been published, and pain syndromes 
in multiple sclerosis have been poorly characterised. 
Spasticii>' is a highly complex phenomenon, composed 
of both signs observable to assessors and symptoms 
reported by patients. Our results, using the Ashwonh 
score as the priman* outcome measure, exclude any major 
effect of treament of spasticity' with cannabinoids, but the 
effect of spasticity and pain as assessed by patients 
indicates a symptomatic subjective clinical effect. There 
was also a beneficial effect on walking time. Our findings 
therefore provide some evidence that cannabinoids could 
be clinically useful in treatment of symptoms related to 
multiple sclerosis, but more work is necessary-, using 
outcome measures that more adequately assess the effect 
of symptoms in chronic disease. 
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Objective: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS), in a 
follow up to the main Cannabinoids in Multiple Sdcrosis (CAMSJ study. 
Methods: In totol, 630 policnts with stable M S with muscle spasticity from 33 UK centres were randomised 
to receive oral tetrahydrocannabinol ( A ' - T H C ) , connobis extract, or placebo in the main 1 5 week 
C A M S study. Jho primary outcome v/os chonge in the Ashworth spasticity scale. Secondary outcomes 
were the Rivermeod Mobility Indtat, limed 10 metre wolk, UK Neurological Disobility Score, postal Borthel 
Index, General Health Chjcstionnairc-30, and a series of nine category rating scales. Following the main 
study, patients vt^re invited to continue medicotion, double blinded, for up tol2 months in the follow up 
study reported here. 
Results: Intention to treat onolysis of data from iho 80% of patients followed op for 12 months sfrowed 
evidence of a small treatment effect on muscle spasticity as measured by change in Ashworth score from 
baseline to 12 months ( A ' T H C mean reduction 1 -82 (n = 154, 95% confidence interval (CI) 0.53 to 3.12), 
connabisextroct0.10(n«I72, 9 5 % C I -0.99 to 1.19), placebo -0.23 (n=176. 95%CI -1.41 toO.94); 
p = 0.04 unodjusted for ombulotory status and centre, p = 0.01 adjusted). There was suggestive evidence 
for treatment effects of A ^ - T H C on some aspects of disobilily. There were no moior safety concerns. 
Overall, patients felt that ifwse drugs were helpful in treating their disease. 
Conclusions: Those data provide limited evidence for o longer term treatment effect of cannabinoids. A 
long term placebo controlled study is rvow needed to establish whether cannabinoids may hove o role 
beyond symptom omeliorotion tn MS. 
Cannabis a n d its cumiiotigni cnnnabinoids (['^•'ticulorly i c i r a h y d r o c a n i u b i m i l ( A ' - T H C ) , bc l ic \ct l to be l l ic major . ic l ivc cannab ino id ) have been c la imed anccdo-
lal ly lo improve sy inpioms related lo mult iple sclerosis 
( M S ) , ' a l though unt i l recently there has been l i l i le scienltflc 
evidence of effcci . There is also experimental evidence that 
cnnnabinoi i l s m a y have a ncuroprmec i ive aciion.'"'' 
T h e C . \ M S study* was the first large scale study designed to 
test the hyiMxhesii: that cannabino ids may have a beneficial 
ef fcci on M S sy inpioms. T h e primary' uuicoine measure was 
the A s h w o n h assessment of m u s c l e spasi ic i ly . a n d the s tudy 
also cvaluaied other M S related symptoms, disability, and 
safety. T h e main study covered 15 weeks, w i th al l patients 
d i sconi inuiny f rea imen i dur ing week 14. There was no 
evitlcncc of i r e a i m e n i effects o n change i n A s h w o n h score or 
other measures o f disability from baseline to week 13. 
However, there w a s evidence of improvement in walk ing 
tintc for ambulatory paiienLs a n d in patient peree|]iion.s of 
spasticity, musc le spasms, pain , a m i sleep. There was 
evidence of patient untnasking, complicat ing interpretation 
(if paticnl as>essed outcomes. 
Fnl lowing the m a i n study, [laiients were given the 
npi ion of re tonin ienc ing metlicaitun. double bl inded, up to 
week 52. Tlte results from the follow up study are presented 
here. 
METHODS 
T h e study was approved by the South West M u l i i c c n i r e 
Research Ethics C o m m i i i c c a n d conducted under licence 
from the U K Home Off ice . A l l p a n i c i p a n i s provided w r i i i c n 
informed consent. 
Study design 
Details of ihe m a i n C A M S study have been rejMrted else-
where.* Patients aged years w i t h cl inical ly rtermiic m 
laboratory stipporied M S , stable disease for the previous 
6 months ( i n the opinion of ihe treating physician, rather than 
as-tneasurcd by E U S S ) a n d problematic s i u s l i c i i y ( A s h w o r i h 
sirorc of at least 2 in two or more musc le groups), were 
reCTuitetl across 33 U K neurology a n d rehabilitation cenues 
(sec end of pajHrr) b c i w c c n December 2000 a n d Ocio l jcr 2002, 
O f vhe group. 97% h a d progressive disease a n d -19% were 
ambulant . Dur ing the m a i n study, patients aitendett eight 
cl inic visits over 15 \veeks, w i th a screening a n d randoni isa-
lion visit 2 - 4 weeks before commencement o f i rca iment wi th 
cither one of two active ireatmenis or ihcir match ing placebo, 
randomly allocated. Dur ing the fol low up phase (weeks 16-
52) , patients were assesseti a i I h r e c f i m h e r d i n i c visits. 
Treotment regimens 
Active treatment consisted of either s>i i ihc l ic A ' ' - T H C 
( M a r i n u l ; Solvay P l i a n n a c e u l i c a l s . At lanta . G A , U S A ) or a 
carmabis extract conta in ing A * - T H C a n d cani iab id lo l ( C B D ) 
as the m a i n cannab inn ids ( C a n n a d o i : Inst i tute for C l in i ca l 
Research, I K F . Ber l in , G e r m a n y ) . Capsu les were m a n u f a c -
tured to conta in 2.5 m g of A**-THC equivalent , 1.25 mg of 
C B D , a n d < 5 % other cannab ino ids |>er capsule . Treatment 
was titrated over the first 5 weeks of the m a i n study, wi th the 
Abbreviations: A -THC, A'-fEtrohydrocannobifxJ; BI, Barthel Index; 
CAMS, Connobinoids in Multiple Sclerosis; CBD, cannabidtol; G H O - 3 0 , 
General Hedlh Oucsfionnoiro-30; MS, multiple sderojls; RMl, 
Rivcrmcod Mobility Index; UKNDS, UK Neurological Disability Score 
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dose of mcdicii i ioii bciny adjusicd, dcpcndini; on side 
cffccis, 10 .1 maximum of 2 5 mg A ' ' - T H C daily, depending 
on body wcig l i i . Trentincni was inkcn orally in two divided 
doses. OiKc op i imuin dosage had been achieved, paiicnis 
remained on • steady dose for 8 weeks, before gradually 
reducing mcdicalion to zero during week 14. Oihcr an l i -
spasiiciiy inedicaiion was optimised prior lo siudy enlr^-. and 
any alieroiions lo conconiiinni medication were doaimcnied. 
At the end o f week 15 , paiiems were offered the 
opportunity to resume medication at the previously deter-
mined dose, for a maximum of 5 2 weeks. I f {vilienis decided 
not lo continue medication, the reasons for non-continuance 
were documented. Tliroughout ihc study, capsule compliance 
was clieckcd at clinic visits by couni i i i f i the number nf 
capsules returned. Urine samples for cannabinoid analysis 
were collected ai each clinic visit during the follow up phase 
in order to identify cannabis use i n the placebo group. 
Assessmenis -
In order lo retluce the [loiential for unmasking bias f r o m 
ireatmcnl side c f fcas , iwo study personnel were used at each 
centre. A treating physician inoniiorcd the dosage, side 
effccis, and patient wellbeing. while an assessor (usually a 
phy.siothcrapist) measured the Ash^vorlh score, timed 10 
metre walk, and Rivermcad Mob i l i t y Index (RA11). During 
the fol low up phase these data were collected at each of the 
three monthly Wsils. Assessors remained blinded to any 
disaission of dosage or side effects, and when evaluating 
patients' spasiiciiy. were instructed not to have access lo their 
assessment scores f r o m previous visits. Self completion 
booklets containing the General Health Questionnaire-30 
(GHQ-iO), category rating scales (asking patients to assess 
any change in their symptoms at thai po'ml in the study 
compared wi th how they were before they started medica-
tion, and measuring irr i tabil i ty, depression, tiredness, muscle 
stiffness, tremor, pain, sleep, muscle sjiasnis. and energy 
levels), the UK .Veurological Disability Scale (UKNDS), and 
the Barthel Index (BI ) were .sent to panicipanis jusi prior to 
week 2 7 and week 5 2 . The Expanded Disability Status Scale 
(EOSS) was used at week 5 2 . 
Starisl ical ana lys is 
The primar>* outcome was mean change i n Ashwonh score 
from baseline fsiar i o f main study) lo end o f follow up period 
www.jnnp.com 
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Rgurc 2 95% Confidence infervali for differences in means (odivc 
minus pbccbo) oS changes in tolol Ashworlh score a) eoch visit. PasitivQ 
voluos favour treoMienl. In total, 55 patients (19 on cannobts extract, I d 
A9-THC, end 22 placebo) started fho triol towards the end of tfie 
fwuitmcn) phase for iho main study and wero therefore necessarily 
unaWc to complete 52 weeks (11 visits) of follow up. For these policntj, 
their last Ashworth score (visit 10) was carried forward as their Final 
measured response. Top panel, all patients; Mickfto panel, elected to 
continue medication; Bottom panel, elected to discontinue medication. 
ami was compared using an analysis of variance model," w i i h 
trc.umcnis as fixed effecis. Ccnircs and ambulnrory suius 
were also added to the model. 
Times taken to complcic a 10 metre walk were analysed 
using ihc Kruskal-Wallis icsi, and tion-parnmeiric methods 
were used lo produce confidence inicrvals for l l ic median. 
The RAIL UKNOS, (wsial Bl. and G H Q - 3 0 were c.ich analysed 
using non-paramciric analysis of variance lo compare the 
groups. EDSS scores were analysed using Fisher's exact icsi. 
Category raring scales were analysed using conlingcncy table 
analysis. Comparison was made belwcen palienis choosing lo 
continue on medication and those who chose to disconiinue. 
by baseline Ashworih scores, RAIL EDSS, age, weight, 
ambulatory siaiiis, tyTJc of disease, sex, and use of urinary 
catheter. No adjustments w-ere made for multiple compar-
isons. 
RESULTS 
Ashworih score dam were obtained for 502 (SO%i of the 630 
patients in the intention to treat sample of the main study: 
154 patients on A ' - T H C (117 continued medication),.172 on 
cannabis extract 0 ^ 7 continued). 176 on placebo ( I I I 
continued) ( f ig I ) . Mean (SD) difference in Ashworih scores 
frotn baseline lo end of study were 1.82 (8.12), 0.10 (7.25), 
and -0.23 (7.37) in the A ' - T H C . cannabis cvtraci. and 
placebo groups re?;iJectiveiy. There was no evidence f rom 
I ! 
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Figure 3 Trcafmonl effect on change in RMI odjustcd for baseline, 
ambulotory status, ond trcotment centre. Top panel, all patients followed 
up; middle ponel, poticnts followed up who cnosc to continue treatment; 
bottom panel, patients fdbwed up who choso not to continue treatment. 
PcuiHva values favour treatment. CM, choso to contiraie medication; DM, 
chose to discontinue medication. Data ora number of episodes (number 
of potients). 
baseline values that patients for w h o m data were missing at 
final assessment or those who chose l u i i to continue 
me<licaiion diffcre<I f rom those in whom monitoring and 
medication continued throughout. 
Comparison of ihc three groups using analysis of variance 
on the change iit total Ashwonl i sairc showed evidence of a 
small uealmeii t effect (p = 0.Ol adjusle<l for ambulatory 
status and centre, p = 0.04 without adjustment) ( f ig 2). 
Both centre (p<0.0001) and ambulatory status (p = 0.006) 
had an effect on change i n Ashwor ih score, as might be 
exiKCted due to different sizes of centres and the nature of 
the ambulatory status, but ihcre wa.s no evidence of an 
interaction between either uca imcn i and centre, or treat-
ment and ambulatory status. This illustrates that the 
t icaimeni effect is similar i n oil centres and in the two 
ambulatory status groups. 
Suggestion of treatment effccl was found in the RMI 
(f ig 3). particularly in (he A ' - T H C group. This effect was 
strongest at the week -10 visit. No treatment cffcct.s were 
evident i n the BI or UKNDS (all assessed using non-
iwramcir ic analysis of variance to compare groups). 
Evidence would suggest thai the RiMI is the most responsive 
of the outcome measures used.' In iiaiicnts who chose to 
discontinue medication, there were no significant treatment 
effects in any of ihc outcome measures. 
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Table 1 Caiegory rating scales analysed using contingency table analysis 
Impnjvomanl Soma OctoHoratian 
A'-THC CE Placebo A'-THC C£ Placebo . \ ' -THC CE Pkxebo P* 
Po.n (n-3561 30(28) 33(31) 17 (U) 61 (56) 53(44) 70 (56) 18(16] 31 (25] 38 (X) 0002 
Shak^ (n.323) 25 (26) 38 (33) 23(20) 53 (55) 56(49) 64 (55) 19(19] 20(18) 30(251 0 015 
Spcnrni (n-^38) 39 (291 55 (361 35(23) 62 (46) 72(47] 69 [45] 33(251 25(17] 48 {32} 0.002 
47 (331 45 (29) 27(171 48 (34) 66(42) 71 (46) 47 (33) 45(29) 58 (37) 0 004 
Slocp [n-3971 40 (3.11 54 (38) 36(26] 63 (54) 68 (48] 80(581 14H2) 19(141 23(16) 0016 
Ertgrgy (n-476) A] (24} 36(23) 36(13) 79 (56) 87 (54) 90 (581 28(20) 33(21} 46(29) 0.004 
Tirodncst ;n-422} 32 (25) 26(18) 17(11} 70 (5^1 81 (56) 88 (60) 28(21) 37 (261 43 (29) 0025 
Dcprcision \n^37i] 27 (26) 38 (34) 20(18} 59 (57) 55 (50) 71 (65) 17(17] 18(16] 19(17) 0 135 
Inrtc^itity [n-3n) 31 (30) 32 (30) 20(20] 56 (551 64(60) 61 (60) 15(15) 11(10) 21 (20} 0.125 
•Obroincd by oor'paring >hr<x trco^cit groups on ihc angind 11 po'in' laalc Oato arc n [n) cxrpt fcr p volucs CE, conrabis o*ior 
Uingcr icrni ircncl.-i were also .seen in ihc wdlkiny lime 
daui, wi th ii reduction in vv.ilkinj; time, fnllnwcd by an 
increase, ahhough su t i s i io i l significance wa^ not rciichcd. 
Tlic |)ro[K>rtio[is of paliciiis unable (o walk al the end t i f the 
Mudy. but whncouhl walk at baseline were 6%. 1-1%, and 13% 
in the A''-THC, cannabis extract, and placebo ^yoiips 
le.'.jM-'ciively. Rating scales showed highly significant cfrecis 
on pain, Sfjasins, spasiicily, and sleep, a i in the main study 
(table 1). 
Evidence of trcairneni effects on ratings of shakincss, 
energy level, and tiredness vvas founti at 27 and 52 weeks, 
bui not on depression or irr i inbil i iy. snggcsiing tvidcr 
symptomatic benefit w'ith time, hut interpretation is diri lenli 
due to unmasking ideniified m the main study period. There 
were no major differences bclsvccn the active treatment 
groups in these subjective measures, in contrast to the 
Ashworth and RMI results. 
DuritiR ihis study, all hospital aibnissions were classed as 
serious adverse events. I \ A O M o f the 7A serious ailverse events 
reported (24 A^-THC, 27 cannabis extract. 23 placebo; table 2) 
were as expected in this patient iwpulaiion. 
Unblinding of treatment was not required for any event. 
The first phase of i l ie study slinwed a reduction in rcJapse 
rate i n the active treatment groups comjiared wi th placebo, as 
measured by the number o f relapses requiring hospital 
admission. This vvas not sustained in the follow uj) period, 
w h e n relapses were itlcniinetl f rom all sources (coriicoslcr-
oid administration, adverse events and serious adverse 
events), there appeared to be a similar number of relapses 
in each of the three gi«u}is. This also .suggest.s that the 
reduction in disability seen in the A ' - T H C group camtoi be 
accounted for by a reduction in relapse rate. 
There were six deaths during the fol low up phase (three 
f rom pneumonia, one f rom carcinoma o f the cervix diag-
nosed after study randomisation, and one each f rom seizures 
and ischacmic iicart disease). A further patient ( A ' - T H C 
group) died in week 42 f rom urinary/respiratory infections 
coniraclcd during week 12 of the main study. Overall, there 
wcic no major safety concerns. Minor adverse events were 
rci>oried by 361 patients (109 on A^-THC. 125 on cannabis 
extract, 127 on placebo; table 3). 
Urinalysis for t:annabinoids throughout the study demon-
strated low levels of illicit cannabis use in the placebo group. 
%viih no more than ftiur patients demons I rating urinary 
caimabinuid pre^sence at any time. 
D I S C U S S I O N 
/Mthotigli patients ielt that both cannabis extract and A ' * - T H C 
hcl iKd ihei i spasticity (accoiding to rating scales), this was 
confirmed objectively by the Ashworth score only in the A'*-
THC group. An improvement of approximately 2 points on 
the Ashwonl i scale f rom a baseline mean of around 22 
occurred in this group, compared w i t h a placebo deterioration 
of around 0,2. We consider this change to be small, alihougti 
the cliidcal significance of this change f rom the patient 
persijcctivc requires further investigation. The reasons for the 
differences between the two active treatment groups compar-
ing subjective and objective measuicmcnls cannot be 
Table 2 Frequency of serious odvcrse events 
A ' - T H C (n = 241 Cannabis extroct [n = 77] Pkxabo (n = 231 
CM DM CM DM CM DM 
ej 2 8 1 2 2 
3 0 3 0 3t 1 
1 0 5\{\ d.od] t [d-cdl 1 1 (d»cd} 
0 0 1 (d;odl 0 1 2 
0 0 1 1 0 0 
0 0 1 0 1 0 
8 ? 3 2 B 1 
?O(IB; 4 (4} 22(71] 5 [5] 16(15) 7(7) 
Rolopie/pcttsible rolopio 
Urinory troct iofwOion 
Prwumonio/chesl irfcchon 
Inwrion of bodofen puinp 
Umb fracture 
No. of cvenfj (no of po*ien;i) 
Doki ore ncmfaor of porwiti uolcij othco-wiw indico'cd. CM, chose X> con'lnuo modioTion; DM, c^ OiC k) 
dtKonfinuc medkotioo. r6 potionts; t2 porientj; 44 poiefVi. ' O tw even's were oi Wlo«wi (* indicoKi whoro 
poiwnt dx)vc not la conhnue tiiol fred-cunon c4 the end ol mom shxJy] Connob** evcroa group blocVod/ 
injortioo of lopropubic coflWcT*, hoofnaJixio', relopia/unnory heict rtfedion, jympfcx^ S of narvoLi brcc .^down 
(inopproprtato serious ocf»wse ewV (epOf); wirol gattroentorBii .\'-THC groL>p. cofci'vamo of cervix (cfied)', 
cekilitii, d^zzineis - cfios' poin (non cordioc). drug indocod cKoJeikJSis*. gfO-n obsceis; lympi) node btopiy 
(cofcmomo of broochus; <iiod 9 moivfu post trkJ]. pfeurol effusion; possible irofitioni iscfvMoik oHoct; i-rinory 
tract infooian end bi^ wel problem; uinory icoc! infcc'ton ond relapse Placebo group e.erebrap/oso.tor episode, 
d^ Mt po.n; diieoic piogresikxi (not reiopse), hoipiStJiMjrioo (or phyiioAwifTf. iscJmcmlc hoon dijcose (dpcdij 
overdow of onolaesics; pi^hxxxjry embo^  jm', rcJGfMe/cellJi*Ts; review/'•eip '^e. 
vuvrtw.jnnp.com 
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Tabic 3 Frequency of minor odvcrse evenls 
Connobii e • troct Plwebo 
CM DM CM DM CM DM 
(nx125i (n*9I} (nx13S] (nzfil) (n=:12ai (n=l02} 
Bkidckr 26(161 9(6) 37 (24) 3(3) 42(22) 12(11} 
D«pr*»ion or orui»ty n 191 3(31 11 ())) 3(3) 10(10) 2(2) 
Dizxincu or TigMtoodcdnui 19(I7( M U 27(20) 1 (1) 5(^1 1 (U 
l>y rrou^ 3|3» 1 i l ) 217) 0(0» 1 (1) 1 [1} 
Fall 10 (7J I 0) 10(10] 5(5) 1(3) 4(41 
FcriiQtM or litop dhiwhoKm 15(U1 3(3) 15(15) 3(3) U( i3 ) 10(8) 
GoilroHVoWinal troo 22(I7J 3(3) 30(24) 2(2) 14(11) 5(5) 
17(U| 7(5) 76 m 7(5) 20(17) 10(71 
Momory or cooamlrtvion 5(5} 0(0) 5(4) 0(0) 1 (1) 1 (1) 
MiKcloneoui 17(13) 3(3) 15(11) 9(5) 13(11) 6(51 
MS r«topM Of aMicArbahon H (PI 2(2) 13(10] i(4) 9(9) 5(51 
9(8) 2(2) 5(4) 5(5) 5(5} 3(3) 
Oitm skin problen> 3(3J 0(01 7(7) 5(4) 10(81 6(5) 
2.1(18] 5(31 36(26} 15(11) 20(U) 9(91 
f^ fUHM-* torn 1 (II 0(0) I (I) 5(5) 1 (I) 
Spowni Of itiHnou 30(26) 6(5) 35(23) 10(9) 36(231 7(71 
Tn»ax>r or hcV of coordinotion 9(9) 1 (1) 4{d) 1 (II 2(2) 3(31 
Viuon lymptoms 4(4) 1 i n 1 (11 4(4) 1 (1) 0(0) 
W«oln«u or r9cluc«d mob r^^  16(15) 9(7) 20(19) n (7) 24(22) 15(13) 
W 252 (87) 57(22) 301 (95) 89(30) 236 (85) 100 (42) 
CM. c h o M lo con(inv« m w l K o t i o n : DM, c h o M to d i K o r ^ i r u a mAcfexition. 
explained by differences in side elfecis, vvliich were similar 
for both active irroups. Although the study was not designed 
lo deicci differences bci^vccn llie two active trcnimcni 
grouiis. i l is possible that ihcsc differences mny be mediated 
( I I the receptor level, tlius fu i iher work is necdctl to 
differentiate phnrniacodynainic from |iharinacokine(ic 
effecrs. 
Recent work suKgcscs i l ia i ?<pa.siiciiy is a very complex 
[(henonienon, w i i t i cuniribuiinnh from patient sympioms 
physical runcitoniiit;, and (jNyeholoyical impact." The way in 
wii ich patients' syinpioms impact on physical disability is not 
well uniierstood. ami the considerable symptomatic effects 
seen over ihc course of this study may have influenced the 
results seen in disability scores. Whether any effect on 
disability could be explained solely by a reduction in 
spasticity requires luriher long tci in studies. The complcx 
intciacitnn between symptoms and disability lias affected 
pro'ious studies, notably the DAT.ATOP study of selcBiline in 
Ihc treaimeni of l*arkinson'.s disease.'" Alihongh experimen-
tal evidence demonstrates a potential neuroprotective effect 
of caiinabinoitls,^ more work is needed to define ncuroino-
icctton before such a role can be icsicd i n humans. 
This suidy was designe<l jirimarrly as a short term 
symploinaiic study, wi th a voluntary continuation phase 
leading to incomplete long term follow up data. Two 
important sources of bias that require consideration i n the 
interprciaiioii of the lung term follow up data arc the losses 
10 fo l low up (around 20%, w i t h some differential loss in the 
A ' ' - T H C grotrp), and the disconlinualion of medicaiion after 
the first phase in a pro|>nriion of patients ( 3 5 % A ' ' - T H C , 3 3 % 
cannabis extract, 4 1 % placebo). Side effc-cis were similar in 
both carmabis extract and A ' - T H C groups, and there is 
nothing lo suggest that there were any differences in reasons 
foi loss lo fol low up between the two active treatment arms. 
In order lo l imit any self selection bias, data were analysed 
by treainienl group irrespective of whether |}attcnis con-
linued treatment. The absence of difference in characteristics 
bciwccn ihc group continuing medication and those origin-
ally randomised (o receive treatment also suggests thai 
patients continuing medication did not have a substantially 
differeni disease course. The numbers deciding to stop trial 
medicaiion were similar in each of the three study arms, but 
ihc reasons given were different. Of the paiienis in the 
placebo group who decided not to coii i inue treaimeni, 7 4 % 
felt that the medication produced no benefit, compared w i i h 
4 5 % i n the cannabis c.-ttraci and 4 2 % i n the A^-THC groups. 
Adverse effects were more commoniy cited in the active 
treatment arms. We evaluated degree of masking in the main 
study, which demonstrated that, although patients and 
treating physicians coircctly guessed treatment allocation in 
the active t rcatmcm arms more of ten than i n ihc placebo 
group, the assessors remained blinded to t rcaimcni alloca-
tion. We did noi evaluate further potemial unmasking over 
the 1 2 month fol low up period as wc felt it unlikely lo alter 
after the Rrsi 1 5 week ixrriod. As in the main siudy, all results 
need to be interpreted \ v i i h a degree o f caution owing to 
ITOicntlal bias f rom unblinding. However, the Ashworlh score 
and RAII were both performed by assessors who were likely 
to have remained blinded over the course of the study. 
There is now an tirgeni need to constnici a long icrm study 
in progressive MS to establish whclhcr A^-THC has a role i n 
long term disease management or may be restricted to 
symptomatic amelioration i n this disablhig condition. 
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Cannabinoids have been suggested as possessing immunomodulatory prop-
erties, and cannabinoid receptors are present on leucocytes. Clinically, there is 
some evidence that cannabinoids may be therapeutically useful in treating 
multiple sclerosis, which is generally believed to be an autoimmune condition. 
This paper reports data derived from the Cannabinoids in MS (CAMS) study, 
which was the largest randomized controlled trial yet conducted to evaluate 
the therapeutic efficacy of cannabinoids. We found no evidence for cannab-
inoid influence on serum levels of interferon (IFN)-Y, interleukin (IL)-IO, IL-
12 or C-reactive protein as measured using enzyme-linked immunosorbent 
assay (ELISA), in comparison to control values. Mitogenic stimulation exper-
iments also failed lo demonstrate any significant reduction in percentage of 
CD3*, IFN-y producing cells after exposure to cannabinoids in vivo, although 
numbers were small. Further work is needed to establish the functional sig-
nificance of cannabinoid receptors on immune cells. 
Keywords: cannabinoids, cytokines, multiple sclerosis 
Introduction 
Multiple sclerosis (MS) is the most common cause of neu-
rological disability in young adults, with a prevalence of 
around one in 800 in most of the United Kingdom I U . While 
the precise aetiology of MS is unknown, there is much evi-
dence implicating an autoimmune mechanism, with central 
nervous system while matter tracts providing the focus for 
inflammation and demyelination. It has been suggested that 
MS is predominantly a TTil-mediated disease, with good evi-
dence that interferon (IFN)-Ymakes the disease course worse 
[2]. Repeated inflammatory attack eventually provokes 
axonal loss and glial scarring, which constitute the neuro-
pathological basis for chronic disability and progressive 
disease. Most MS starts with repealed clinical episodes 
(relapsing-remitting MS, RRMS). Unfortunately, after pass-
ing through the RRMS phase, the majority of patients 
will ultimately develop chronic progressive clinical decline 
(secondary progressive MS, SPMS, approximately 80% after 
20)'ears). About 15% of patients may follow a progressive 
course from onset (primary progressive MS, PPMS). 
Treatments for MS can broadly be divided into symptom-
atic (such as muscle relaxants and bladder treatments) and 
so-called disease modifying, most of which are immuno-
modulatory, such as beta-interferons and glatiramer acetate. 
The recent Cannabinoids in MS (CAMS) study (3) was 
designed to evaluate whether cannabinoids had any thera-
peutic benefit in treating MS-related symptoms, and ran-
domized 657 patients to an oral extract of cannabis, A*-
tetrahydrocannabinol (A'-THC), believed to be the major 
active ingredient of cannabis, or the respective placebo cap-
sules. Although cannabinoids have been used mainly to alle-
viate symptoms, there is experimental evidence to suggest 
that they may be immunomodulatory. Cannabinoids have^ 
been reported to suppress experimental allergic encephalo-
myelitis (EAE) |4,5l, reduce Thl responses in mouse models 
of infection [6] and high concentrations (5-20 ng/ml) of A'-
THCand cannabidiol (CBD) block iFN-y release m vitro (7). 
However, physiologically relevant concentrations compara-
ble to plasma levels after smoking marijuana (lO-IOO ng/ml) 
may increase IFN-y levels in vitro [7] and recent evidence 
from a small cross-over study in humans has suggested that 
cannabinoids may even have some proinflammatory effects 
(8|. 
We investigated the nature of potential cannabinoid 
immunomodulation on samples obtained from patients 
with MS taking part in the CAMS study, and report the 
results here. 
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Materials and methods 
Patients 
Patients with stable MS were recruited into a double-blind 
placebo-controlled trial looking at the effect of oral cannab-
inoids on spasticit)', the CAMS study (31- They received pure 
synthesized A ' - T H C (Marinol), natural cannabis oil extract 
(Cannador) and matching placebo in equally divided 
groups. The cannabis oil extract contained equivalent dose 
of A ' - T H C per capsule as the synthetic A * - T H C , but with 
other components of natural cannabis, the other major can-
nabinoid being CBD. Doses were adjusted according to side 
effects, with maximal oral dose of 0-25 mg/kg/day of A'-
THC. Patients from tsvo centres (Plymouth and National 
Hospital, Queen Square, London) provided blood samples 
for further laboratory analysis. The full inclusion and exclu-
sion criteria have been published elsewhere (3], but patients 
were required (o have had stable MS for the 6 months and no 
corticosteroids for 30 days prior to study entry. Any relapses 
or corticosteroid medication during the study were recorded. 
Blood samples 
Serum was available from patients taken before treatment 
and at the end of treatment, 13 weeks later for cytokine and 
C-reactive protein (CRP) measurements. Because timing of 
clinic attendance varied between patients, it was not possible 
to obtain samples at the same point after medication in all 
patients, although wherever possible each patient attended at 
the same time of day at each clinic visit. The relatively long 
half-life of cannabinoids and pharmacokinetic modelling 
suggested that after a number of weeks patients would 
achieve a steady state of serum cannabinoid levels, so we 
would not expect short-term confounding of any longer-
term effects. Lithium heparin blood samples were taken for 
cell culture at visits 2 and 7. Controls were obtained from 
random anonymized patient samples sent to the immunol-
ogy laboratory for routine immunological analyses. Periph-
eral blood mononuclear cells (PBMC) were isolated within 
12 h of blood samphng (see below). 
Measurement of serum cytokines [IFN-y, interleukin 
(IL)-IOand IL-121 
Serum cytokine levels (IFN-y, lL-10 and IL-12) were mea-
sured using commercially available, highly sensitive enzyme-
linked immunosorbent assays (ELISAs) (Insight Biotechnol-
ogy Limited, Wembley, UK). Cytokine levels were measured 
in pg/ml. 
Measurement of C R P 
CRP Ie\els were measured as a marker of concurrent infec-
tion and a surrogate marker of lL-6. CRP was measured on 
serum samples remaining after cytokine assays on a MIRAS 
analyser using a routine immunolurbidimetric assay capable 
of measuring levels as low as 2 mg/ml [9|. 
Quantiftcalion of numbers of cytokine-secreting cells 
after stimulation in vitro 
As described previously (10), PBMC were isolated by density 
gradient cenirifugation, washed and resuspended at a con-
centration of 1 X 10* cells/ml in culture medium in duplicate 
in 24-well culture plates. Phorbol myristate acetate (PMA), 
ionomycin and monensin were added to the wells to give 
final concentrations of 20 ng/ml, I nM/ml and 3 Hg/ml, 
respectively. Control wells contained monensin only. The 
plates were placed in a humidified incubator at 37''C, 5% 
COi for 7 h. The cells were subsequently harvested, washed, 
fixed and permeabilized using a commercial kit (Dako 
Inirastain; Becton-Dickinson, Oxford, UK). Cells were 
labelled with surface FITC CD3 and cytoplasmic phyco-
crythrin (PE) IFN-y. Murine surface IgGI fluorescein 
isothiocyanate (FITC) and murine cytoplasmic IgGl PE 
monoclonal antibodies were used as controls. Numbers of 
IFN-y-expressing T cells were quantified by two-colour flow 
cytometry'. Measurements were taken in duplicate using 
samples from each of the cell culture wells. The proportion 
of cells expressing surface CD3 that also expressed cytoplas-
mic IFN-yvs-as calculated. 
Addition of T H C to cell cultures 
Initial experiments using T H C produced by Sigma (Gilling-
ham, Dorset, UK), dissolved in ethanol and added in 
increasing concentrations, showed that only concentrations 
above 40 )ig/ml caused a significant fall in the percentage of 
IFN-y-producing T cells. This dose of A'-THC was then used 
to see whether any reduction of IFN-y positive cells could be 
achieved in vitro using patient cells from the end of the treat-
ment period. 
Statistical analysis 
AlJ experiments and data collection were completed prior to 
unblinding. Analysis was performed using SPSS (Chicago, 
IL, USA) with appropriate parametric and non-parametric 
tests. 
The study was approved by the South-West multi-centre 
research ethics committee and was undertaken under licence 
from the UK Home Office. All participants provided written 
informed consent. 
Results 
A total of 130 patients were recruited to the main CAMS 
study from the t\fo centres (Plymouth, 79; Queen Square, 
51) after the initial pilot phase of 20 patients had been 
recruited in Plymouth. Samples were available from 102 
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patients, r\vo of whom did not commence medication. The 
characteristics of the 100 patient cohort vvere broadly similar 
to the whole CAMS cohort 13), so that mean age was 52 (SD 
7-7), 51% were unable to walk, 75% were female, 25% had 
PPMS and 75% had SPMS. The disposition of patients 
according to treatment group and disease type is shown in 
Table 1. Only two patients in this cohort had a relapse treated 
with 1 g methylprednisolone for 3 days during the study 
period, one in each of the cannabis extract and placebo 
groups. 
Effect of T H C and cannabis extract on serum cytokines 
and CRP 
Using Kruskal-Wallis non-parametric evaluation, there was 
no significant detectable difference between pretreatmenl 
and treatment levels of serum IFN-y. IL-10, IL-12, or CRP 
levels (Table 2). Grouping the two active treatment groups 
together gave similar results and there were no significant 
treatment effects on measured cytokines when the cohort 
was analysed according to disease type (PPMS or SPMS). 
Results of cytokine change according to disease group are 
shown in Figs 1 and 2. Serum IFN-7, IL-10 and IL-12 levels 
correlated with each other with Kendall and Spearman cor-
relation coefficients > 0-35 with all P-values < 0 001. 
Comparison between control and MS serum cytokine 
levels 
Using the Mann-Whitney t/-test and Wilcoxon matched 
pairs, there was no evidence of a significant difference in 
serum cytokine levels between controls and MS patients 
(Table 3). 
Effect of in vivo T H C and Marinol on in vitro IFN-y 
expression in CD3* T cells 
Data from 20 patients was available before and during treat-
ment for analysis of the effect of IFN-y secretion following 
co-incubation of patients cells with A'-THC (placebo n = 6, 
caiinabis extract n = 7, A*-THC n = 7) and results are shown 
in Fig. 3. Although five of seven patients treated with can-
nabis extract and six of seven patients treated with A'-THC 
showed a decrease in IFN-y before and after treatment, 
Tablr 1. Cross-tabulation of trealment (CE ~ cannabis extract) against 
disease type (PPMS = primary progressive MS, SPMS = secondary pro-
gressive MS). 
Table 2. Number of pairs for fCruskal-WalUs analysis and P-values. 
Placebo 
Cannabis 
extract THC P-values 
IFN-Y 22 22 22 0-692 
[L-IO 21 2) 20 0-60S 
1L-)2 18 21 19 0-816 
CRP 17 19 19 0-271 
compared to only two of six patients in the placebo group, 
these differences were not statistically significant. Addition 
of A ' - T H C to cells iM virro following treatment at a concen-
tration of 40flg/ml achieved a further small reduction of 
IFN-7 in all cases across all three groups. A paired-samples 
test showed a mean reduction of 2-31% (95% CI, 0-14-4-49), 
P = 0 04. A representative FACS plot is included (Fig. 4). 
Discussion 
Results from the present experiments do not demonstrate 
any significant effects of cannabinoids on the cytokine pro-
files examined. However, numbers are small and standard 
deviations large, so that relatively small but possibly clini-
cally useful effects cannot be excluded from these results. The 
small numbers also make it very difficult to distinguish any 
differences benveen cytokine profiles in primary and second-
ary progressive disease patterns. Although we did demon-
strate a small reduction of IFN-y expression in CD3* T-cells 
IM vitro at very high concentrations of T H C (several orders of 
magnitude higher than measured serum levels), this suggests 
that there is unlikely to be any significant effect on IFN-y at 
therapeutic doses. 
The majority of cannabinoid actions are thought to be 
mediated via cannabinoid receptors, two types of which have 
been identified and cloned. CB, receptors [ 11J are found pre-
dominantly in the central ner\'ous s>'stem whereas CB^ 
receptors (12] are principally located peripherally, especially 
on leucocytes. The majority of experimental evidence sug-
gests that cannabinoids are anti-inflammatory and may be 
associated with a T h l to Th2 shift. For example, in, virro 
A T H C suppresses T cell proliferation, inhibits the produc-
tion of IFN-Y and shifts Th 1 to Th2 (13]. This may be medi-
ated via a reduction in IL-12 [14]. T N F - a release from 
microglia has also been shown to reduce after cannabinoid 
exposure m vitro [\5]. Both in rat EAE (4,5) and Theiler's 
Table 3. Mann-Whitney {/-test comparing serum cytokine results in 
Disease wvo between MS patients and controls. 
PPMS SPMS Total Mean rank (total number of patients) 
CE 10 23 33 Serum IFN-y Serum IL-IO Senim IL-12 
A'THC 4 28 32 MS patients 69(102) 52 (75) 51 (74) 
Placebo 12 23 35 Controls 55 (29) 64 (34) 45 (34) 
Total 26 74 100 Sig. (two tailed) 0-083 0-066 0-301 
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Fig. I . Box-plot presentation of data from patients widi primary progressive M S for change in interferon ( I F N ) - Y (a), interleukin ( I L ) - I O (b). IL-12 
(c) and CRP (d). The asterisk represents an extreme ralue more than three interquartial ranges from the box hinges. 
murine encephalomyelitis vinjs affected mouse models [16], 
cannabinoids appear to ameliorate the effects of the disease 
by reducing T h l effector functions and inhibiting central 
nei^ous system (CNS) expression of mRNA coding for 
proinflammatory cytokines TNF-a, IL-lp and IL-6. It 
should be noted, however, that doses of A'-THC used in ani-
mal experiments have tended to be between 8 and 40 mg/kg. 
compared to human doses of around 0-25 mg/kg. Similarl}'. 
levels used in vifro have been l-40ng/ml (3-127 (4,13], 
whereas serum levels in humans following oral dosing is 
rarely higher than 5 ng/ml (16 nM, unpublished data). At a 
receptor level, the Kj of A'-THC is around 40 nM at both CB, 
and CB2 receptors [17], so doses used in vitro would seem to 
be excessive. The correlation between serum level and symp-
tomatic or immunological effect is the focus of ongoing 
work. The data are difhcuh to interpret as high lipid solubil-
ity of this group of drugs means that serum le\'ek may not 
necessarily reflect therapeutic doses, due to concentration 
within particular compartments such as the central nen-ous 
system. 
These differences in doses may explain partly why the sit-
uation in humans appears to be more complicated than 
experimental data would suggest. In people smoking can-
nabis, levels of both CB, and CB^ receptor mRNA increase on 
PBMC, with an apparendy preser\'ed ratio of ICB, :3CB2 
[ 18]. Cannabis use has also been associated with a decrease 
in IL-2 levels and Thl-type cytokine profile and an increase 
in IL-IO and Th2 cytokines [19j. However, in the only other 
study examining cytokines in people with MS treated with 
cannabinoids [8], although no change was seen in plasma 
levels of TNF-a, lL-10 and IL- i2 , after LPS stimulation of 
whole blood the authors reported a slight increase in TNF-a 
production in patients taking whole cannabis extract and not 
T H C . It is difficult to assess the significance of these results, 
as numbers were small and no adjustments were made for 
multiple comparisons. The fact that anti-TNF therapy has 
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584 O 2005 British Society for Immunology. Oinical and Experimental Immunology. 140: 580-585 
Cannabinoid influence on cytokines in MS 
been shown to worsen the course of MS [20] suggests that 
classical concepts of proinflammatory cytokines being detri-
mental to the disease course may be an over-simplification of 
disease pathogenesis. Overall, the bulk of evidence would 
suggest that cannabinoids are anti-inflammatory. Interest-
ingly, there has been a recent report of a new diagnosis of MS 
occurring following treatment with a cannabinoid receptor-
1 antagonist for obesity [21 J, and longer-term follow-up 
results from the CAMS study suggest that cannabinoids may 
have more than just a symptomatic role in the treatment of 
MS (221. More work is now needed both to determine the 
functional significance of cannabinoid receptors on cells of 
the immune system, and to investigate whether cannab-
inoids have an immunomodulatory role at doses likely lo be 
used therapeutically. 
Acknowledgement 
The Medical Research Council sponsored the main CAMS 
study 
References 
1 Fox CM, Bensa S, Bray 1, Zajicek JP. The epidemiology of multiple 
sclerosis in Devon; a comparison of the new and old classificaiion 
criteria. J Neurol Ncurosurg Psychiatry 2004; 75:56-60. 
2 Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations 
of multiple sclerosis in patients treated with gamma interferon. 
Uncet 1957; l:89>-5. 
3 Zajicek J, Fox P, Sanders H et ol. for the UK MS Research Group. 
Cannabinoids for treatment of spasticity and other symptoms 
related to multiple sclerosis (CAMS study): multicentre ran-
domised placebo-con trolled trial. Lancet 2003; 362:15)7-26. 
4 Wirguin 1. Mechoulam R, Breuer A, Schezcn E, Wcidenfeld J, 
Brenn T. Suppression of experimental autoimmune encephalomy-
elitis by cannabinoids. Immunopharmacology 1994; 28:209. 
5 Lyman WD. Soneit JR. Brosnan CF, Elkin R. Bornstein MB. Delta 
9-tetrahydrocannabinol: a novel treatment for experimental 
autoimmune encephalom>-eIitis. I Neuroimmunol 1989; 23:73-81. 
6 Klein T\V, Newton C Larsen K, Chou j , Perkins 1, Nong L, Fried-
man H. Cannnbinoid receptors and T helper cells.) Neuroimmu-
nol 2004; 147:91-4. 
7 Watzl B, Scuderi P, Watson RR, Marijuana components stimulate 
human peripheral blood mononuclear cell secretion of inierferon-
gamma and suppress interleukin-1 alpha in viiro. Inl J Immunop-
harmacol 1991; 13:1091-7. 
8 Killesiein |, Hoogervorst EL, Reif M er at. Immunomodulatory 
effects of orally administered cannabinoids in multiple sclerosis. 
I Neuroimmunol 2003; 137:140-3. 
9 Whicher J. C-reactive protein (CRP). In: Thomas l . . . ed. Clinical 
laboratory diagnostics: use, assessment of clinical laboratory 
results, Ist edn. Frankfurt/Main: AACC Press, 1998:700-10. 
10 Cartwright N . Demaine A, lahromi M . Sanders H. Kaminski E. 
A study of cytokine protein secretion, frequencies of cytokine 
expressing cells and IFN-ygene polymorphisms in normal Individ-. 
uals. Transplantation 1999; 68:1546-52. 
t l Matsuda LA, Lolaii S|. Brownstein M). Young AC. Bonner TL 
Structure of a cannabinoid receptor and functional expression of 
the cloned cDNA. Nature 1990; 346:561-4. 
12 Munro S, Thomas KL. Abu-Shaar M . Molecular characterization of 
a peripheral receptor for cannabinoids. Nature 1993; 365:61-5. 
13 Yuan M . Kierlschcr SM, Cheng Q, Zoumalan R,Tahkjn DP, Roth 
M . Delta 9-tetrahydrocannabinol regulates Th]/Th2 cytoline bal-
ance in activated human T cells. I Neuroimmunol 2002; 133:124-
31. 
14 Klein TW. Newion CA, Nakachi N. Friedman H. A*-tetrahydro-
cannabinol treatment suppresses immunity and early IFN-y. lL-12 
and IL-12 receptor P2 responses to Legionella pneumophila infec-
tion. I Immunol 2000; 164:6461-6. 
15 Fachinelti F.dcl Giudice E. Furegato S, PassarottoM, Leon A. Can-
nabinoids ablate release of TNFa in rat microglial cells stimulated 
with lipopolysaccharide. Glia 2003; 41:161-8. 
16 Ooxford JL, Miller SD. Immunoregulation of a viral model 
of multiple sclerosis using ihe synthetic cannabinoid 
R(+)WIN55,212.1 a i n Invest 2003; 111:1231-40. 
t7 Howleii AC. Barth F, Bonner T I cl at. Inlernationat union of phar-
macology, XXVII,classification of cannabinoid receptors. Pharma-
col Rev 2002; 54:161-202. 
18 Nong L, Newton C Cheng Q, Friedman H, Roih MD, Klein TW. 
Altered cannabinoid recptor mRNA expression in peripheral blood 
mononuclear cells from marijuana smokers. I Neuroimmunol 
2D02; 127:169-76. 
19 Pacifici R, Zuccaro P, Pichini S er at. Modulation of the immune 
system in cannabis users. JAMA 2003; 289:1929-31. 
20 van Ooslen BW, Barkhof F. Truyen t et aL Increased MRl activity 
and immune activation in two multiple sclerosis patients treated 
with the monoclonal anti-tumour necrosis factor antibody cA2. 
Neurology 1996;47:1531-4. 
21 van Oosten BW. Killestcin J, Maihus-Vliegen EM, Polman CH. 
Multiple sclerosis following treatment with a cannabinoid recep-
lor- l anatagonisi. Mull Sdcr 2004; 10:330-1. 
22 Zajicek J, Fox P. Teare L ef at Canrubinoids in multiple sclerosis 
(CAMS) study, follow-up data suggesting an effect on disease pro-
gression. J Neurol 2004; 251 (Suppl. 3):44. 
O 2005 British Society for Immunology. OinicalandSxpen'mentallmmunology. 140: 580-585 585 
Clinical Radiolozy (2000) 55, 36-59 
Computerized Strain-Gauge Plethysmography - An 
Alternative Method for the Detection of Lower Limb 
Deep Venous Thrombosis? 
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AIM: To test the ability of computerized strain-gauge plethystnography to act as a screening test for 
lower limb deep venous thrombosis (DNT). 
MATERJAl-S AND METHODS: Over an 8-month period, all patients referred to* our Medical 
Assessment Unit with suspected tower limb D \ T were considered for inclusion in the study. Each 
patient underwent both plethysmography ond ascending venography within 24 h, and the presence or 
absence of thrombus in the popliteal, superficial femoral or iliac veins was noted. The results of the 
two tests were then used to determine the accuracy of computerized strain-gauge plethysmography in 
detecting above knee DVT. 
RESULTS: The screening tests and venograms of 239 patients referred with clinically suspected 
lower limb DVT were compared. The false negative rate of plethysmography was 15.4%, which is 
significantly different from tbe 4^% claimed by the manufacturers of this device (P = 0.00003). 
CONCLUSIONS: in a population of acute admissions with suspected lower Kmb DVT, computerized 
strain-gauge plethysmography is not suitable for use as a screening test due to an unacceptably high 
proportion of false negative screens, J. Elford et al. (2000). Clinical Radiology SS, 36-39. 
© 2000 The Royal College of Radiologists 
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INTRODUCTION 
Many studies have shown that clinical examination alone is 
accurate in only about 50% of cases for the diagnosis of lower 
limb deep venous thrombosis (DVT) in symptomatic patients 
[ 1,2]. The very fact that there arc so many difTercni methods in 
use for the diagnosis of DVT is an indication that to date no 
completely reliable and accurate technique has been developed. 
For many years, ascending lower limb venography [3.4] has 
been regarded as the 'gold standard' investigation for the 
diagnosis of DVT [5]. It is, however, relatively invasive, it 
exposes the patient to ionizing radiation, has a small but real 
incidence of reactions to inttBvascular contrast media, should 
be avoided in pregnant women, and cannot be performed if 
venous access to the fool cannot be obtained. The '~'l-labelled 
fibrinogen uptake test has been shown to detect DVT (6), but its 
interpretation is flawed [7] and enthusiasm for its ability to act 
as an accurate test has fallen since it was first introduced in the 
1970s. 
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Ultrasonography, and in particular colour flow duplex ultra-
sonography 18], have emerged within the last decade as 
accurate non-in\'a5ivc methods for the diagnosis of DVT. 
Ultrasonography is simple ond accurate where above-knee 
DVT is concerned [9], and although more challenging to 
perform below the knee, with experienced operators it is just 
as accurate as venography [10], if not more so [11]. 
Impedance .plethysmography has also claimed to be a sub-
siinite for a.<;cending venography. Initial studies were promising 
[12,13], but more recent work suggests that is has a far lower 
sensitivity than originally claimed, even for proximal DVT 
[14]. 
Much work has also recently been published regarding 
computerized strain-gauge plethysmography, in which a strain-
gauge pleihysmograph is linked to a computer, which analyses 
capacitance and venous outflow to determine the presence of 
proximal DVT. The Belfast DVT Screcner (Advanced Medical 
Technology. Coleraine, N Ireland BT 51 5JZ) is such a device. 
It consists of an indium-gallium strain-gauge linked to a 
computer, and a printer (Fig. 1). Most of the published studies 
of the efficacy of the Belfast DVT Screener have been under-
taken by the manufacturers of the device [15.16]. in s>-mpto-
motic post-operative patients although there is one published 
study of an independent analysis [17]. These studies claim a 
© 2000 The Royal College of Radiologi!>ts 
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Fis. 1 - The Be l f j i i DVTSercener. The device consists ofa blood pressure 
cuff (on the right) nnd a sirain-itaugc (on the left) Imked to • computer. 
very high sensitivity of the device for the detection of proximal 
DVT, with extremely low false negative rates. 
A Medical Admissions Unit was introduced in our institution 
to manage admissions in a timely way so that unnecessary 
hospital stay could be avoided. Significant delay in the diagnosis 
oflower limb DVT can occur following referral to the Imaging 
Department for contrast venography or duplex ultrasound. It 
was hoped that the ward-based diagnosis of DVT using the 
Belfast DVT Scrcener might assist in the management of 
admissions, so reducing pressure on beds. In view of th2 
claimed low false negative rate, the intention was to achieve 
this by discharging patients in whom the screening test was 
negative, but to refer for venography those in whom it was 
positive. It was hoped that this would reduce referrals to the 
Imaging Department for unnecessary venography by around 
60%. A Belfast Screener was therefore purchased, and this 
study evaluates the performance of the device, v^hen used as a 
screening test for the detection of proximal DVT in sympto-
matic patients in every day clinical practice. 
Between October 1997 and May 1998, 275 patients were 
referred to our Medical Assessment Unit v.'ith clinically sus-
pected lower limb D \ T . .Ml of these paiienis underwent a 
Belfast DVT Screening Test, using the technique described by 
its manufacmrers. The leg is elevated and placed in a foot rest, 
with the knee flexed such that it lies level with the heel. A 
standard thigh cuff is placed around the upper thigh, and the 
indium-gallium strain-gauge placed around the point of max-
imum circumference of the calf. The computer then controls the 
lest, by inflating the thigh cuff to a level above venous pres.iure 
but below arterial pressure (c. 55mmHg) for 2min. and then 
calculating the venous capacitance and venous outflow follow-
ing deflation of the cuff. The computer then compares the result 
with its own database, and clearly displays the result as positive 
or negative for the presence of proximal DVT (Fig. 2), which is 
defined as thrombosis in the popliteal, femoral or iliac veins 
[15]. All operators of the Belfast DVT Screcner were trained in 
its use by the manufacturers, and the strain-gauge was replaced 
every 50 tests in accordance with their guidelines. 
For the purposes of the study, only those patients referred for 
ascending venography within 24 h of the screening test were 
included in the analysis, and this leaves 250 patients eligible for 
comparison of screening test with venography. Of these, 
ascending venography could not be performed in eight patients, 
in 5L\ because of failure of canalisation of a peripheral vein in 
the foot, in one because the patient was pregnant, and in one 
because the patient was a diabetic taking Metformin, which in 
our department is a contraindication to the concomitant admin-
istration of intravascular contrast media. 
All of the remaining 242 patients underwent ascending 
venography, according to the method described by Rabinov 
and Paulin [3]. The venograms were then interpreted indepen-
dently by two radiologists. For the purposes of the study, it was 
agreed that the ability of the Uvo methods to detect thrombus in 
the popliteal, femoral or iliac veins would be determined. 
Right leg 
20 
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120 122 
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Left leg 
VO 
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Fig. 2 - Two sample traces produced by the Scrccner. showin3 a po$iii\-c nnd p.cQati^ -c resuh for the presence of proximal lower limb DVT. 
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Table 1 - A coinparisun of the Belfast DVT Screencr with ascending 
venography for ihc presence nrproiima) DVT in 239 patients 
Result of 
venou'ram 
+ Totals 
Result of Belfast 55 28 S3 
DVT screen - 10 146 156 
Totals 65 174 239 
Sensitivity - 55/65 = 84.6%; specificity 
tivc rate - 10/65=15.4%. 
146/174= 83.9«/o; false nega-
Although deep venous thrombosis confined to the calf veins 
was detected on contrast venography, this was considered a 
negative resuh, as the Belfast Scrcener is insensitive in the 
detection of calf vein thrombus and the manufacturers do not 
sell the device as being able to deieci such thrombosis. Also, 
in our unit, the decision to anticoagulate is based largely on 
(he presence or absence of thrombus in the popliteal vein or 
above. 
RESULTS 
In three cases, the radiologists disagreed in their interpreta-
tion of the venogram. Coupled with the eight cases where 
venography could not be performed, iliis gives an overall 
failure rate for venography of 11/250 = 4.4%. This compares 
favourably with other published data. Thus» there arc 239 cases 
in which the perfomiance of the Belfast D\'T Screener can be 
measured against the accepted gold standard investigation. The 
results are set out in Table 1. Our results show that the Belfast 
DVT Screener has a sensitivity of S4.6%, a specificity of 83.9% 
and a false negative rate of 15.4%. 
Our study identified the presence of proximal DVT in 65 
patients, giving a sample size for comparison with previous 
published data of 65. This gives our results a power of 74%. 
The manufacnjrers of the device claim a false negative rate of 
4.8% with a sample size of 21 [16]. The hypothesis under test 
(Ho) is ihat the false negative rate of the Belfast Screener is no 
greater than one in 21 (0.0476). Our data were used to assess 
the evidence against this hypothesis. 
The appropriate statistical test is for a single proportion 
where pf represents the true proportion of false negative Belfast 
Screener tests in the population. 
Ho:pfs 1/21(0.0476) 
H,4)f > 1/21 
Our study estimates pf at 10/65 (0.1538), so the test statistic is 
0.1538 - 0.0476 0.1062 
y0.0476(l - 0.0476)/65 0.0264 
= 4.021 
The test statistic is compared with standard Normal Tables 
giving a /*-valuc of 0.00003, which is highly siati.'stically sig-
nificant. We therefore reject Ho in favour of Hj. A 95% 
confidence interval for the tme false negative rate is 6.6-24.3%. 
DISCUSSION 
Although initial results for the performance of plethysmo-
graphy in the detection of DVT were encouraging [12.13], 
several authors have more recently drawn into question its 
ability to act as a suitable screening test [14,19,20-22]. The 
reasons for the relatively poor performance of plethysmo-
graphy in detecting DVT are unclear, although the presence 
of a non-occlusivc thrombus has been identified as one area 
of potential inaccuracy [17]. Poor fitting of the thigh cuff 
in patients with large circumference thighs and slippage of 
the strain-gauge may also contribute to sub-optimal screener 
performance. 
A further reason for the inaccuracy of the Belfast DVT 
Scrccner lies in the possible difference in outcome when the 
device is used in a busy admissions unit setting, as opposed to 
under ideal experimcmal conditions. The manufacturers of the 
device have suggested that these results could be improved by 
further, meticulous attention to the technique of performing the 
screening test. However, we feci that the best possible arteniion 
to technique, in a busy clinical ward sening. was given in our 
study. Indeed, the qualified staff permitted to use the device 
in the study were all specifically trained in its use by the 
manufacturers. 
It is worth noting that there was no paiicm to the venographic 
appearance of the false negative Belfast Screcner results. The 
venograms showed a wide variety of appearances from above 
knee DVT to small non-occlusive femoral thrombus to throm-
bus affecting the whole limb from calf to pelvis. The DVTs 
missed by the Belfast Screcner were no different from those 
that it detected. 
We would conclude that in a population of acute admissions 
with calf pain and or swelling, the Belfast DVT Scrcener has a 
false negative rate of 15.4%. In practice, this means that a 
patient with thrombus above the knee joint, who is referred for 
a Belfast DVT Screening Test, would run a risk of the thrombus 
being missed of nearly one in six. 
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Oxygen administration and explicit memory: no improvement 
found in healthy volunteers 
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It has been suggested thai oxygen administration to healthy volunteers could improve their 
memory. We tested this hypothesis v/ith a twin, double crossover, placebo-controlled study 
in 20 healthy non-smokers, allocated randomly to one of two groups. Blinded to the nature 
of the gas. group A breathed air first then oxygen on day I . and then oxygen first, followed 
by air on day 2. Group B had all exposures in reverse order. After each gas exposure a written 
memory lesi with a list of 20 words was carried out and evaluated by a blinded observer. 
Recall after oxygen exposure (mean 8.3 words) was not significantly different from that after 
air exposure (mean 9 words). 
BfJ Anoest/i 1999; 83: 801^ 
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Oxygen administration to hypoxaemic individuals to 
normalize arterial oxygen content can improve cognitive 
performance. This has been demonstrated during acute 
hypoxaemia of high altitude in otherwise healthy indi-
viduals. Subjected to conditions simulating 4300 m altitude 
in a decompression chamber for 2.5 days, volunteers com-
pieied a bancry of tests four times daily while breathing 
through an aviator mask. During one session per day, 35% 
oxygen was administered 2 min before and throughout the 
test battery. On day 1, performance was impaired but 
improved with oxygen administration in some aspects 
of memory, grammatical reasoning and susceptibility to 
interference. On subsequent days, performance had recov-
ered to baseline and did not improve further with oxygen.' 
Even in chronic hypoxaemia (arterial oxygen tension 
<7.3 kPa at rest) caused by severe respiratory disease, 
improvement in neuropsychological function could be 
achieved by continuous oxygen administration for 4 weeks. 
After baseline testing, oxygen was supplied al 2 litre 
min"' for 24 h per day via nasal cannulac. At re-test after 
4 weeks, performance had improved in a number of standard 
neuropsychological tests.^  
Recently, Moss and Scholey^ suggested that in healthy 
normoxaemic volimteers, exposure to 100% oxygen for 
1 min could enhance memory, as tested with lists of 15 
words. In their first experiment, volunteers were allocated 
randomly to one of three groups to receive oxygen via a 
face mask before presentation of a word list or before recall 
testing, or no mask and no gas manipulation. The three 
groups recalled a mean of 8.1, 4.3 and 5.3 words, respect-
ively. In a second experiment, the same open label design 
was used, but the learn to test interval was 24 h. The group 
that received oxygen before learning scored 7.2 words 
compared with 5.4 words in the control group. In a third 
experiment, where the oxygen and control groups were 
both breathing via a face mask, recall was 6.4 and 5.4 
words, respectively ( P O . O S ) . 
An extension of this work, with a wider range of tests 
and various periods of oxygen exposure, was subsequently 
published by the same group.^ Memory for words again 
appeared enhanced, but several other indices of cognitive 
function did not. The authors hypothesized that oxygen 
acted by augmenting cerebral metabolism. How this might 
occur is not clear as the healthy brain autoregulates its 
blood flow, and therefore oxygen delivery, and can also 
increase its oxygen extraction. Moreover, an increased 
inspired fraction of oxygen does not substantially increase 
oxygen delivery in health, as haemoglobin is already nearly 
100% saturated with oxygen. Lastly, I min of quiet breathing 
does not allow for equilibration of alveolar gas with the 
inspired oxygen concentration. 
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Table I Gas exposure by group and snjdy day 
Table 2 Experimental procedure 
Day I Day 2 Time (mta) 
Tcsl I Test 2 Test 3 Tcsl 4 
Croup A 
Group B 
Air 
Oxygen 
Oxygen 
Air 
Oxygen 
Air 
Air 
O.xygcn 
Nevertheless, enhanced memory by oxygen administra-
tion would be of wide general interest. Anaesthetists would 
take a special interest, as they frequently administer 100% 
oxygen at the most critical periods during an anaesthetic, 
periods that are more likely to be associated with memory 
formation and subsequent recall of a traumatic experience. 
Also, in anaesthetic drug research, volunteers frequently 
breathe increased concentrations of oxygen, which could 
lead to unexpected bias. Therefore, we sought to reproduce 
this effect under conditions similar to those described by 
Moss and Scholcy,^  but with a twin, double crossover design. 
Methods and results 
After obtaining approval from the Regional Ethics Commit-
tee, we studied 20 healthy non-smoking volunteers, allocated 
randomly to group A or B. The two groups were exposed 
to both air and oxygen on each of two separate days 
(Table I), at least 48 h apart. 
Gases were administered for 60 s from concealed cylin-
ders using a non-rebrea thing system composed of a reservoir 
bag, pressure release valve and Laerdal resuscitation valve. 
A fiher/hcat and moisture exchanger, connected to the 
Lacrdal valve, served as a mouthpiece. Subjects wore a 
nose clamp, or pinched iheir own noses during inhalation 
of oxygen or air. They were blinded to the nature of the 
gases. One minute after administration of the gas, tape 
recorded lists of 20 words each, standardized for accuracy 
and frequency, were presented over 40 s. The test words 
were obtained from a psycholinguistic data pooL^ Eighty 
seconds later, volunteers performed a p-deletion test, as a 
distracter task, for 3 min. After another I min, they wrote 
down the words they remembered. Two minutes were 
allocated for this task. After a S-min break, the same 
procedure was repeated with exposure to the corresponding 
second gas (Table 2). During the second study session the 
gases were administered in reverse order. 
A blinded observer evaluated the written records. Words 
remembered in an incorrect grammatical form were counted 
as O.S and words that differed by one sound (e.g. cattle vs 
kettle) were counted fully, as this was assumed to be a 
hearing error rather than a lapse of memory. 
The results were analysed by gas exposure (i.e. air 
exposures were compared with oxygen exposures). Because 
of the study design, the exposure groups contained equal 
numbers of group A and B volunteers, and were also 
balanced for the word lists that had been used in the 
memory tests. The first exposures of any of the two sessions 
and the second exposures were initially analysed separately, 
0- 1 
1- 2 
2- 3 
3- 4 
4- 5 
5- 6 
6- 7 
7- 8 
8- 9 
9- 10 
10-15 
15- 16 
16- 25 
Adminisiniiion of first gas 
Normal breathing 
Word presentation (40 s) 
Silence 
P-dclctton itsl 
P-<lclciion test 
P-delction tcsl 
Silence 
Word recall 
Word recall 
Break 
Second gas exposure; 
etc. (as 0-10) 
Table 3 Mean (range) 
test of the day 
words remembered by gas exposure and the fir^ t/second 
First lest of the day Second test of the day 
Air 
Oxygen 
8.95 (4-13) 9.125 (3.5-15) 
9-2 (3-15) 7.375 (2.5-13) 
as oxygen as the first gas might have had a long lasting 
effect, still affecting memory after the subsequent air 
exposure. As no such effect was found, the pooled results 
were also compared. Differences were analysed using the 
Mann-Whimey test, with P<0.05 considered significant. 
In the first test of any one session, volunteers remembered 
a mean of 8.9 words (range 4-13) after exposure to air and 
9.2 words (range 3-15) after oxygen exposure. For the 
second test, the mean number of words remembered were 
9.1 (3.5-15) and 7.4 (2.5-13), respectively (Table 3). None 
of the differences was statistically significant {P=OM and 
0.09 respectively). The pooled results after air breathing 
(mean 9.037, range 4-15) were not significantly different 
from the pooled results after oxygen exposure (mean 8.287, 
range 2.5-15) (P=0.28). 
Comment 
Moss and Scholey* reported better memory in a group of 
volunteers after exposure to oxygen for 1 min compared 
with a group of volunteers who had been breathing air from 
a cylinder for I min. Tested with a list of 15 words after 
gas exposure, the groups remembered an average of 6.4 
and 5.4 words, respectively. The authors attributed this 
difference to oxygen exposure and speculated that' increased 
circulating oxygen is sequestered by brain areas undergoing 
task-specific energy demands. This would increase the 
availability of A T P . . . availability of brain o.xygen may 
limit cognitive performance'. 
These hypotheses are difficult to reconcile with the 
current understanding of oxygen delivery and cerebral 
auioregulation. Under normal conditions almost all the 
oxygen in arterial blood is carried by haemoglobin which, 
in healthy individuals breathing air, is already saturated 
with oxygen to approximately 97-99%.* Therefore, I litre of 
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arterial blood carries approximately 195 ml of haemoglobin-
bound oxygen^ assuming a haemoglobin concentration of 
150 g litre''. Inhalation of oxygen increases saturation to 
99-100%, thus increasing haemoglobin-bound oxygen by 
maximally 6 ml litre"'. The amount of dissolved oxygen in 
blood is small and related linearly to its partial pressure: it 
is approximately 3 ml litre"' during air breathing.^ After 
breathing 100% oxygen for 1 min, the partial pressure 
of oxygen in arterial blood increases from 13.3 kPa to 
approximately 70 kPa maximally, allowing for an extra 
carriage of up to 12 ml litre"' (calculated from measurements 
ofend-expiraiory oxygen concentration).^''Therefore, I min 
of oxygen breathing allows a maximum of 18 ml litre"' 
additional oxygen carriage, a maximal change of +9%. In 
summary, in healthy individuals, oxygen delivery is 
increased only marginally by oxygen exposure. This increase 
in oxygen carriage may even be counteracted by a reduction 
in blood flow of 10-15% caused by the increased partial 
pressure of oxygen.'** Therefore, Krop, Block and Cohen, 
who demonstrated improvement in neuropsychological 
function by continuous oxygen administration to severely 
hypoxaemic patients, stated that it would 'certainly not 
improve a nonhypoxemic normal patient*.^  In this context, 
it is also interesting that in the high altitude experiment' 
no improvement occurred with oxygen administration when 
volunteers had acclimatized and recovered to baseline 
performance, despite persisting hypoxaemia (oxygen satura-
tion 83% when breathing air). 
In contrast, the brain has the ability to autoregulate its 
blood Row, adjusting it to regional demands, in addition to 
changing its oxygen extraction ratio. Tasks that activate a 
particular brain region arc associated with a simultaneous 
increase in blood flow and oxygen consumption in that 
region (e.g. moving an arm leads to increased blood flow 
in the contralateral motor cortex)." 
Movement of the mouth, eyes and fool increase flow and 
oxygen consumption in the corresponding motor cortex, 
and thinking of a movement, without actually moving, 
increases flow to the pre-motor region." These changes are 
of the order of 20-30%. Visual stimulation results in 20% 
increased flow in the posterior cerebral arteries which 
supply, among other regions, the visual cortex. The full 
response is reached within 4.6 s.'' Measured in the tissues 
with laser Doppler flowmetiy, peak flow is reached at 5 s 
after a visual stimulus.'^ 
It is therefore unlikely that the brain should normally 
function in a state of relative hypoxia limiting its perform-
ance, or that a 9% increase in oxygen carriage, a change 
much smaller than the brain's autoregulatory range, should 
improve its performance. A degree of uncertainty remains 
about the earliest phase of the autoregulatory response. An 
increase in deoxyhaemoglobin in the optical cortex of 
anaesthetized cats 2-3 s after a visual stimulus was demon-
strated,'^ but oxyhaemoglobin also increased at the same 
lime. As the measurements were non-quantitative, it is 
impossible to say i f the extraction ratio or the demand-
supply ratio changed and i f so in which direction. Hence, 
it cannot be concluded that neurones are transiently rendered 
hypoxic, as was slated in the abstract to the earlier pub-
lication.'* 
Despite these physiological considerations, we attempted 
to reproduce the findings of Moss and Scholey^ but were 
unable to demonstrate any improvement in memory after 
oxygen administration. The major difTercnces between the 
two studies were in the overall design. Our subjects were 
fully blinded in all tests. Moss and Scholey only attempted 
blinding in their third experiment, even though the gas 
delivery devices were still entirely different. We presented 
words from previously recorded tapes and the written recall 
was evaluated by a blinded observer. Moss and Scholey 
presented the words verbally which would have made 
blinding of the presenter difficult and there is no information 
on whether or not recall by subjects was oral or written, or 
on how recall was evaluated. The assertion lhat the possibil-
ity of a placebo effect causing the large (91%) difference 
in their first, open-label experiment was 'ruled out* by their 
third (?single) blind experiment is not supported by the 
data: under blinded conditions, the difference was only one 
word (approximately 18.5%). This would suggest lhat ihe 
91% difference was at least largely a result of subject 
expectations. 
Most importantly, wc used a twin, double crossover 
design, where all subjects served as their own conu-ols, and 
crossover was carried out in both directions. The twin 
system was necessary to balance the word lists used as 
with repeated testing, a different list had lo be used for 
each test. Moss and Scholey compared separate groups of 
volunteers whose baseline memory was unknown. An 
alternative interpretation of their results could be that the 
one word difference found between the blinded groups was 
a result of 'better' volunteers in the oxygen group rather 
than gas exposure. 
A more recent article by the same group,** published after 
our study had been carried out. addressed several of these 
shortcomings. It had a crossover design, volunteers were 
blinded to the nature of the gases and a battery of tests was 
administered and evaluated by computer. Word recall and 
some reaction times were improved by oxygen while 
working memory and picture recognition sensitivity were 
not. 
However, several new design problems were introduced. 
After a baseline test session without any gas manipulation, 
oxygen via a face mask was given for either I or 3 min 
before the whole test battery; for 30 s before each task; 
throughout the session (which took approximately 25 min); 
or air via a face mask was administered throughout the 
session. True placebo control can therefore only be claimed 
for the 'oxygen throughout' condition. Performance after 
each of the five difTcrcnt study conditions was compared 
with baseline performance. In five of 16 indices tested, air 
via a face mask led to impaired perfonnance compared 
wiih the baseline tests. Only in these five indices did 
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some of the oxygen conditions seem relatively beneficial 
(i.e. caused less deterioration or a small improvement). In 
only one task did 'oxygen throughout' compare favourably 
with 'air ihroughoul''.(no change rather than deterioration 
as with air). These results suggest that the noise and 
inconvenience of the face mask during the tests reduced 
atienlion, with a bigger impact than that of the gas delivered. 
The face masks used (not described in the article) were 
Venlicare Oxygen masks (Flcxicare, CardifO (A. Scholey, 
personal communication). These are variable pcrfonnance 
face masks for supplementary oxygen administration, and 
even with a flow of 8 litre min"' do not deliver 'pure 
oxygen' as claimed by the authors. 
A total of 60% of volunteers were smokers and had to 
abstain for only I h before testing. Their carbon monoxide 
concentrations were not assessed but may have been high 
enough to interfere with oxygen transport by haemoglobin, 
and the function of cytochromes. 
The weakness of our study was the unexpectedly high 
inter-individual variability (i.e. 3 to 15 words remembered 
in the same test). While this does not affect the comparability 
of the exposure groups, as all subjects ser\'ed as their own 
controls, it reduces the power to exclude a false negative 
result. Nevertheless, a 91% improvement, as in the non-
blinded experiment in Moss and Scholey*s study,^  can be 
excluded with near 100% power. To exclude a subtle 
difference of one word, as that in their blinded experiment, 
the power of our study was less than 80%, despite the fact 
that it was based on 40 rather than 12 data pairs. 
A further limitation is thai oxygen administration was 
studied for only I min, particularly as I min does not allow 
for full alveolar equilibration with inspired oxygen. It is 
not possible to extrapolate our results to longer exposure 
limes. However, 1 min was the time used by Moss and 
Scholey^ and also appeared to be most effective in the 
group's more recent study.^  
In summary, in our twin double crossover study, with a 
total of 80 memory tests, we found no improvement in 
subsequent semantic memory formation after administration 
of 100% oxygen for 1 min to healthy non-smokers. A large 
or robust effect of oxygen on memory formation can 
be excluded with confidence. The high inter-individual 
variability of memory did not allow us to exclude a 
minor efTect. 
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Histological Indicators of prognosis in glioblastomas: retinoblastoma protein expression and 
oligodendroglial differentiation indicate improved survival 
Aim: To assess the potential prognostic signiiicance of 
a range of molecular and morphological parameters in 
glioblastomas that can be applied In the setting of a 
routine diagnostic neuropathology laboratory. 
Methods and results: A consecutive series of 107 adult 
glioblastomas were studied. Retinoblastoma and dele-
ted-in-colon cancer (DCC) protein expression were 
assessed using immunocytochemistry and chromosome 
10 loss by in-situ hybridization. Loss of retinoblastoma 
expression was associated with a worse outcome, 
which appeared to be independent of age. There was 
Keywords: chromosome 10. DCC. glioblastoma, prognosis, retinoblastoma. sur\'ival 
Abbreviations: DCC, deleted-in-colon cancer: LI, labelling index 
no significant association between chromosome 10 loss 
or DCC protein expression and sur\'ival. Survival was 
significantly increased in the 5% of patients whose 
tumours had focal morphological features suggesting 
oligodendroglial differentiation. 
Conc/iisio/is: Glioblastomas containing areas of oligo-
dendroglial differentiation or showing widespread 
immunocytochemical expression of retinoblastoma 
protein have a better prognosis than those without 
these features. 
Introduction 
Glioblastomas have a median survival of about 
9 months after surgery and radiotherapy, although 
about 2% of patients survive for more than 3 years.* 
Radiotherapy increases survival but produces a signi-
ficant morbidity in many patients^ and it would be 
helpful to provide more accurate prognostic informa-
tion to patients and clinicians when deciding on the 
potential benefit of further treatment. 
Glioblastomas undergo a number of genetic changes, 
the most common of which are losses from chromo-
Addrcss for correspondence: David Hilton. Department of 
Histopathology. Dcrriford Hospital. Plymouth PL6 SDH. UK. 
e-mail: dovid.hilton@phnLswcsLnhs.uk 
some 10. occurring in 56-87% of tumours.'"^ Retino-
blastoma protein is a key regulator of the cell cycle and 
loss of the retinoblastoma gene Is also common, 
occurring in about a third of glioblastomas and 
correlating with loss of protein expression as detected 
by immunocytochemistry.^ Previous studies have 
shown that chromosome 10 loss and reduction in 
retinoblastoma protein expression are adverse prog-
nostic factors in anaplastic astrocytomas,'-^ but it 
is unclear whether they alTect prognosis in glio-
blastomas.'-^-^-^ ° " 
We have used in-situ hybridization and immuno-
cytochemistry. techniques that can be applied to rou-
tinely processed paraflin-embedded tissue, to assess the 
potential prognostic signiiicance of chromosome 10 loss 
and retinoblastoma protein loss, in a consecutive series 
of glioblastomas. In addition, we have looked at the 
O 2004 Dlackwell Publlstiing limllcd. 
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expression of delcted-in-colon cancer (DCC) protein, 
which has roles in cell migration and apoptosis'^ *^  and 
has previously been shown to have reduced expression in 
association with the malignant progression of astrocytic 
tumours.*** The potential significance of the presence of 
areas of tumour with morphological features of oligo-
dendroglial dilTerenliation was also assessed. 
Materials and methods 
TUMOURS 
Formalin-fixed paraffin-embedded tissue from 107 
consecutive adult glioblastomas, removed between 
1993 and 1997 (to ensure a minimum follow-up 
period of 5 years) was used for the study. The sections 
from all cases were reviewed and classified according to 
current World Health Organization guidelines.*^ In 
addition, the presence or absence of foci of oligoden-
droglial differentiation and calcification was noted. The 
guidelines do not provide clear criteria for distinguish-
ing between anaplastic oligodendroglial tumours and 
glioblastomas with areas of oligodendroglial difTerenti-
ation. For the purposes of this study, oligodendroglial 
differentiation in glioblastomas was defined as the 
presence of clusters of cells with round nuclei and clear 
cytoplasm, in tumours in which at least 50% of the 
tumour showed astrocytic features and included prom-
inent microvascular proliferation and/or foci of necro-
sis. Tumours containing sheets of small glial cells 
without the cytoplasmic features of oligodendroglioma 
(i.e. small-cell glioblastomas) were not separately 
identified. High-grade tumours with more extensive 
morphological evidence of oligodendroglial differenti-
ation were regarded as anaplastic oligodendrogUomas 
and excluded. High-grade tumours in which the 
astrocytic component, although mitotically active, did 
not show prominent microvascular proliferation 
and/or foci of necrosis, were classified as anaplastic 
oligoastrocytoraas and also excluded. The clinical data 
were obtained from the hospital records and included 
age. sex, radiotherapy treatment and the survival time 
from the operation. Formal clinical performance scores 
were not available in the case notes: however, patients 
in poor clinical condition were not generally offered 
radiotherapy. 
Sections (4 pm thick) of paraffin-embedded tissue 
were collected onto 3-aminopropyltriethoxysilane-
coated glass slides and dewaxed in graded alcohols. 
Then non-specific peroxidase activity was blocked 
with 3% hydrogen peroxide for 10 rain. Microwave 
pretreatments were used as follows: 15 min in 
10 niM citrate buffer at pH 6.0 (retinoblastoma pro-
tein) or 25 min in 10 mM citrate buffer at pH 6.0 
(DCC protein). Sections were incubated overnight 
with the primary antibody at dilutions of 1 : 300 
(retinoblastoma) or 1 : 750 (DCC protein). Detection 
was achieved with the Elite universal detection kit 
(Vector. Peterborough. UK) and colour was developed 
with diaminobenzidine. 
IN'SITU H Y B R I D I Z A T I O N 
Commercially available digoxigenin-labelled, chromo-
some-specific a-satellite probes to chromosomes 10 and 
12 were used (Appligene Oncor. Harefield. UK). 
Sections of paraffin-embedded tissue (7 pm tliick) 
were collected onto 3-aminopropyltriethoxysilane-
coated glass slides and dewaxed in graded alcohols. 
Sections were incubated in 1 M sodium thiocyanate at 
80°C for 10 min, digested for 60 min with proteinase K 
(10 mg/ml in 0.05 M Tris pH 7.65) at 37°C. then 
dehydrated in alcohols and air-<lried. Probe solution 
(20-50 pi) was applied to the section which was then 
denatured at 94*'C for 15 min and incubated overnight 
at 37°C. Unbound probe was washed off with 
0.5 X SSC at 72°C for 5 min and labelled probe 
detected by applying anti-digoxigenin horseradish per-
oxidase at 1 : 500 for 60 min (Dako. Ely. UK). Colour 
was developed with diaminobenzidine. 
A S S B S S M B N T OF L A B E L L I N G I N D I C E S 
Labelling indices (Lis) were obtained by counting the 
number of immunostained tumour cell nuclei of a 
minimum of 200 tumour cells (100 for iri-situ 
hybridization) in areas of solid tumour. The counts 
were made with the help of an eyepiece graticule, a 
x 2 5 0 objective and a x l O eyepiece. Lis were 
expressed as the percentage of tumour cells that 
were labelled. All scoring and assessment of morpho-
logical features were performed without knowledge of 
survival. 
I M M U N O H I S T O C H E M I S T R Y 
Primary antibodies to the DCC protein (monoclonal: 
PharMingen, Los Angeles, CA. USA) and retinoblasto-
ma protein (monoclonal: Novocastra. Newcastie upon 
Tyne. UK) were used. 
S T A T I S T I C A L A N A L Y S I S 
The survival time data were analysed using Kaplan-
Meier log rank tests and a Cox's proportional hazards 
model. 
9 2004 Blackwell Publishing Ltd. HiitopathcAo^s. 44. SS5-560. 
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Results 
A C E . R A D I O T H E R A P Y AND S U R V I V A L 
The patient ages ranged from 22 to 86 years (median 
58 years). All patients had died by the time of study 
and survival from operation date ranged from 1.4 to 
168 weeks (median 28 weeks). Age was inversely 
correlated with survival (P < 0.01. Pearson's correla-
tion coefRcient -0.564). The 63% of patients who 
received postoperative radiotherapy had a median 
survival of 40 weeks and age of 57 years, compared 
with 12 weeks and 65 years for those who did not. 
O L I C O D E N D R O G L I A L F E A T U R E S 
Oligodendroglial differentiation was seen in 5% of 
tumours, and covered 15-50% of the total tumour area 
and was seen either in a single part of the tumour or in 
multiple foci. These tumours had a median survival of 
70 weeks, compared with 27 weeks for the remainder 
(P = 0.014). Eighty percent of tumours with oligo-
dendroglial foci received radiotherapy, compared with 
61% of the remainder, but there was no significant 
difference in age between these two groups. There was 
no correlation between sur\'ival and the proportion of 
tumour showing oligodendroglial differentiation. Cal-
cification was seen in 7% of tumours, but was not 
associated with either survival or the presence of 
oligodendroglial diderentiation. 
DCC E X P R E S S I O N 
Cytoplasmic DCC protein expression was seen in 
normal neurons adjacent to tumour, and within 
tumour cells. Tumour expression of DCC was highly 
variable, ranging from occasional positive cells to the 
majority of cells (Figure 1). In 62% of cases over 
10% of tumour cells were positive and in 29% of 
cases over 50% of tumour cells expressed DCC: 
however, this was not associated with a significant 
difference in survival. 
R E T I N O B L A S T O M A E X P R E S S I O N 
Nuclear retinoblastoma protein expression was seen in 
most non-neoplastic cells with the exception of neu-
rons. Tumour expression varied from 4 to 97% of cells 
and was predominantly nuclear (Figure 2). although 
cytoplasmic expression was seen in cells undergoing 
mitosis. In tumours showing widespread expression, 
perinecrotic cells showed a reduction in immuno-
reactivity. Regression analysis showed a correlation 
:•#. 
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Figure I . Immunocytochemistry with an antibody lo dctctcd-
in-colon cancer showing a tumour with occasional positive cells (a) 
and another with widespread Immunorcactlvlty (b). 
between expression and survival (P = 0.045). which 
was Independent of age (Figure 3). 
CHROMOSOME 10 LOSS 
Chromosomal status could be assessed in only 73 
tumours, due to poor in-situ hybridization signal 
intensity In many samples. Hybridization with chro-
mosome 12 probe showed 12-39% (mean 25, SD 6.6) 
of tumour cell nuclei to contain only one copy, due to 
the truncation artefact that occurs when using tissue 
sections. Of the cases in which chromosomal status 
could be assessed, 64So had >40% of tumour cells 
showing only one signal with the chromosome 10 
probe and were regarded as having true monosomy 
(Figure 4). The difference in survival between tumours 
showing monosomy (median survival 34 weeks) com-
pared with those without (median survival 23 weeks) 
was not significant (Figure 5). 
O 2004 Bbclwdl Pub'Jshinc Ltd. HlsU^±dc^, 44. 555-560. 
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Figure 2. Immunocytochcmlstry for retinoblastoma protein 
showing endothelial immunoi^acUvlty in a ntjgative tumour (a) 
and widespread nuclear Immunoreaclivity in a posiUve 
tumour (b). 
0 
3 'pj^-'/'^' 
Figure 4. /n-silu hybrldizaUon using probes to chromosorae 12 (a) 
and 10 (b) showing several tumour cells exhibiting monosomy 
for chromosome 10. 
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Figure 3. KapIan-Melcr plot of retinoblastoma expression and 
survival. 
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Rgure 5. Kaplan-Meier plot shoivlng the relaUonshlp between 
monosomy for chromosome 10 and suniva!. 
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Discussion 
In-situ liybrldizaLion has been shown in previous 
studies 10 have good concordance with loss of hetero-
zygosity in demonstrating chromosome 10 losses in 
glioblastomas.'* In this study in-si7u hybridization 
allowed the assessment of chromosomal losses in over 
70% of the tumours: however, the small diflerence in 
survival of patients whose glioblastomas showed 
monosomy for chromosome 10 was not statistically 
significant. This finding is in keeping with the findings 
of most previous studies, which have not found a 
significant association between survival and chromo-
somal 10 loss. '^^  " However, two other studies have 
suggested that losses of specific loci of lOq may be 
associated with a poor outcome in glioblastomas.^ *' 
The presence of areas of oligodendroglial difierenli-
ation in 5% of our series of ghoblastomas was associ-
ated with a significantly increased survival. There are 
no accepted criteria for the distinction between glio-
blastomas with oligodendroglial areas and anaplastic 
oligoastrocytomas^^ and it is debatable how such 
tumours are best classified. The cases included in our 
study were regarded as glioblastomas because of the 
presence of a malignant astrocytic component lhat 
constituted at least 50% of the tumour tissue in 
histological sections and included necrosis and/or 
prominent microvascular proliferation, as well as high 
mitotic activity. The proportion of such tumours In our 
study is similar to that in other recent studies, which 
have reported that between 5 and 15% of glioblasto-
mas contain oligodendroglial areas.^ '^ -^^ ^ We were not 
able to perform detailed cytogenetic studies on our 
cases, but previous studies have suggested that chromo-
somal losses from Ip and 19q are more common in 
glioblastomas with an oligodendroglial component 
than in those without.*^ '^ raising the possibility that 
some of these patients might benefit fi-om chemo-
therapy. However, it is not yet clear whether these 
chromosomal losses predict chemosensitivity in 
tumours with a significant astrocytic component.*^ 
Retinoblastoma protein expression in glioblastomas 
was less extensive than we found in a study of low-
grade astrocytomas.'^ In which 90% of cases showed 
labelling of more than 70% of tumour cells, compared 
with only 53% of glioblastomas. A clear trend between 
loss of retinoblastoma protein expression and poor 
prognosis was found, vvhich is in keeping with a 
previous study of anaplastic astrocytomas^ and a trend 
we found in low-grade astrocytomas.*^ Two previous 
studies of glioblastomas have been reported: one which 
scored tumours as either positive or negative did not 
find a survival diflerence in the 8% of glioblastomas 
scored negative. and the second found a median 
survival of 9 months in tumours with a low LI 
compared with 12 months in the remainder, but this 
difference was not statistically significant. '° Although 
our fmdings indicate that loss of retinoblastoma protein 
expression is associated with an adverse prognosis, the 
survival difference is unlikely to be great enough to be 
useful on an individual basis, unless interpreted 
alongside other prognostic factors. 
DCC expression was highly variable, and it is 
noteworthy that the proportion of tumours showing 
immunorcactivity in more than 10% of cells was only 
slightly less than we found in low-grade astrocyto-
mas.*^ In keeping with a previous immunohistochem-
ical study of glioblastomas.^' DCC protein expression 
did not correlate with survival. A study of 26 glio-
blastomas did find a trend to increased survival in 
tumours with high levels of expression of DCC 
mRNA.^^ but the relevance of this observation needs 
to be assessed in a larger series. 
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Evaluation of Molecular Markers in Low-Grade 
Diffuse Astrocytomas 
Loss of pl6 and Retinoblastoma Protein Expression Is 
Associated With Short Survival 
David A. Hillon, M.R.c.Path., Mark Penney, M.Sc, Barry Evans, B.Sc, 
Hilary Sanders, M.Sc, and Seth Love, F.R.c.Paih. 
Diffuse astrocytomas have a median survival of 6-8 years. 
However, in a minority of cases that are histologically low 
grade, progression is rapid, leading lo death within 2 years. 
Loss of pl6, retinoblastoma protein, and deleted-in-colon-
carcinoma protein expression, and monosomy of chromosome 
10 have been shown to occur in malignant astrocytic tumors. 
We have investigated (he prognostic value of expression of 
these markers, using techniques applicable in many histopa-
(hology laboratories, in diffuse astrocytomas that are histologi-
cally low grade. Paraffin sections from 71.diffuse, supratento-
rial, low-grade astrocytomas, from patients with at least 8-year 
survival data, were Immunostained with antibodies to pl6. 
deleted-in-colon-carcinoma protein. p53. Ki67. and retinoblas-
toma protein. In situ hybridization with a digoxigenin-labeled 
probe to chromosome 10 was used to assess chromosomal loss. 
In most cases there was immunosiaining of virtually all tumor 
cell nuclei with aniibodics to pI6 and retinoblastoma protein. 
Three of the 68 tumors in which assessment of pl6 was pos-
sible included discrete foci with lack of detectable immunore-
acliviiy in tumor cells. The three patients concerned had a 
significantly shortened median survival ( I . I years vs 4.4 years 
in those without loss of pl6; p <O.OI). In six of the 61 cases 
where assessment of retinoblastoma protein was possible, 
<70% of tumor cell nuclei showed immunoreaciivity. These six 
patients had a shoner survival (4.0 years) than had the remain-
ing patients (5.4 years), although this difference was not sta-
tistically significant. The tumor from one of these patients in-
cluded areas where only 36% of tumor cells showed retino-
blastoma protein immunoreactivity, and this patient survived 
only 1.5 years. Tumors showing loss of both pl6 and retino-
blastoma were not seen. p53 and deleted-in-colon-carcinoma 
protein expression was highly variable and did not correlate 
with survival. Tumors with monosomy for chromosome 10 
From the Depanment of Hisiopalhology (D.A.H., M.P., B,E. ) , 
DerrifonJ Hospital. PI>TnouUi. U.K.: ihe Depanmem of Ncuropaiholosy 
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were not identified. Doth polyploidy and the Ki67 labeling 
index were significantly associated with the p53 labeling index 
but not with survival. Focal loss of pl6 or retinoblastoma pro-
tein is demonstrable in approximately 5% and 10% of diffuse 
low-grade diffuse astrocytomas, respectively. Tumors with fo-
cal loss of immunoreactiviiy for these proteins are associated 
with shorter survival than those without, suggesting that im-
munohistochemistry for pl6 and retinoblastoma protein may be 
a useful adjunct to other methods for assessing (he prognosis of 
astrocytomas. 
Key Words:Astrocytoma—Ploidy—Prognosis—p 16—p53— 
Retinoblastoma. 
Am J Sur^ Pathol 26(4): 472-478. 2002. 
Low-grade diffuse astrocytomas are one of the most 
common types of primary brain tumor, occurring most 
often in young adults, and have a median survival of 6-8 
years. However, a significant number of patients with 
histologically low-gradc diffuse astrocytomas progress 
rapidly to malignant astrocytic tumors.*^'^ The inability 
to identify which tumors will undergo rapid progression 
with standard histologic techniques makes it difflciilt to 
give accurate prognostic information to patients. Pro-
gression to high-grade tumors is associated with a num-
ber of genetic changes that result in loss of expression of 
tumor suppressor gene products, including deteted-in-
colon-carcinoma (DCC) proiein.'^*'^^ pl6,^°-^^ and ret-
inoblastoma protein.*®"^^ Tlie most frequent genetic ab-
normalities in gUoblastomas are losses from chromo-
some 10,* often encompassing an entire copy of the 
chromosome.'-^^ Although the frequency of p53 muta-
tions is similar in low- and high-grade astrocytic tumors, 
a number of studies have demonstrated that the propor-
tion of tumor cells with abnormal p53 immunoreactivity 
increases in astrocytic tumors as they.undergo malignant 
progression.^*^^ 
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We have used immunohistochemisiry to evaluate the 
expression of these proteins and in situ hybridization for 
chromosome 10 in a retrospective, consecutive series of 
low-grade diffuse supratentorial astrocytomas in adults, 
to assess the prognostic significance of expression of 
these markers. We were interested to know whether or 
not tumors about to undergo malignant change would 
show focal loss of expression of these tumor suppressor 
proteins that could be demonstrated with techniques that 
could be routinely applied in the setting of a diagnostic 
histopathology laboratory. 
MATERIALS AND METHODS 
Tumors 
Formalin-fixed, paraffln-embedded tissue from adult 
supratentorial diffuse astrocytomas, removed between 
1980 and 1991 (to ensure a minimum follow-up period 
of 8 years) was used for the study. The sections from all 
cases were reviewed and classified according to World 
Health Organization guidelines'^ by a consensus of two 
neuropathologists (D.A.H. and S.L.). Tumors with insuf-
ficient tissue for reliable assessment or inadequate 
follow-up clinical information were excluded, leaving a 
total of 71 evaluable cases of low-grade diffuse astrocy-
toma, from the archives of the neuropathology depart-
ments at Frenchay Hospital (Bristol. UK; 53 cases) and 
Denriford Hospital (Plymouth, UK; 18 cases). The tissue 
samples had been fixed and processed in an identical 
manner in the two centers. The clinical data were ob-
tained from the hospital records and included age, sex, 
and the survival time from the initial operation. Addi-
tional survival data were obtained from Ihe Regional 
Cancer Intelligence Unit and, in some cases, the patient's 
general practitioner. Details of treatment for most of the 
patients in this series were included in a previous study, 
in which we found no significant effect of radiotherapy 
on survival." 
minutes in 10 mmol/L citrate buffer at pH 6.0 (DCC 
protein). Sections were incubated overnight with the pri-
mary antibody at dilutions of 1:300 (retinoblastoma). 
1:4000 (MiB- l ) . 1:64,000 (p53), 1:1000 (pl6). or 1:750 
(DCC protein). Detection was with "Elite" universal de-
tection kit (Vector, Peterborough, UK) and color was 
developed with diaminobenzidine. 
In Situ Hybridization 
Commercially available digoxigcnin-labeled. 
chromosome-specific a-saiellite probes lo chromosome 
10 and 12 were used (Appligene Oncor, Harefield. UK). 
Seycn-micron sections of paraffin-embedded tissue 
were collected onto 3-aminopropyItriethoxysilane-
coated glass slides and dewaxed in graded alcohols. Sec-
tions were incubated in 1 mol/L sodium thiocyanatc at 
80°C for 10 minutes, digested for 60 minutes with pro-
teinase K (10 iig/mL in 0.05 mol/L Tris, pH 7.65) at 
37'C. then dehydrated in alcohols and air dried; 20-50 
j i L of the probe solution was applied to the section, 
which was then denatured at 94^C for 15 minutes and 
incubated overnight at 37°C. Unbound probe was 
washed off with 0.5x SSC at 72''C for 5 minutes and 
labeled probe detected by applying anti-digoxigenin 
horseradish peroxidase at 1:500 for 60 minutes (Dako, 
UK), and color was developed with diaminobenzidine. 
Assessment of Labeling Indices 
Labeling indices (Lis) were obtained by counting the 
number of immunostained lumor cell nuclei of a mini-
mum of 1000 tumor cells in areas of solid tumor. The 
counts were made with the help of an eyepiece graticule, 
under a x250 objective and a xIO eyepiece. Lis were 
expressed as the percentage of tumor cells that were 
labeled. 
Immunohistochemlstry 
Primary antibodies to DCC protein (monoclonal. 
PharMingen, Los Angeles. CA, USA), pl6 (polyclonal, 
PharMingen, USA), Ki67 (monoclonal M i B - l , Dianova, 
Hamburg, Germany). p53 (polyclonal CM I . Novocastra, 
Newcastle upon Tyne, UK), and retinoblastoma protein 
(monoclonal. Novocastra) were used. 
Four-micron sections of paraffin-embedded tissue 
were collected onto 3-aminopropyllriethoxysilanc-
coaied glass slides, dewaxed in graded alcohols, then 
nonspecific peroxidase activity blocked with 3% hydro-
gen peroxide for 10 minutes. Microwave pretreatmenis 
used were as follows: 15 minutes in 10 mmol/L citrate 
buffer at pH 6.0 (retinoblastoma protein. M i B - l . p53). 15 
minutes in 0.2 mol/L acetate buffer at pH 1.5 (pl6). or 25 
Statistical Analysis 
The survival time data were analyzed using Kaplan-
Meier log-rank test and Cox proportional hazards model. 
RESULTS 
The patients had a median age of 38 years (range 
19-72 years). Increasing age was associated with a 
shorter survival (p <0.05). Fifty-five of the 71 patients 
died during the period of study; for this group the median 
survival was 2.7 years (range 0.I-I6.3 years). For the 16 
survivors median follow-up time was 10.3 years (range 
9.3-18.8 years). Survival was measured from the time of 
surgery and histologic assessment, rather than the onset 
of symptoms, and the figures tend therefore to be lower 
Am J Sttrs PaihoJ. Vol 26. AH 4. 20O2 
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FIG. 1. (A) Immunohistochemislry for pi 6 in a diffuse low-grade astrocytoma showing a focus with loss of Immunoreac-
tivity. (B) At higher magnificalion loss of nuclear immunoreactivity can be seen in several tumor cells, some of which have 
a gemistocytic morphology (arrows). 
than ihe overall survival limes thai are usually quoted for 
patients with tumors of this type." 
MiB- l labeled at least some tumor cells in the major-
ity of ihe astrocytomas, although <Wo of the cells were 
labeled in most cases. The Lis ranged from 0 to 9.42 with 
a median of 0.49. There was no conelation between Ihe 
length of survival and the MiB- l L I . 
p53 Lis were much more variable, ranging from 0 to 
77 with a median value of 10. Log-rank tests showed that 
with division of p53 into those above and below 10% 
there was an inverse association trend between the p53 
L I and survival; those cases (n = 33) with a p53 LI <I0 
having a median sur\'ival of 5.2 years and those with a 
p53 LI >10 having a median sur\'ival of 3.1 years. How-
ever, this difference did not quite reach statistical sig-
nificance (p 0.059). 
pl6 and retinoblastoma protein expression was seen in 
the majority of both neoplastic and non-neoplastic cell 
nuclei (with the exception of neuronal cell nuclei) in 
most cases. In three of the 68 cases in which pl6 protein 
could be assessed, the tumors contained discrete foci 
with loss of nuclear immunopositivily (Fig. I) . These 
three cases died as a direct result of their tumors and had 
a median survival of I . I years, compared with 4.4 years 
for the remaining cases (p <0.0I) (Fig. 2). Of the 62 
tumors in which retinoblastoma protein could be as-
sessed, in six cases <70% of tumor cell nuclei were 
immunolabeled, the areas with nonlabeled nuclei being 
less well circumscribed than was the case for tumors 
with loss of pi6. Although these cases had a shoner 
survival than had the rest (4.2 years vs 5.4 years), the 
difference was not significant (Fig. 2). However, one 
patient, whose tumor included areas in which only 369& 
of tumor cell nuclei were immunoposilive for retinoblas-
toma protein (Fig. 3). survived only 1.5 years, dying as a 
direct result of tumor grow th. Cases with loss of both p l6 
and retinoblastoma protein were not identified. Patients 
whose tumors showed pl6 loss had a median age of 56 
years and MiB- l LI of 1.15. compared with 38 years and 
0.44, respectively, for those without loss. Cases with 
reduced expression of retinoblastoma protein had a me-
dian age of 41 years and MiB- l LI of 0.98, compared 
Am J Siirs; Pathol Vol. 26. A'o. -I. 2002 
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FIG. 2. Scatter-ptot showing Ihe 
relationship between survival 
and p16 and retinoblastoma im-
munohislochemislry. 
with 38 years and 0.43. respectively, for those without 
reduced expression. The differences in age and MiB-1 LI 
between cases with loss of retinoblastoma or pl6 and 
those without were not statistically significant. Wc were 
interested in determining whether or not regions of tumor 
suppressor protein loss showed focally increased prolif-
erative activity, but Ihe MiB-1 LI in these regions was 
similar to that in adjacent tumor tissue. Of those cases 
with loss of either retinoblastoma or pI6, two cases with 
loss of retinoblastoma had follow-up biopsies, 2 and 5 
years after the original surgery, which showed progres-
sion to a glioblastoma and an anaplastic astrocytoma, 
respectively. In both of these cases immunocytochemis-
try did not reveal any increase in the proportion of cells 
showing loss of retinoblastoma and neither showed pl6 
loss. 
DCC was variably, but usually weakly, demonstrable 
in the cytoplasm of between 1% and 11% of tumor cells 
(median 17%). Cytoplasmic immunoposilivity was also 
noted in neurons. DCC labeling did not correlate with 
survival. 
Sections 7 p.m thick were found to be optimal for 
assessment of the in situ hybridization signal. Thinner 
sections resulted in large numbers of cell nuclei contain-
ing only one chromosomal copy, and thicker sections 
were difficult to assess because of overlapping nuclei. In 
54 cases strong signal was obtained with in situ hybrid-
i7.aiion. In these cases 301-1067 tumor cell nuclei (me-
dian 625 nuclei) were assessed for chromosome 10 copy 
-number. Between 6% and 30% of cell nuclei had only 
one chromosomal signal visible in the section (median 
15%). None of the tumors contained areas in which in-
creased numbers of cells had only one chromosomal sig-
nal. All cases had varying numbers of cells with >2 
chromosomal copies, paniculariy in large pleomorphic 
cell nuclei, where up to 8 chromosomal copies were seen 
(Fig. 4). After hybridization with probes for chromosome 
12, the same proportion of cell nuclei contained addi-
tional chromosomal copies, suggesting that these were 
due (o polyploidy. Between 2% and 46% of tumor cell 
nuclei had 3 or more chromosomal copies (median 19%). 
Although polyploidy tended to be associated with short 
survival, this association was not statistically significant. 
Those cases (n = 12) in which >30% of cells were 
polyploid had a median survival of 3.1 years, and those 
(n = 12) in which <I0% of cells were polyploid had a 
median survival of 5.0 years. 
The p53 LI was significantly correlated with the 
MiB-1 L I (p <0.01) and the proportion of cells with 
polyploidy (p <0.01). 
DISCUSSION 
We have evaluated a range of markers thai might be 
expected lo be associated with prognosis in astro-
cytic tumors. Although a trend between expression and 
survival was seen for niost of these, only focal loss 
of pl6 expression was a statistically significant indi-
cator of poor prognosis in this large cohort of diffuse 
astrocytomas. 
In an eariier study that included many of the present 
cases, we found that p53 LI did not correlate with sur-
vival ." With longer follow-up, the trend toward worse 
survival with high p53 Lis appears stronger but is still 
not statistically significant. Several previous studies have 
assessed the possible prognostic sigtiificance of p53 
abnormalities in astrocytomas.^ *^*^*'^ '^ -'"* Most of these 
studies included much smaller numbers of low-grade 
astrocytomas than in the present series, and although 
one study found an improved survival in patients with 
Am J Surg Paibol. Vol 26. A'a 4. 2002 
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FIG. 3. (A) Immunohistochemtstry for retinoblastoma protein in the low-grade astrocytoma showing focal loss of tumor cell 
immunoreactivity. (B) At higher magnification loss of nuclear immunoreactivity can be seen in numerous lumor cells. 
\ . 
FIG. 4. In situ hybridization for chromosome 10 demonstrating that the majority of tumor cells contain two copies; 
however, in Ihe large pleomorphic nuclei multiple chromosomal copies are present (inset). 
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p53-negaiive tumors ai 5 years o f follow-up, ihis was 
not siaiisiically significant.'^ A consistent finding is thai 
(he proponion o f p53-immunopositive cells is higher 
in recurrent than initial tumors from the same indi -
vidual. '"" '•^^ It has been suggested that the number o f 
p53-positive cells increases by clonal expansion because 
they have a survival advantage.^' In our study the p53 L I 
was strongly associated with both the M i B - l L I and 
polyploidy. Associations between p53 L I and prolifera-
tion rate, and p53 mutations and polyploidy, have been 
noted in previous studies o f astrocytic tumors^-* ' ' "* ' and 
presumably relate to the loss o f the normal functions o f 
p53 in D N A repair, apopiosis, and cell cycle control. 
In situ hybridization for chromosome 10 did not reveal 
any tumors with foci of convincing monosomy. In situ 
hybridization is a sensitive and specific method o f dem-
onstrating monosomy in astrocytic (umors,'* and although 
one study found monosomy of chromosome 10 in one o f 
1 i low-grade astrocytomas, this tumor occurred in a 74-
year-old and showed enhancement on computed tomog-
raphy scanning; so it was probably a glioblastoma.^' Our 
findings are in keeping with chromosome 10 loss as a 
late event in glioma progression. Although polysemy has 
been noted previously in low-grade astrocytomas,^' i t 
has not been associated wi th prognosis or p53 abnormali-
ties. Chromosomal abnormalities have been found in 
many low-grade astrocytomas,"'^ ' and tumors wi th 
multiple genetic changes have tended to have a worse 
prognosis." 
Al though originally described i n colonic tumors,* re-
duced expression o f DCC has been noted in a range 
o f human malignancies, including brain tumors.''*^*'^^ 
Reduced DCC mRNA levels were found in 77^88% o f 
glioblastomas by a semiquantitative reverse transcrip-
tase-polymerase chain reaction-based method.*'-^^ In a 
study using immunohistochemistry, 93% of low-grade 
astrocytomas, 47% of secondary glioblastomas, and 77% 
of de novo glioblastomas were classified as "positive." 
i.e., wi th immunolabeling o f > I 0 % of tumor cells.'* B y 
the same criterion. 74% of low-grade astrocytomas in our 
study were positive. However, we did not find a corre-
lation between immunohistochemical detection o f DCC 
and survival. 
As in our previous s tudy," M i B - I L I d id not correlate 
with survival. This is in contrast to two other studies o f 
low-grade astrocytomas."-^^ One o f these found survival 
to be significantly shorter in cases with an M i B - I L I 
> 8 % , ' ' although the proportion o f such cases was not 
indicated ( in our study only one tumor had an M i B - l L I 
>8%) . The other study recorded significantly shorter sur-
vival in the 56% of cases with an M i B - I L I >2%,* ' a 
higher proportion of cases with this level o f M i B - I la-
beling than the 34% o f cases in our study. Although the 
mean and median M i B - l L i s were not reponed in either 
o f these studies,"*" in both o f them the proportion o f 
cases wi th high M i B - l L i s seems to have been consid-
erably greater than in our study, raising the possibility 
that they included tumors that we would have considered 
to be o f higher grade. 
Focal loss o f immunoreactivity for p l 6 and retinoblas-
toma protein was found in approximately 5% and 10% o f 
low-grade astrocytomas, respectively. These tumors, par-
ticularly those with p l 6 loss, had a relatively short sur-
vival , suggesting that immunohistochemistry for these 
proteins may help in identifying a proponion o f low-
grade astrocytomas that w i l l undergo rapid malignant 
progression. Unexpectedly, tumors with focal loss o f im-
munoreaciivity for p l 6 or retinoblastoma protein had 
only a marginally higher M i B - l L I than had those wi th -
out loss. A lack o f correlation between p i 6 loss and 
proliferation has been noted in some studies o f higher 
grade astrocytic tumors,"*^^ although in other studies 
loss o f p I 6 ' ° or retinoblastoma protein '^ was asso-
ciated wi th increased proliferative activity. Loss o f p l 6 
and retinoblastoma protein has been associated wi th 
shorter survival in some studies o f hish-gradc astro-
cytic tumors,'"* but not others." It is possible that addi-
tional genetic changes, not present in low-grade astro-
cytomas, are needed for increased cell proliferation to 
occur. Loss o f p l 6 may also result in increased expres-
sion o f vascular endothelial growth factor (VEGF) and 
increased angiogenesis in gliomas,^ which arc factors 
known to be associated with poor prognosis in low-grade 
astrocytomas.* • 
R E F E R E N C E S 
1. A l x l u l r a u f S I . Edvardsen IC, H o K L . et a l . Vascular cndoihel ia l 
g r o w i h Tactor expression and vascular densiiy as prognostic mark-
ers o f survival i n patients w i t h low-grade asiroc>tonias. J Netiro-
surs 1998;88:513-20. 
2 . C l ioz ick BS . Pczzullo JC, Epstein M H . et a l . Prognostic impl i ca -
tions o f pS3 overcxpression i n supratentorial astrt)c>-tic tumors. 
Neurosurgery 1995:35:831-8. 
3. Cunningham J M . K i m m e l D W . Schcithauer B \ V , c i a l . Analys is o f 
pro l i fe ra t ion markers and p53 expression i n g l iomas o f astrocytic 
o r i g i n : relationships and prognostic value. J Neurosttrg I997;86: 
121-30 . 
4 . Da1r)'mpte SJ, Heraih JF, Ri t land SR, c t a). Use o f fluorescence i n 
situ hybr id iza t ion to detect loss o f c h r o m o j o m e 10 i n astrocyto-
mas. J Neurosurg 1995;83:316-23. 
5. El l i son D W . Sieart P V . Baicman A C et a l . Prognostic indicators i n 
a range o f astrocytic tumours: an immunohis tochemical study w i t h 
Ki -67-and p53 antibodies. J Neurol Neiirostirg Psyctiintry 1995; 
59 :413-9 . 
6. Fcaron ER, Cho K R , K e m SE, ei a l . Ident i f ica t ion o f a ch romo-
some 18q gene (hat is altered i n colorectal carcinoma. Science 
1990;247:49-56. 
7 . FuIis D . Pcdonc C D c l c i i o n mapping o f the long arm o f ch romo-
some 10 i n gl ioblastoma mu l t i r o rmc . Genes Chromosomes Cancer 
1993:7:173-7. 
8. Haapasalo H . Isola J. Sal l inen P. e l a l . Aberrant p53 expression i n 
a s i r o c j i i c neoplasms o f the brain: association w i t h p ro l i fe ra t ion . 
Am J Pathol 1993:142:1347-51. 
9. Harada H . Nakagawa K , Iwata S, et a l . Restoration o f w i l d l y p c 
p l 6 d o w n regulates vascular endothel ia l g rowth facior expression 
Am J StiTR ratltnl. Vol. 26. A'o. 2002 
Supplied by The British Library - 'The world's knowledge' 
478 D. A. HILTON ETAL 
and inhibi ts angiogennis in h u n u n gliomas. Cancer Res I999 ;59 : 
3783 -9 . 
10. Mcnson J W . Schniikcr B L , Corrca K M . ei a l . The m i n o b b s i o m a 
gene is invo lved i n malignant progression o f asiroc)'tomas. Ann 
Neiiml 1994;36:714-21. 
1 1 . H i l i o n D A . Love S, Barber R. e i al . Accumula t ion o f p53 and 
K i - 6 7 expression do not predict the survival o f patients w i t h f i -
b r i l l a ry astroc)iomas, o r the response o f these tumors to n d i o -
Iherapy. Neurosurgery 1998:42:24-9. 
12. luzzol ino P, Chimenton C. Nico la io A . et a l . p53 prDieln i n l o w -
grade astrocytomas: a study w i t h long-term fo l l ow-up , Br J Cnjtcer 
1994;69:586-91. 
13. Jaros E . Perry R H . A d a m L . et a l . Prognostic implications o f p53 
prote in , cpldennal g rowth factor receptor and K i - 6 7 labetins in 
brain tumours. Br J Cancer 1992;66:373-85. 
14. K i r i a R , Salminen E. I luhta la S, ei al . Prognostic value o f the 
expression o f tumor suppressor genes pS3. p 2 l . p l 6 and p R b . and 
K i - 6 7 label ing i n h igh grade astrocytomas treated w i t h radio-
therapy. J Neitrooncol 2000;46:71-80. 
15. Kleihues P. Kavcnec W K . Paihology and Genetics of Tumours of 
lite Nervous System. L y o n . France: l A R C Press. 2000. 
16. Lev ine A . p53: the cellular gatekeeper f o r g r o n i h and d i v i s i o n . 
Cell 1997:89:323-31. 
17. M c K e c v e r PE. Sirawderman M S , Yamin i B . et a l . M I B - I p r o l i f -
eration index predicts survival among patients w i t h grade I I osiro-
cy ioma . J Neuropathol Exp Neurol 1998;57:931-6. 
18. Nakamura M . Konish i N . Tsunoda S. el a l . Retinoblastoma protein 
expression and M I B - I correlate w i t h sur\-i%-al o f patients w i t h ma-
lignant a s t rocy iomx Cancer 1997;S0:242-9. 
19. NaJcatani K . Yosh imi N , M o r i H . et a l . The significance o f the 
expression o f tumor suppressor gene D C C in human gl iomas. J 
Neurooncol 1998;40:237-12. 
20. Ono Y , Tamiya T . Ichikawa T , et a l . Malignant astiDcyiamas w i t h 
homozygous C D K N 2 / p l 6 deletions have higher K i - 6 7 pro l i fc ra -
l i o n indices. J Neurvpathol Exp Neurol 1996,55:1026-31. 
2 1 . Peny A . T o n k V , Ntclnt i rc D D . ct al . Interphase cylogenetic ( in 
- .^s i tu hybr id iza t ion) analysis o f astrocytomas using archival , fonna-
l i n - n x c d . parafl in-embeddcd tissue and nonfluorescent l ight m i -
croscopy. Am J Clin Pathol 1997:108:166-74. 
22. Piva R. Cavalla P, Bor to lo l to S. et al . C D K N 2 / p l 6 inaci iva t ion and 
p I 6 immunohis iochemis t ry i n a s t r w y t i c gliomas. Int J Oncol 
1998:12:55-8. 
23. Puduvall i V K . Kyri ts is A P . I lcss K R . c i a l . Patterns o f expression 
o f Rb and p l 6 i n astroc)'''*^ g l iomas , and corre la t ion w i t h survi\-al. 
Int J Oncol 2000; 17:963-9. 
24. Reifcnbcrger J. R ing G . Gies U , et a l . Ana lys i s o f p53 mutat ion and 
epidermal growth factor receptor a m p l i f i c a t i o n in recurrent g l io -
mas w i t h malicnani progression. J Neuropathol Exp Neurol 1996: 
55 :822 -31 . 
25. Rey J A . Bel lo NtJ. Campos J M . ct a l . Chromosomal composi t ion 
o f a series o f 22 human low-grade g l iomas . Cancer Genet Cvto-
genet 1987;29:223-37. 
26. Rcyes-Mugica M . Reigcr-Christ K . O h g a U H . et a l . Loss o f D C C 
expression and g l ioma progression. Cancer Res 1987:57:382-6. 
27. Sallinen SL, Sallinen P. Haapasalo H . ei a l . Accumula t ion o f ge-
netic changes is associated w i t h poor prognosis i n grade I I astro-
cytomas. Am J Pathol 1997;151:1799-807. 
28. Schcck A C . Coons S\V, Expression o f the t u m o u r suppressor gene 
D C C i n human gl iomas. Cancer Res 1993:53:5605-9. 
29. Schi f fe r D , Cavalla P. C h i o A . e i a l . Pro l i fe ra t ive act iv i ty and 
prognosis o f low-grade astrocytomas. J Neurooncol 1997:34:31-5. 
30. S c h m i d t E E . I c h i m u r a K , R c i f e n b c r g e r G . et a l . C D K N 2 
( p l 6 / M T S I ) gene deletion o r C D K 4 ampl i f i ca t i on occurs i n the 
ma jo r i ty o f glioblastomas. Cancer Res I994;54;632l—4. 
3 1 . SidransWy D , M i k k c l s c n T . Schwechhcimcr K . et a l . C lona l ex-
pansion o f pS3 mutant cells is associated w i t h bra in tumor pro-
gression. Nature 1992;355:846-7. 
32. Tsuzuki T . Tsunoda S. Sakaki T , c t al . Al tera t ions o f retinoblas-
toma. p53. p l 6 ( C D K N 2 ) and p l 5 genes i n human astrocytomas. 
Cancer 1996;78:287-93. 
33. van M e y e l DJ. Ramsay D A . Casson A G . ei a l . p53 mutat ion, 
expression, and D N A ploidy i n e v o l v i n g g l iomas : evidence f o r t w o 
pathways o f progression. J Natl Cancer Inst 1994:86:1011-7. 
34. Vertosick FT . Selkcr R G , Arena V C . Su rv iva l o f patients w i t h 
wel l -different ia ted astrocytomas diagnosed i n the era o f computed 
tomography. Neurosurgery 1991;28 :496-501 . 
35. von D c i m l i n g A , von A m m o n K , Schoenfc id D . ct a l . Subsets o f 
glioblastoma m u l t i f o r m e def ined b y molecular genetic analysis. 
Brain Pathol 1993;3:19-26. 
36. Watanabe K . Sato K . Biemat W . ct a l . Incidence and t i m i n g o f p53 
mutations dur ing astrocytoma progression i n patients w i t h mul t ip le 
biopsies. Clin Cancer Res 1997;3:523-30. 
^ n i J Surg Pathol Vol. 26. No. 4. 2002 
Supplied by The British Library - 'The world's knowledge' 
J O U R N A L O F T H E R O V A L S O C I E T Y O F M E D I C I N E V o l u m e 9 3 J u n o 2 0 0 0 
Randomized controlled trial of nettle sting for treatment of 
base-of- thumb pain 
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SUMMARY 
There are numerous published references to use of nettle sting for arthritis pain but no randomized controlled trials 
have been reported. We conducted a randomized controlled double-blind crossover study in 27 patients with 
osteoarthritic pain at the base of the thumb or index finger. Patients applied stinging nettle leaf {Urtica dioica) daily 
for one week to the painful area. The effect of this treatment was compared with that of placebo, white deadnettle 
leaf {Lamium album), for one week after a five-week washout period. Observations of pain and disability were 
recorded for the twelve weeks of the study. 
After one week's treatment with nettle sting, score reductions on both visual analogue scale (pain) and health 
assessment questionnaire (disability) were significantly greater than with placebo (P=0.026 and P=0.0027). 
INTRODUCTION 
The sting o f the common stinging nettle has long been use<l 
for self-treatment o f arthritic pain. We have previously 
reported two cases seen in general practice' and an 
interview study o f 18 patients using this treatment^. There 
are anecdotal reports o f urtication (external stinging) f o r 
j o in t pain w o r l d w i d e ^ ^ , including use by soldiers in 
Roman times^, but we find no record of a randomized 
controlled t r ia l . 
In preparation f o r our o w n trial we conducted in-depth 
interviews w i t h 18 patients who had used nettle sting f o r 
their jo in t pains, analysing the results by a grounded theory 
approach^. The information obtained ( in particular, 
method, duration and frequency o f application) was used 
to plan a randomized controlled double-blind crossover trial 
o f common stinging nettle versus white deadnettle 
(placebo). 
METHODS 
The nQuery Advisor computer statistical package was used 
to calculate sample size. W e estimated that the difference i n 
health assessment questionnaire score between nettle-treated 
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and placebo-treated patients would be 0.4 units. A sample 
size o f 18 in each group wou ld have 8 0 % power to detect a 
difference in means o f —0.40 (the difference between a 
group \ mean o f 0.00 and a group 2 mean o f 0.40), on the 
assumption that the common standard within-patient 
deviation is 0.40 w i t h a group i-test on the period I -
period I I differences wi th a 0.05 one-sided significance 
level. 
The inclusion criteria were persistent pain at the base o f 
thumb or index finger o f at least ten weeks' duration 
consistent wi th a clinical diagnosis o f osteoarthritis, in a 
patient over 18 years old and English-speaking. Exclusion 
criteria were a history o f drug dependency, severe systemic 
disease, diabetes, pregnancy/lactation, and learning dis-
abihty. Patients were given or sent an information leaflet 
before being seen, to offer fur ther informat ion and facilitate 
enrolment wi th wr i t t en consent. The study was approved 
by the local ethics committee. 
Pat ien ts 
A l l the patients who were invited to participate accepted, 
and 27 patients were recruited. 22 were attending 
rheumatology outpatient departments and S were attending 
a general practice. None had previously used nettles as a 
treatment. There were 4 men and 23 women , mean age 60 
years (range 4 5 - 8 2 ) , mean duration o f the complaint 3.8 
years (0 .2 -16) . 26 patients had persistent pain in the base o f 
the thumb consistent w i t h osteoarthritis; in addition 2 o f 
these had rheumatoid arthritis and 1 had ankylosing 
spondylitis. A further patient had osteoarthritis o f the base 
J O U R N A L O F T H E R O Y A L S O C I E T V O F M E D I C I N E V o l u m e 9 3 J u n e 2 0 0 O 
of the index finger and wrist . A t the start of the study 19 
were taking analgesics and 13 anti-inflammatories. 10 
patients had received steroid injections for their hand 
osteoarthritis but none o f these had had a steroid injection 
in the previous three months. Existing treatment was 
continued during the trial as required by the level o f pain. 
Trial des ign 
A first week o f treatment was fol lowed by a washout period 
of five weeks. There was then a second treatment week 
wi th a furdier washout period o f five weeks. Patients and 
assessing doctor were blinded to the treatment order. A 
final assessment was made at the end o f the twelve-week 
tr ial . 
Intervention 
White deadnettle {Lamium album) plant was chosen as a 
placebo since when non-flowering i t is almost indistinguish-
able f r o m the common stinging nettle but does not sting. 
Plants were gro^vn in pots and distributed non-flowering to 
the patients who were randomly allocated at initial clinic 
attendance (by numbers drawn f r o m an envelope) to 
stinging nettle first or white deadnettle first. Patients were 
instructed how to cut a leaf (wi th hand in a plastic bag) and 
apply the underside to the painful area of thumb or index 
finger base wi th gentle pressure for about 30 seconds, 
moving the leaf twice. This was to be done once a day. 
Patients were given an instruction leaflet. We told them we 
were investigating the potential beneficial effects o f t w o 
types o f 'net t le ' and warned them they might experience 
stinging which would not be harmful . 
A s s e s s m e n t 
Patients were assessed clinically at each attendance and 
completed a pain diary and a health assessment ques-
tionnaire. They were observed over the twelve weeks o f the 
study as shown in Figure 1. Mult iple outcome measures 
were used, as recommended by Bradley'®. The visual 
analogue scale and verbal rating scale for pain, and the 
Stanford Health Assessment Questionnaire for disability, are 
wel l validated cr i te r ia '^*^ . The visual analogue scale 
consists o f a 100 m m horizontal line wi th endpoints that 
are anchored by descriptors 'no pain* and 'worst pain ever*. 
The patient was asked to mark the point on the scale that 
represented the intensity or unpleasantness of his or her 
START OF T R I A L 
22 patients f rom hospital 
rheuinatology tfirac 
5 patients f rom one 
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Table 1 Resul t s o l o u t c o m e measu re s b e f o r e and a f t e r one w e e k ' s t r e a t m e n t 
Wo, of After 1 week's 
patients Pretreatment treatment Reduction 
Reduction: 
stinging nettle-
placebo 9 5 % CI 
Pa in v i s u a l a n a l o g u e 
sca l e 
S l i n g i n g n e t t l e 
P l a c e b o 
H e a l t h a s s e s s m e n t 
q u e s t i o n n a i r e 
S t i n g i n g n e t t l e 
P l a c e b o 
Dai ly a n a l g e s i c u s a g e 
( n o n - a n t i - i n f l a m m a t o r y ) 
S t i n g i n g n e t t l e 2 7 
P l a c e b o 2 7 
Da i ly a n t i - i n f l a m m a t o r y 
u s a g e 
S t i n g i n g n e t t l e 2 7 
P l a c e b o 2 7 
Pa in v e r b a l r a t i n g 
s c a l e 
G r o u p A : 
S t i n g i n g n e t t l e 13 
P l a c e b o 
G r o u p B : 
P l a c e b o 
S t i n g i n g ne t t l e 
2 7 
2 7 
2 7 
2 7 
3 8 . 3 0 ( m e a n ) 2 3 . 6 7 ( m e a n ) 
3 6 . 5 9 ( m e a n ) 3 7 . 0 4 ( m e a n ) 
13 
1.53 ( m e a n ) 
1.39 ( m e a n ) 
2 . 3 3 ( m e a n ) 
2 . 0 4 ( m e a n ) 
1.04 ( m e a n ) 
0 . 9 3 ( m e a n ) 
2 ( m e d i a n ) 
2 ( m e d i a n ) 
2 ( m e d i a n ) 
1 ( m e d i a n ) 
1.36 ( m e a n ) 
1.43 ( m e a n ) 
1.44 ( m e a n ) 
2 . 1 1 ( m e a n ) 
0 . 7 0 ( m e a n ) 
0 . 9 3 ( m e a n ) 
1 ( m e d i a n ) 
2 ( m e d i a n ) 
2 ( m e d i a n ) 
1 ( m e d i a n ) 
pain experience. A visual analogue pain scale is more 
sensitive to treatment-related changes than are numerical 
and verbal rating scales'**. I t is an interval scale, thus 
parametric procedures (e.g. t-test) may be used to analyse 
responses'**. The verbal rau'ng scale used was a simplified 
five-category scale modified f r o m the seven-category scale 
described by Bradley***: no pain; faint pain; moderate pain; 
strong pain; worst pain ever. 
Analgesic and anti-inflammatory medication usage, sleep 
analogue scale scores and side-effects were also monitored. 
A t the end o f the study patients completed an eight-
question satisfaction questionnaire. 
Stat is t ica l ana lys is 
Two-sample t-iests were applied to period 1-period I I 
differences calculated for each patient. Kolmogorov— 
Smimov tests on these variables showed the assumption 
of' Normal i ty had a reasonable justification. Pain visual 
analogue scale and health assessment questionnaire scores 
were the t w o best-validated measures and were nominated 
1 4 . 6 3 ( m e a n ) * 
- 0 . 4 5 ( m e a n ) 1 5 . 0 8 ( m e a n ) 
0 . 1 7 ( m e a n ) 
- 0 . 0 4 ( m e a n ) 0 . 2 1 ( m e a n ) 
0 . 8 9 ( m e a n ) 
0 . 0 7 ( m e a n ) 0 . 9 5 ( m e a n ) 
0 . 3 4 ( m e a n ) 
0 ( m e a n ) 0 . 3 4 ( m e a n ) 
0 . 0 2 . 3 0 . 7 2 0 . 0 2 6 
0 . 0 7 . 0 . 3 5 2 0 . 0 0 2 7 
> 0 . 0 5 
> 0 . 0 5 
1 ( m e d i a n ) 
0 ( m e d i a n ) 
0 ( m e d i a n ) 
0 ( m e d i a n ) 
1.0 ( m e d i a n ) 
0 ( m e d i a n ) 
0 . 0 2 8 
> 0 . 0 5 
as the key outcome measures. The mean reductions in 
visual analogue scale scores and health assessment 
questionnaire scores were compared fo r stinging nettle 
versus placebo, the 9S% confidence interval being 
calculated f o r each. 
The verbal rating scale was a categorical/ordinal score, 
thus non-parametric analysis was used (Wi lcoxon paired-
samples test). Reduction o f analgesic and anti-inflammatory 
drug consumption was analysed w i t h two-sample t-tesis. 
R E S U L T S 
Completion rate o f pain diaries was 99% and attendance 
rate at review clinics was 96%. At the end-of-trial final 
assessment clinic 6 patients did not attend, but 3 of these 
were interviewed by telephone and completed pain diaries/ 
end-of-trial assessments. 
Pain and disabihty scores are shown in Table 1. The 
visual analogue scale scores for stinging nettle treatment fell 
below those f o r placebo after day t w o and remained lower 
for the rest o f the week (Figure 2). 
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Twice daily pain VAS score 
Figure 2 M o a n p a i n v i s u a l a n a l o g u e s c a l e (VAS) s c o r e d u r i n g t r e a t m e n t w o c k : n e t t l e v e r s u s p l a c e b o . — Mean net t le VAS; m e a n p l a c e b o 
VAS 
After one week's treatment the score reduction wi th 
stinging nettle was significantly greater than that wi th 
placebo. A week into the washout period there was still a 
difference in favour of stinging nettle, though no longer 
significant (P=0 .1 ! , see Figure 3). 
Verbal rating scale scores showed greater pain reduction 
w i t h stinging nettle but the difference was statistically 
significant only in the group who had stinging nettle first 
(see Table 1). The health assessment questionnaire scores 
showed a significant reduction for stinging nettle versus 
placebo after one week's treatment (see Table 1). 
After one week's treatment daily use of analgesic and 
anti-inflammatory drugs showed a decline in the stinging 
nettle group but the difference versus placebo was not 
significant (at the start o f the study only 19 were taking 
analgesics and 13 were taking anti-inflammatories). 
I" m 
11 1 I 
Pre^ealmenl Aftei 1 •reort Aliw 1 week's 
washout was^oul 
Figures C o m p a r i s o n o f n e t t l e / p l a c e b o m e a n p a i n v i s u a l 
a n a l o g u e s c a l e (VAS) s c o r e s w i t h 9 5 % c o n f i d e n c e i n t e r v a l s . 
^ N e t t l e ; ^ p l a c e b o 
I t became clear during the study that sleep was an 
unsatisfactory outcome measure. Only 6 of 27 patients 
considered their hand pain to be the predominant factor 
affecting sleep. There was a non-significant improvement in 
sleep w i t h stinging nettle (3 .8% versus 0.6%). 
No serious side-effects were reported or observed. The 
localized rash and slight itching associated w i t h stinging 
nettle was accepuble to 23 of 27 patients; 2 patients 
reported the sting as unpleasant but not distressing. 
1 patient had a persistent rash on her forearms after 
treatment but this had occurred before and was not 
necessarily due to stinging netde. The stinging nettle 
treatment caused a rash on the hand o f one patient who 
discontinued treatment because he needed heavy gloves fo r 
his job . 
O n the measure o f patient satisfaction, 14 patients out 
of 27 preferred netde sting treatment to their usual 
treatment and 17 wished to use the treatment in the 
fu ture . 
DISCUSSION 
The results o f this trial demonstrate an analgesic effect and a 
reduction o f disability after one week of daily treatment 
wi th stinging nettle. A weakness o f the design was that the 
'b l inding ' o f both doctor and patients was incomplete; some 
patients reported stinging and a rash wi th the application o f 
one plant treatment. Patients were not, however, given to 
understand that any benefit might be associated w i t h the 
sting, and the patients did not seem to make this 
assumption. The sample size was small, but the crossover 
of treatment considerably increased the power o f the 
results. Patient compliance was also high. Pain perception is 
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subjective and diff icul t to measure, which is why we used 
mult iple validated indices of pain and funct ion. 
The stinging nettle is a freely available plant and its sting 
seems a safe treatment for musculoskeletal pain. Nett le 
sting contains serotonin, acetylcholine, histamine and 
leukotrienes, among other substances'^. Serotonin and 
histamine are involved in the cascade o f stimulation 
affecting levels of ner\'e gro%vth factor, which in tu rn 
increases activation o f nociceptive pain n e u r o n s ' T h e 
mechanism o f nettle-sting analgesia could be hyperstimula-
don o f the sensory nociceptors causing a TENS-like 
effect^^-^', a substance P depletion effect similar to that 
o f capsaidn^^, an acupuncture-like effect^^-^* or a counter-
irr i tant effect^^'^S stinging rash might also have a 
power fu l effect on patients' cognitive perception o f pain^^. 
Tlte potential of this treatment deserves further research. 
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O e n t o l A n x i e t y a n d S e d a t i o n I n P r i m a r y D e n t a l Care I 
TiGfgency Dental Clinic Patients in South Devon,Their Anxiety 
iveb, Expressed Demand for Treatment Under Sedation sflti 
stability for Hanagement Under Sedation 
b e r t A Baker, Susan Farrer, Vanessa J Perkins and Hilary Sanders 
K e y w o r d s : Emergency D e n t a l Patients, D e n t a l A n x i e t y , D e n t a l Sedat ion 
O b j e c t i v e : To assess the anxiety levels of patients attending 
two salaried dental service emergency clinics, their expressed 
demand for treatment under sedation, and their medical suit-
ability for dental sedation. 
D e s i g n : A questionnaire survey, incorporat ing the Modified 
Dental Anxiety Scale (MDAS) and assessment of American Soci-
ety of Anesthesiologists' (ASA) physical status classification, of 
all adul t patients a t tending two emergency dental clinics in 
Torquay and Newton Abbot. 
R e s u l t s : 513 patients r e tu rned quest ionnaires . Only f ive 
dedined to take p a n in the study. The mean MDAS for patients 
attending the two emergency dental dinics was 14.09 (SD 6.04) 
and 4 1 . 9 % of patients were classified as dental ly anxious 
© P r i m a r y D e n t a l C a r e 2006 ; 13(1): I 1-18 
(MDAS > I S ) . A preference fo r treatment under sedation was 
expressed by S6.3%. of a l l pa t i en t s , of w h o m SO.5% were 
classified as ASA I (without health problems) and would have 
been suitable for sedation in primary dental care. 
C o n c l u s i o n s : The reported dental anxiety levels of patients 
attending the two emergency dental clinics were found to be 
much higher than those found by previous studies in general 
dental practice and at dental school emergency dinics. There 
was a high expressed demand for treatment under sedation. 
Further studies are needed to assess the levels of dental anx-
iety seen at other dental emergency clinics and a health needs 
assessment to determine need as opposed to expressed demand. 
In recent years, in the United Kingdom (UK), there has been a 
policy emphasis in the National Health Service (NHS) for the 
establishment o f new clinics, run by salaried stafT. These have 
incliuled dental access centres and emergency clinics established 
under the provisions of section 5fi of the 1977 iWiiiottuI Hcdlifi 
Service Acf.^ The primary role o f these clinics has been to 
provide emergency dental care and courses o f treatment for 
unregistered patients. Little information has been published 
regarding effectiveness of these clinics. The majoriw o f patients 
who attend them are normally not registered with a general 
dental practice. 
Two recent publications provide some indication o f the 
number o f unregistered adult patients in the U K . The first 
was the 1998 Adiili Dental Health Survc)'. which indicated that 
in that year 59% of adults attended 'regularly' for dental carc.^ 
h can be deduced by implication, therefore, that the other 
4 1 % may have been irregular attendcrs and were, as a conse-
quence, unregistered. The second was the British Household 
Panel Surrey^ (an annua! survey o f social and economic 
change at tlie household and individual level in Britain) that 
suggested that \n 2000.62,3% of the population (46,3% NHS. 
14.0% private. 2% both) attended for a dental check-up. thus 
implying that 37.7% of the population had not received a 
check-up and may be assumed not to have accessed regular 
dental care. 
In the event o f oral health problems or dental pain, these 
unregistered patients must access dental care wherever they 
can. Although in some geographical areas this can be in general 
dental practices, in others it wi l l be through either Personal 
Dental Service access centres or Salaried or Emergency Dental 
Service clinics. In recent years there has been a decline in the 
numbers o f general dental practitioners (GDPs) wil l ing to offer 
dental care under the NHS."* A greater number of patients have 
therefore sought emergency dental care through access centres 
and emergency dental clinics. 
Questions which arise include: what are the fears and expec-
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tacions of patients who attend these clinics and what are their 
treatment preferences? 
A commentary^ on the 1998 Adult Denial Health Survey^ 
reported respondents' attitudes about fear, the value of treat-
ment and the organisational aspects of going to the dentist. O f 
all respondents 32% answered 'yes' to the statement, 'I always 
feel anxious about going to the dentist'. However, of those 
who said 'they only attended when they had some trouble*, the 
percentage answering 'yes' to this question was 46%. This 
suggests that those patients who only attend when in pain will 
have a higher than average level of anxiety. It follows therefore 
that, as they are far more likely to be irregular attenders, those 
patients who attend in pain at emergency clinics may well be 
likely to have a higher level of anxiety than those who attend 
regularly in general dental practice. 
A number of studies have suggested that the percentage of 
patients who are dentally anxious may vary from country to 
countr)'. This may suggest that cultural influences play a part. 
U K studies have found the percentage of patients with dental 
anxiety in different patient groups as follows: 15% in adult staff 
of a U K retailing company,^ 14.2% (DAS 2 13) in Scottish 
children aged 13 and 14 years^ and 13% (DAS a 13) in British 
adults aged 60 years and over.^  All these studies included both 
regular and irregular attenders, however, data are lacking on 
dental anxiety in irregular attenders. 
One technique used to assess dental anxiety is the Modified 
Dental Anxiety Scale (MDAS).^This scale was devised^ as a 
development from the Dental Anxiety Scale (DAS).'** " The 
original D A S " made no reference to local anaesthetic. An 
additional question relating to local anaesthetic was introduced^ 
to create the MDAS. 
A study published in the U K in 1995^ found a mean MDAS 
of 10.79 (± 4.63) for patients attending a general dental prac-
tice and a mean MDAS of 21.51 (± 2.94) for dental phobic 
patients. In the United Sutes of America an investigation'^ was 
carried out into factors that were thought to be associated with 
higher levels of dental anxiety. Dental anxiety was found in 
28.2% of low income patients, 23.7% of patients with a check-
up frequency of less than once per annum, and in 31.4% of 
patients with no usual place of dental care. It may well be that 
patients attending emergency dental clinics would be more 
anxious because they too demonstrate factors such as low 
income (cannot afford to access private dentistry) and irregular 
attendance/no regular dental practice. A recent study of those 
attending an 'out-of-hours' emergency clinic in the North of 
England found that over a three-month period, 60% of those 
who claimed to be irregular attenders cited fear as a reason 
for non-attendance.'-* 
A BraziUan study, using the MDAS, found that 28.2% of 
patients were denully anxious.'^ Two other studies that used the 
DAS, rather than the MDAS, found that 21.8% of new patients 
attending an emergency dental clinical at a North American 
Dental School'^ and 30% attending a dental emergency clinic 
in Gothenburg'* had high dental fear. However, these percent-
ages should be interpreted with care because, as described 
above, the DAS and MDAS scales are not directly comparable. 
Research^ has suggested that British patients with high 
anxiety levels had a greater experience of sedation/GA and 
preference for sedation/GA. I f there were higher levels of 
dental anxiety in emergency dental clinic patients, it might be 
anticipated that there would be a higher demand for dental 
sedation. In order to manage such clinics in an optimal manner, 
it is important to establish the level of this demand and, more 
imporuntly, need. It is also important to establish whether or 
not patients requesting sedation are suitable for management 
in a primary care setting or whether they need to be managed 
in a hospital setting. 
Against this background, the current study sought to estab-
lish the anxiety levels of patients attending two emergency 
dental clinics in South Devon, and their demand and suitability 
for dental treatment under sedation. 
Method 
A self-completion questionnaire {Figure I) was developed and 
piloted. Statistical advice was sought with regard to the selec-
tion of an appropriate sample size (500). Ethical approval for the 
study was obtained from the Local Ethics Research Committee. 
The questionnaiTe 
A structured questionnaire that used the M D A S ' u-as developed 
and piloted {Figure I) . The MDAS consists of five questions each 
of which has five alternative answers, ranging in degree of 
anxiety from no anxiety (1) to extreme anxiety (5). Once the 
questions are answered the lowest possible score is 5 (no anxi-
ety reported when answering all five questions) and the highest 
score is 25 (extreme anxiety reported in answer to all five 
questions). Patients with a score between 16 and 19 inclusive 
are dentally anxious, and patients with a score of 20-25 inclu-
sive are dentaJ phobics. 
In addition to the five questions in the MDAS patients were 
asked: 
I Have you previously experienced treatment with sedation? 
I If a\'ailable, would you prefer your treatment to be with 
sedation? 
Procedure 
After completing the usual medical history form, all adult 
patients attending at two emergency dental clinics (in Torquay 
and Newton Abbot) were given a paper copy of the question-
naire, together with an information sheet (explaining the pur-
pose of the research and providing assurance of confidentiality). 
The questionnaire was completed in the waiting area prior to 
treatment. Patients were deemed to have consented to take part 
in the study by completing the form. Following treatment, the 
individual patient's anxiety characteristics were completed and 
a copy of the medical history was attached. Completed ques-
tionnaires were collected until 100 had been collected for each 
session worked at each clinic.There were three sessions per day 
at Torquay (morning, afternoon and evening) but only morning 
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South Devon Hcahhcare Tnist emergency dentists wish t o offer the txist possible service. W e want t o 
kr>cw how jrou a r« f c e l l n j and if you are w o r r i e d o r anxious about dentaJ t reatmenLYour t ime t o 
complete the f o l l o w i n j questions, wou ld be valued and your reply wi l l remain anonymous and 
complfitidy-cbnTidential; 
Please hartd t h e c o m p l e t e d f o r m to r ecep t i on . T h a n k y o u 
No 
C A N Y O U T E L L U S H O W A N X I O U S Y O U G E T . I F A T A U ^ A B O U T Y O U R D E N T A L VISIT? 
(Pl<ase indt<3te by F ^ n g an')C h the a f ^ ^ - • ' , ' ' 
, N o t . Slightly -^FaHy- ^ f e r y ^ ^ E j t & w n ^ 
. 'v* ' V * aiudous ' aiiiJota' aiuiom iadtm anxbiB 
I . If you went to your dentist fbr.TKEATMENT 
TOMORROW, how would you feel? • 
i If you Were srttf^ig liT tJw WATTING ROOM (waiting ^ 
for beatmcnt). how Woukl you fed? H 
3. If you were about to have a T O O T H DRILLED, 
how wtxj id you feel? H • I 
4. If you were about to have your TEETH SCALED & 
POUSHEn how would you fccir • • I 
5. I fyouwcns a b o u t t o h a v e a t o c a l A N A ^ ^ 
INJECTION in your gum. above an upper back tooth. 
how would you fcdl • • I 
D e n t a l t r e a t m e n t a t ' t h i s cl inic Is c u r l e d o u t unde r local anaesthetic 
6. Have you previously experienced treatment wi th sedation! 
.7. If available, would you prefer your treatment to be with scdadonf 
F igu re I Questionnaire given to all patients vi^o took part^In the study. 
and afternoon sessions at Newton Abbot. A target total o f 500 
replies was therefore anticipated. 
Patients were excluded from this study i f they were: under 18 
years, unable to speak English, intoxicated (with either alcohol 
and/or controlled drugs), suffering from dementia, or for any 
other reason which would prevent their understanding o f the 
questionnaire. 
Patients were characterised according to: 
I Age. 
I Gender. 
I Location at which they were treated. Torquay or Newton 
Abbot. 
I American Society o f Anesthesiologists' (ASA) physical status 
classification (see below). 
I Anxiety status and demand for dentai sedation. 
The ASA physical status classification*^ was devised in 1941. 
It describes a patient's pre-operative condit ion and its pur-
pose is to facilitate the ^tabulation o f statistical data in anaes-
thesia'.'^ The classification permits comparison o f populations 
w i t h reference to thei r physical state alone, regardless o f 
surgical procedure. It is widely used in hospiul practice and 
is recorded pr ior to surgical procedures. The classifications 
are: 
I ASA 1: A normal healthy patient. 
I ASA 2: A patient wi th a mild systemic disease. 
I ASA 3: A patient with a severe systemic disease that limits 
activity but is not incapacitating. 
I ASA 4: A patient wi th an incapacitating systemic disease 
that is a constant threat to life. 
I ASA 5: A m o r i b u n d pat ient , no t expected to survive 
24 hours wi th or without operation. 
Patients wi th an ASA o f 1 are suitable for treatment in primary 
dental care. Patients classified as ASA 2 
present a higher risk. Some may be con-
sidered suitable for dental sedation in 
p r imary dental care, but w i l l require 
appropriate precautions. Those patients 
wi th very high anxiety w i l l have higher 
levels o f endogenous adrenaline, older 
patients are more sensitive to sedation 
agents, and patients wi th a high body 
mass index may have a reduced respir-
atory capacity. Therefore many patients 
in ASA 2 and those in ASA 3 and 4 are 
no rma l ly on ly considered fo r dental 
sedation in a hospital setting. Patients 
classified as ASA 5 are mor ibund and 
are very unUkely to be encountered in 
primary care. 
Reiiabitity study 
The reliability of the questionnaire was 
investigated fo r i n t e rna l consistency 
using Cronbach's alpha procedure.*^ This 
is not a statistical test but provides a co-
efficient o f consistency (reliability). It assesses how well a set o f 
variables (the first five questions in the questionnaire) measure 
a single unidimensional latent construct (dental anxiety). 
Internal consistency 
The consistency w i t h which the investigator assessed ASA 
categories was checked by repeating a random sample o f 25 
ASA assessments, blind o f the results o f the first assessment. 
Data entry and analysis 
Data from the completed questionnaires were entered into 
Excel (Microsoft Off ice 2000) by the South Devon Healthcare 
N H S Trust s Clinical Effectiveness Department. The informa-
tion was transferred to SPSS version 11.5.1 (SPSS Inc. Chicago, 
USA) fo r statistical analysis at the University o f Plymouth. 
Ca tegor ica l data such as gender and anx ie ty status were 
analysed using the chi-squared test. 
Results 
Reliability and internal consistency 
Application o f Cronbach's test gave an alpha value o f 0.925 
which demonstrated a high level o f reliability for the ques-
tionnaire. 
When the same investigator repeated assessment o f the 
random sample o f 25 ASA assessments, bl ind o f the results o f 
the first assessment, 24/25 (96%) were the same.The exception 
related to a patient who was originally assessed as ASA 3 and 
was reassessed as ASA 2. 
Characteristics of the respondents 
A total o f 513 completed questionnaires was collected. This 
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T a b l e 1: M D A S s c o r e s b y g e n d e r 
No. of patients Mean (SD) P-value 
AM patients 513 14.09 (6.04) 
Males 250 12.31 (5.65) 
P<0.00l 
Females 263 15.79 (5.92) 
T a b l e 2 : M D A S s c o r e s b y a g e g r o u p 
No. of patients Mean (SD) P-value 
All paclents 513 14.09 (6.04) 
Under age 60 465 14.43 (6.02) 
P<O.OOI 
Age 60 & over 48 10.83 (5.29) 
was more than the original chosen sample size of 500, due to 
staff continuing to collect questionnaires to the end o f a session 
rather than stopping when the chosen sample was achieved. O f 
the patients who completed the questionnaires. 263 (51.3%) 
were female and 250 (-18.7%) male. The mean age o f all those 
who completed the questionnaires was 38.1 years (range 18-83 
years). 
Non-completion 
Overall only five patients (less than 1%) declined to complete 
the questionnaire. 
Anxiety levels 
The mean MDAS score for all patients was 14.09 (±6.04) . 
Wi thn i this overall mean, the mean MOAS for males o f all 
ages was 12,31 (±5 .65) and for females 
15.79 (±5 .92) {Table / ) . A n independent 
samples r-iesi showed strong statistical 
evidence (P<0.001) o f a difference in 
mean MDAS scores between males and 
females. The females were estimated to 
have scores 3.5 points higher than the 
males (95% confidence interval for this 
mean difTerence was 2.46, 4.46). 
There was also strong evidence 
(P<0.001) of a diiTercncc in mean MDAS 
scores for those under 60 years of age, 
14.43 ( ± 6 . 0 2 ) . and those over 60 years 
of age. 10.83 (±5.29) {Table 2). wi th the 
under 60-ye3r-olds estimated to have 
scores 3.6 points higher on average than 
those aged over 60 years (95% confidence 
interval tor this mean difference was 
1.82. 5.37). 
A significant difference was found between increased 
reported an.xieiy and gender: in males 14.8% were classified as 
dental phobics (MDAS score 20-25), whereas 32.7% of women 
were in this category (P<0.001) {Table J). 
Age was also related to reported dental phobia, which was 
reported by 25.6% of those less than 60 years o f age but by only 
8.3% of those aged 60 years and over (P=0.003) {Table 4). 
When considering dental pliobia chi-squared tests showed 
strong evidence (F<0.001 and 0.003 respectively) of an associ-
ation between this an.xiety group and gender and between this 
anxiety group and age. 
In Newton Abbot. 64.4% of respondents reported that they 
had no dental anxiety. In Torquay, 53.7% reported no dental 
anxiety. There was some evidence (P=0-048) of an association 
between anxiety levels and c l in ic loca t ion . O f patients at 
1 T a b l e 3 : A n x i e t y g r o u p b y g e n d e r 
No. of patients No dental anxiety Dental anxiety Dental phobia P-value 
No. (%) No. (%) No. (%) 
All patients 513 298 (58.1) 92(17.9) 123 (24.0) 
• Males 250 178 (71.2) '35 "(14.0)' 37 (14.8) 
' P<0.00l ' 
Females 263 120 (45.6) 86 (32.7) _ 
1 T a b l e 4 : A n x i e t y g r o u p b y a g e g r o u p 1 
No. of patients No dental anxiety Dental anxiety Dental phobia P-value 
No. (%) No.(%) No. (%) 
All patients 513 298 (58.1) 92 (17.9) 123 (24.0) 
Under age 60 465 259 (55.7) = 87(18.7) 119 (25.6) 
' P=0.003 
Age 60 & over 48 39 (81.3) 5 (10.4) 4 (8.3) 
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1 Table 5: Distribution of dental anxiety by cHnic location : | 
Torquay 
No. (%) 
Newton Abbot 
No. (%) 
Total 
No. 
P-value 
No dental anxiety 162 (53.6) 136 (64.S) 298 
\ Dental anxiety 61 (20.2) 31 (14.7) 92 
Dental phobia 79 (26.2) 44 (20.8) 123 P=0.048 ^ 
Total 302 (100) 211 (100) 513 
1 Table 6: Numbers of patients with anxiety compared with ASA status 
S 
Patient group Total 
No. (%) 
ASA 1 ASA Z 
No. (%) No. (%) 
ASA 3 
No. (%) 
ASA 4 
No. (%) 
No dental anxiety 298 (100) 164 (55.0) 64 (21.5) 56(18.8) 14(4.7) 
Dentally anxious 92 (100) 51 (55.4) 19 (20.7) 19(20.7) -3(3.2) 
Dental phobic 123 (100) 57 (46.3) 26 (21.1) 29 (23.7) 11 (8.9) 
Total 513 (100) 272 (53.0) 109 (21.2) 104 (20.3) 28(5.5) 
Torquay 26.2% reported ihnt they were dental phobics, whereas 
f o r those who attended at N e w t o n Abbo t it U M S 20 .S% 
(P=0.04R) {Tahle 5). 
ASA classification 
The proportion o f patients in each ASA classification category 
associated to anxiet\' status is sliown in Tabic 6. Just over half. 
272 (53%). were ASA 1 (healthy). However. 241 (47%) were 
categorised as ASA 2 or above. O f these 132 (25.H%) suffered 
w i t h either .severe systemic disease or an incapacitat ing 
condi t ion that was a constant threat to life {Ttihk 6). 
Previous treatment under sedation 
Tlie percentage of paticnt.s who had previously experienced 
sedation was 42.1% (216/513). There was no statistically sig-
nificant association between experience of previous .sedation 
and anxiety levels. 
Demand Jor sedation 
Two hundred and eighty-nine (56.3%) patients requested 
sedation, i f it was available. The proportion o f patients request-
nig sedation was highest (82.1%) among those whose MOAS 
scores classified them as dental phobics, lower (65.2%) in those 
whose MDAS scores cla.ssified them as dentally anxious, and 
lowest (43.0%) in those whose M I M S scores classified them as 
with little or no anxiety. A chi-squared test showed that there 
was very strong statistical evidence (P<0.0O01) of an association 
between dental anxiety status and whether there was a request 
for sedation {Table 7). 
O f the 289 patients who requested sedation 152 were classi-
fied as ASA 1: suitable for sedation in primary dental care.The 
other 137 were classified as ASA 2, 3, and 4 and were all poten-
tially unsuitable for sedation in primary dental care because 
o f their ASA categorisation. O f these. 62 (20.8% o f those 
who requested sedation) were ASA category 2 and a further 
75 (28.7% of those who requested sedation) were ASA 3 (56 
patients) or ASA 4 (19 patients) {Tabic S and Tij^urc 2 ) .The 
highest percentage o f those who requested sedation, 67% 
(19 out o f 28). came from the group ASA 4. the least suitable to 
receive it in a primary dental care clinic, and the lowest—56% 
(152 out o f 272)—from the ASA 1 group ie those suitable to 
receive sedation in a primary dental care setting. 
Table 7: Demand for sedation against anxiety status 
No. of patients 
. (%) 
No anxiety 
No. (%) 
Dental anxiety ' 
No. (%) 
Dental phobia 
No. (%) 
• p-value' • 
Would request sedation 289 (56.3) 128 (43.0) 60 (65.2) 101 (82.1) P<0.000l 
Would not request sedation 206 (40.2) 161 (54.0) 28 (30.4) 17(13.8) 
Did not repty [8 (3,5) 9 (3.0) ,-.4(4.4) 5(4.1) 
Total . 513(100). 298(100) •92 (100) 123 (100) • 
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Table 8; Proportion of patients requesting sedation compared to ASA status 
Count 
A S A A S A 2 A S A 3 A S A 4 
152 62 56 18 
50.5 20.8 23.6 5.1 
T o t a l 
289 
100 
300 
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700 
150 
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SO 
0 
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Figure 2 Distribution of demand for sedation by ASA score. 
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F igure 3 Emergency clinic MDSA scores compared to UK normative vaiuei. 
Discussion 
h was pleasing to note ihai only five out of more than SOO 
paiienis who were invited to complete the ciucstionnairc de-
clined to do so. Patients frequeiuly expressed their gratitude at 
being able to inform the dentist of their anxiety in a written 
format. It appeared that the patients were pleased that their 
dentists and the staiT of the clinics were interested that they 
might be anxious and that, because o f the survey, they would 
be aware that they were anxious. No e.\act records o f this v«."ere 
kept, because it was not pan o f the study. 
Dental anxiety 
Studies o f the prevalence o f dental anxiety show a range o f 
scores, but it is not clear whetlier these reflect real differences 
among populations or whether they are the result o f the use o f 
different assessment methodologies.^ Nevertheless, the current 
study confirms the results o f previous studies'*-'** which have 
suggested that women have higher reported anxiety' levels than 
men and thai older patients have lower anxiety levels than 
younger patients. l-k)wevi.T, it has been claimed"^ that anxiety 
is experienced by both sexes and is more readily reported by 
women than by men. 
As shown in Fiiiurc J. (he overall level of mean dental an.\-
iety in patients in the current study (MOAS M.09) was higher 
than the normative value for UK general dental practice o f 
MOAS 10.79 but lower than that for patients attending a 
special clinic for dental phobics ( M l ' M S 2 1.5 1 ).^ This may 
reflect the fact that in the current study the patients were 
irregidar attenders but were not drawti exclusively from a 
group ol dental phobics. 
The difierences in percentages of Torquay and Newton 
Abbot patients report ing no dental anxiety may reflect the 
socioeconomic and cultural backgrounds o f the populations o f 
the [ W O areas. 
The percentage o f patients in the current study (41.9%) who 
reported dental anxiety or phobia (MDAS 16-25) was signifi-
cantly higher than in a lirazilian study'"* that used the MDAS 
methodologv' and found 28.2% were dentally anxious. Inter-
estingly, although not comparable because they use the DAS 
methodologv', two further studies'"*"' in which patients were 
asked to complete a questionnaire while waiting to be treated 
at an emergency dental clinic found (hat 21.8% and 30% of 
those attending reported dental anxiety or phobia. Both of these 
studies also included patients who were regular and irregular 
aticndcrs. However, the study that reporteti the lower percent-
age'^ was performed in the emergency clinic o f a dental school. 
As such it may not be representative because it has been 
reported elsewhere^' that 19% of patients who attended a Scot-
tish dental school did so because they preferred to be treated in 
a 'centre o f excellence". Other reasons such as referral from pr i -
mary care practitioners and an awareness that they were Hkely 
to be treated by dental students suggest that the patients who 
attended the dental school emergency clinic were more likely 
to be regular attendcrs and not anxious (of treatment by stu-
dents). In this respect, it could be argued that the current study 
demonstrates tlie importance o f carrying out studies, which 
involve patients, outside dental schools, as they are more likely 
to be based on representative samples of the general population. 
Expressed demand for sedation 
The current study c o n f i r m e d the h igh level o f expressed 
demand for dental sedation recently reported by a study'"* in an 
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'oui-of-hours'emergency dental clinic in North-East England. 
Interestingly, both studies showed that 56% of patients would 
prefer sedation. These percentages are far higher than the 31% 
of anxious patients undergoing'routine* dentistry whose pre-
ference was for sedation reported by an earlier study.^ This 
difference may in part be explained by the fact that the earlier 
study took place during the 1980s. 
Patient health and suitability for sedation in a primary dental 
care emergency clinic 
ASA assessments are usually performed in a hospital setting. It 
is therefore unsurprising that when searching the literature the 
authors have been unable to find ASA normative values for a 
community setting. It is of interest to note that in a large study, 
involving over 34,000 patients attending a large municipal 
hospital, 54% were assessed as ASA 1 (healthy).''^ This percent-
age for ASA 1 is broadly similar to the percentage assessed as 
healthy in the current study. However, it should be borne 
in mind that the hospital study took place between 1965 and 
1969 and it seems likely that, thanks to improved medication, a 
higher percentage of today's population survive into old age in 
spite of severe systemic disease. 
Nevertheless, the current study has shown thai, during the 
period of the study, because of their medical histories, nearly 
half of the patients who attended the two clinics in South 
Devon were unsuitable for treatment under sedation in a 
primary dental care setting and required management either in 
a specialist sedation practice or in a hospital. This finding has 
significant implications for those planning dental services. 
Implications for dentists working in dental access centres and 
emergency clinics 
It is widely recognised that the management of patients with 
dental anxiety is among the most difficult tasks within dentistry. 
It has been suggested^ that 47.4% of dentists find treating 
extremely nervous patients stressful and 64.8% find coping with 
difficult, uncooperative patients stressful. For highly anxious 
patients, it is important to achieve a favourable result first rime, 
as they may not be able to allow a clinician to take extra time 
and/or repeat a procedure. Even the most perceptive practi-
tioner can miss observing a patient's anxiet>'. Anxious patients 
will often wish to, and may be able to, successfully conceal their 
anxiety initially. Patients will use many techniques to mask 
what may be to them unbearable fear, for example aggression. 
While these behaviours may of themselves be difficult to 
manage, they can actually make the patient's management more 
difficult when the mask slips and his or her anxiety is revealed, 
since the clinician may have already mismanaged the situation. 
Dentists who are uncomfortable dealing with patients with 
high anxiety (or those with a lack of experience in treating 
these patients) may feel that they would rather work in a 
different practising environment. It is therefore not surprising 
that practices and clinics with a high percentage of dentally 
anxious or phobic patients have often found it difficult to 
recruit staff. 
Implications for dental access centre managers 
A further problem is that anxious patients invariably need more 
treatment time, whether they are treated under sedation or 
not. Managers must be aware of this, allow their clinical staff 
time in their schedules, and be prepared to defend this decision 
to their own higher management, GDPs and the general 
pubHc. Furthermore, anxious patients will seek compassion 
from the dentist. T h e constant seeking of compassion can 
eventually drain all the sympathy from any clinician, rendering 
the clinician 'hard' to patients' desire for compassion. Managers 
should be avvare of this problem and plan accordingly. 
It is important to recognise that although the current study 
indicated that there was a high level of dental anxiety and 
phobia among patients who attended two emergency clinics 
in South Devon, it assessed expressed (patient) demand and 
not need. It is also important to recognise that sedation is only 
one of the options for treating patients with dental anxiety 
or phobia. 
Conclusions 
The level of reported dental anxiety found in two emergency 
dental clinics in South Devon was higher than has been 
reported for other primary care clinical situations and there 
was a high expressed demand for dental treatment under seda-
tion. There would appear to be considerable scope for further 
research into the patients who use these clinics. The authors 
recommend that a proper dental health needs assessment 
should be carried out to establish the need for the management 
of fearful dental patients (including the option of sedation) and 
mechanisms to meet the needs that may be identified. 
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Thermal injury through intraradicular 
heat transfer using ultrasonic devices 
B a c k g r o u n d 
The use o f ultrasonic energy i i a highly efficient method o f removing 
obstrvciions and cements w i t h i n the root canal space when rctreanncal 
or rehabil i tat ion o f that ultrasonic energy dislodges and removes 
cemented objects f r o m the bonded interface o f the canal wall . When 
using this method, there is less potential for structural loss o r root 
damage and significantly less operator stress than when using other 
methods. 
Case d e s c r i p t i o n s 
There is l i t t le evidence in published research o f the considerable hcai 
transfer that occurs during use o f ultrasonic donees to remove poics, 
pastes and separated instruments in teeth. The authors present three 
cases o f patients w h o experienced serious bu rn injur ies dur ing 
application o f ultrasonic energ\- for restorative dentistry. The authors 
also o f f e r techniques and strategics f o r safe and effec t ive use o f 
ultrasonic devices. 
C l i n i c a l i m p l i c a t i o n s 
O n the basis o f the besi available evidence, the authors recommend 
strategies to provide safe and effective therapy whi le usbg ultra-
sonic devices in iniraradicular obstruction removal. The intern 
o f the suggested protocols is to provide ad\-anced and 
sophisticated therapies in a safe and regulated manner 
with patient safety as an overriding priori ty. 
Fundamentals of Color: Shade 
Matching and Communication in 
Esthetic Dentistry 
C h u , S t e p h e n J; Dev igus , A le s sand ro ; and MIe l e szko , A d a m J 
C h i c a g o . I L : Qu in t e s sence ; 2004 
£ 4 7 . 0 0 : S o f t c o v e r : 168 p p : 426 c o l i l lus . 
I S B N : 0 8 6 7 I S 434 9 
There have been man / books on the subject of matching dental materials 
to human tee th and the study of colour has been ongoing since Sir Isaac 
Newton 's day. It is all t oo easy for books approaching this subject mat ter 
f r o m ei ther d i r e c t i o n to become over- technical o r an excuse f o r an 
overwhelming montage of wonder fu l clinical cases. However this book, in 
only 168 pages, progresses breezily through a wonderfu l ly lucid explan-
ation of co lour science, discusses both conventional shade matching and 
technology-based shade matching, recommends the authors ' Seven Steps 
to a Successful Shade Match pro tocol and, finally, finishes vnch ten clinical 
cases that reprise and illuminate much of the preceding tex t . 
For the general pract i t ioner the whole book wi l l be of interest, if only 
because it w i l l surpass everything ever learned at undergraduate level on 
the subject in one sitting. Al though i t is we l l -known that male co lour 
blindness is widespread, how many dentists could know that Viagra is 
' no tor ious f o r causing vision t o have a blue t in t , which makes i t d i f f i cu l t 
to distinguish between blue and green"? Layering techniques in b o t h 
porcelain and modern composite systems have changed in recent years 
and there is an admirably concise chapter oudining and demonstrating 
these developments. However, the chapter that w i l l mos t interest the 
prac t i t ioner developing a special Interest in Esthetic Den t i s t ry {sic) wi l l 
be that on Technology-Based Shade Matching. This describes the develop* 
ment o f single-point-source spect rometers to the commercial b i r t h of 
the m o d e m systems that measure shade over a comple te too th surface. 
The first machine to map the ent i re surface, the Spectroshade, v^as only 
marketed in 2001 and there arc now several such machines available. 
Because of the explosion in this technology this is the one area o f the 
book where the subject mat ter is covered in relatively great depth. The 
three categories of electronic clinical device. RGB devices, spectro-
photometers and co lor imeters are compared and contrasted. Although 
technology has clearly moved the subject on , the authors are keen to 
stress that w e l M i t re ference photographs remain an essential adjunct 
to these modern devices and chapter S stresses that the clinical shade-
matching p ro toco l involves both . 
A t the end o f each chapter the key points are clearly defined wi th 
bullet points and key l i tera ture references are given. My only real crit icism 
of the book w o u l d be its cover. This is o f the thick card type that almost 
'clat ters ' as the book is handled. A p a r t f r o m this the p roduc t ion values 
are as expected f r o m Quintessence and the level o f a r t w o r k and photo-
graphy keep pace w i t h o the r recent t i t les In this field. Some photo-
graphs are r ep roduced w i t h pe rmiss ion f r o m w o r l d - r e n o w n e d 
clinicians, including o u r o w n Irfan Ahmad. 
S T E P H E N J O N E S M S C . B D S , M R D , M G D S . 
SPEOAUST JN PROSTHOOONTICS A N D RESTORATIVE DENTISTRT, 
NEWBURY, BERKSHIRE. 
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An audit of the quality of a referral document, designed in 
accordance with Scottish Intercollegiate Guidelines Network, 
for paediatric exodontia under general anaesthesia 
R. A. B A K E R ' . L . A N T H O N Y ' & H . SANDERS2 
'5our/i Devon Healthcare NHS Trust. Torquay. Devon. UK and -University of Plymouth. Plymouth. UK 
Dental ircaimeni under general anacsihesia (GA) in 
the UK is confined to hospital. Patients are seen by 
referral, which provides all the administrative and 
clinical details for the receiving secondary-care 
surgeon. In the U K . Maintaining Standards stales 
the requirements for such a referral (1), including 
(i) clear justification for the use of general anaesthesia 
and ( i i ) details of relevant medical and denial 
histories. 
There have been few studies of referrals f rom 
dental practices [ 2 - 8 ] . Thomas* «/ . 17] showed 
that only 39-8% of referrals included a f u l l medical 
history. Research in other dental specialities f3,5,6,8] 
reported significant omissions o f information. These 
studies stressed the importance o f high-quality 
referrals and concluded that the use o f a referral fomi 
could improve the quality of referral communications. 
In 1998, the Scottish Intercollegiate Guide-
lines Network (SIGN) published the Report on a 
Recommended Referral Oocnnteni [91 and made 
recommendations on a minimum essential data set 
for communication from primary to secondary care. 
The administrative problems o f the paediatric 
referral G A exodontia service o f the South Devon 
Healthcare NHS Trust, at Torbay Hospital, were raised 
during the clinical governance process. The problems 
ideniified were data capture of administrative details 
(unidentified referring dentists and unnamed patients) 
and compliance with maintaining standards. It was 
decided to develop a new referral document, including 
all the information fields recommended by SIGN, 
and comply wi th Maintaining Standards in a format 
familiar to general dental practitioners. The format 
Correspondence: M r R. A . Baker. Midvale Healih Cenire. 
Midvflle Road, Paignton. Devon T Q 4 5 B D . U K . E-mai l : 
ro ben. bake rta)iihs. net 
chosen was the Denial Practice Board form FPI7, used 
by dental practitioners to claim payment o f fees. 
A prospective quantitative audit o f all new referral 
forms received (other referral methods were excluded), 
collected monthly, until 200 referral forms were 
received was undertaken. The study time period was 
May to November 2004. July and August were omit-
ted. Table 1 shows the results. 
A postal survey o f referring general dental practi-
tioners (GDPs) was undertaken. Questionnaires were 
received f rom 96 o f 133 (72%) GDPs. Ninety-three 
percent of GDPs found the fo rm simple lo compicie. 
This study shows a high rate of data capture relative 
T:ihlf I . Rclernil documenl. 
completed. 
S I G N ' essential iiifornution fields 
Number Percentage 
Referring denlisi's name 
Referring deniisi's address 
Referring deniisi's iclcphone number 
Patient's surname 
Patient's forename 
Patient's address 
Patient's D . O . B . 
Paiiem's telephone number* 
Troaimeni plan 
Urgency - patient in pain 
Urgency - orthodontic extractions 
Relevant denial history 
Reason for general anacsiheiic 
Dentist's signature contirming 
l£ \planat ion of general annesiheiic 
Risks and aliematives 
Date of referral 
C M P ' s name/Address 
Medical history 
Parent or guardian's signature 
Confirming consent and explanation 
of general anaesthetic risks* 
209 
209 
177 
209 
209 
209 
207 
204 
209 
.'>7 
31 
125 
204 
2{)> 
200 
205 
209 
208 
100 
100 
84-7 
100 
100 
100 
99 
97-6 
100 
27-3 
14-8.1 
59-81 
97-6 
ys-oi 
95-7 
9S-0I 
100 
99-52 
•Not a S I G N essential information ileld. 
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10 previous studies [2—5]. confinning previous authors' 
( 2 - 5 ] suggesiions thai a referral form w i l l capture 
high rates of data. Adininisiraiive data capture was 
excellent; during this study no forms had to be rciumed 
because of poor patient details, facil i tat ing appoint-
ment booking by pernii i i ing telephone booking and 
avoiding misaddressed posied appointments. 
Thomas et al. [1\ found thai practitioners using a 
form were more likely to omit their own details, only 
90-4% were identifiable. Snoad ei al. [5] suggested 
that relative low prominence given to the practitioner's 
address contributed to the number o f i^eferrals lack-
ing administrative detail on referral forms. In this 
study, the practitioners' details were included in 
100% of referrals. The explanation of the difference 
lies in the adoption of the FP17 format; its familiarity 
encouraged correct completion. For the same reason, 
this study showed a higher rate o f treatment plan 
data capture than Thomas ct al. \7\. 
The quality of referrals for GA cxodontia has caused 
concern recently. This study, provides evidence that 
a referral form designed using the SIGN guidelines 
can achieve a very satisfactory rate of data capture 
o f both administrative data and data required to 
achieve regulatory compliance. Both patients and 
clinicians benefit i f the recognized guidelines are 
used in a clinical setting. 
The authors feel that the future o f referrals lies 
in electronic transmission and would suggest the 
importance of research in that area. 
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